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ABSTRACT OF THE DISSERTATION 
Uropathogenic Escherichia coli Employ a Conserved Intracellular Infection Pathway that 
can be Inhibited by Novel Anti-Virulence Therapeutics 
By 
Corinne Katherine Cusumano 
Doctor of Philosophy in Biology and Biomedical Sciences  
(Molecular Microbiology and Microbial Pathogenesis) 
Washington University in St. Louis, 2009 
Professor Scott J. Hultgren, Chairperson 
 
Urinary tract infections (UTIs) affect 13 million women annually in the United 
States and are predominately caused by uropathogenic Escherichia coli (UPEC).  In a 
murine cystitis model, UPEC utilize a multistep pathogenic pathway in which they invade 
and form intracellular bacterial communities (IBCs) within bladder facet cells.  Type 1 pili 
expressing the adhesin, FimH, are necessary for UPEC binding and invasion of 
urothelial cells and formation of IBCs.  UPEC ultimately disperse from the IBC, many 
with filamentous morphology, and infect other host urothelial cells.  Using a panel of 
UPEC clinical isolates, this work evaluates the conservation of the IBC pathway across 
UPEC, the function of a UPEC pathogenicity island (PAI) in the UPEC pathway, and the 
therapeutic effect of inhibition of FimH.   
Investigation of 18 clinical isolates revealed that the majority of isolates proceed 
through the IBC cascade confirming its relevance in UPEC infection.  Due to the 
commonality of the UPEC pathway, this panel of clinical isolates was used to investigate 
other determinants important in UPEC infection.  One potential virulence determinant is 
pUTI89, isolated from UTI89.  pUTI89 has many characteristics of a PAI thus it was 
evaluated for its presence in UPEC isolates and its role in pathogenesis.  Evidence of 
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pUTI89 was found in 67% of UPEC isolates tested.  Studies revealed that while there 
was no observable phenotype in vitro in the absence of pUTI89, there was a significant 
defect in binding, invasion and colonization at early time points post-infection, however, 
infection levels were restored by 24h post-infection.  Since pUTI89 is not essential to 
UPEC infection, type 1 pili were used to develop a therapeutic against UPEC infection.  
Binding and invasion are critical to the UPEC pathway, thus inhibition of these early 
steps could result in unsuccessful colonization of the bladder.  Knowledge of the FimH 
mannose-binding pocket enabled the rational development of mannosides that 
competitively inhibit binding to mannosylated uroplakins on the bladder surface.   
These studies demonstrated the commonality of the IBC pathway among UPEC 
isolates as well as the importance of pUTI89 in early stages of UPEC infection.  
Knowledge of the UPEC pathway facilitated the development of novel therapeutics to 
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CHAPTER ONE 
INTRODUCTION TO THE DISSERTATION 
 
Urinary Tract Infections 
The urinary tract is a common site of infection in women, resulting in an estimated 8 
million outpatient visits yearly in the U.S. with an estimated cost exceeding $2.5 billion 
(22).  It is thought that acute urinary tract infections (UTI) develop when bacteria from 
the fecal flora colonize the vaginal and periurethral areas and are subsequently 
introduced into the bladder by ascension via the urethra.  The vast majority of patients 
are female.  Women have a 50% chance of developing an acute UTI within their lifetime 
(45, 51).  This gender difference in UTI is presumed to be due to the anatomical 
differences between males and females, with females having a relatively short urethra 
as well as a shorter distance between the urethral opening and the anus.  In addition, 
higher rates of infection are associated with some subpopulations, such as the elderly, 
diabetics, those with anatomical abnormalities and pregnant women (4, 49).  UTI can 
lead to a number of serious sequelae including renal scarring and premature birth (4, 
49).  Nosocomial infection is extremely common and can result in sepsis with significant 
morbidity and mortality particularly for elderly patients (18).  Uropathogenic Escherichia 
coli (UPEC) is the leading causative agent of UTI, responsible for up to 85% of 
community-acquired UTI and 25% of nosocomial UTI (50). 
 
Recurrent infection 
Recurrence is a serious problem for many women.  Women who present with an initial 
episode of acute UTI have a 25-44% chance of developing a second and a 3% chance 
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of experiencing three episodes within six months of the initial UTI (19).  Recurrence 
occurs despite appropriate antibiotic treatment and clearance of the initial infection from 
the urine.  A large percentage of recurrent UTI (rUTI) are caused by the same strain of 
bacteria as the initial infection.  One study followed 58 women and found that 68% of 
recurrences were caused by the same initial index strain of UPEC as determined by 
restriction fragment length polymorphism (RFLP) analysis (54).  In a separate study, 
50% of recurrent strains isolated from female college students appeared genotypically 
identical to the bacterial strain corresponding to the initial UTI (20).  Another long-term 
prospective study demonstrated that the same strain of UPEC can cause a rUTI up to 3 
years later (9).  The high frequency of same-strain recurrences supports the notion that 
a UPEC reservoir can exist in the affected individual.  The current dogma is that all rUTI 
result from the re-inoculation of the urinary tract with bacteria originating from a reservoir 
within the gastrointestinal tract (GIT) and/or vagina (26).  Consistent with this idea, it has 
been demonstrated that the GIT and the vagina/periurethral areas can support UPEC 
reservoirs (54, 64).  In addition, vaginal epithelial cells from women that are prone to 
rUTIs tend to support higher levels of bacterial adherence, as compared to cells from 
healthy control patients (59).  However, the presence of perineal bacterial or GIT 
colonization does not explain how a first time urinary tract infection predisposes for the 
risk of recurrence in girls or women with anatomically normal urinary tracts (61, 62).  
Furthermore, daily application of antibacterial ointment to the perineal area fails to 
prevent recurrent infections, even though such a treatment would be expected to block 
fecal/vaginal-to-urinary tract transmission (11).  Women who get frequent rUTIs have 
been offered a variety of prevention strategies.  Often these women are given antibiotics 
to take upon first presentation of symptoms, after sexual intercourse, or daily as UTI 
prophylaxis (42, 65, 66).   These courses, however, promote uropathogen antibiotic 
resistance.  Additional studies have looked at cranberry products (5), Lactobacillus 
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probiotic therapy (70), and vaccination against bacterial adhesins (35, 36).  While many 
of these strategies are promising, they have yet to be validated in large-scale clinical 
trials.    
 
UPEC Pathogenic Cycle 
Clinically, it has been presumed that UPEC infection consists of a relatively simple 
extracellular colonization of the luminal surface after inoculation of fecal flora into the 
bladder via the urethra.  In contrast, using a murine model of UPEC infection of the 
urinary tract, we have detailed an unexpectedly complex UPEC pathogenesis cycle that 
involves both intracellular and extracellular niches (Figure 1).  Using genetic, 
biochemical and cell biological approaches together with a variety of imaging techniques 
including transmission, quick freeze-deep etch and scanning electron microscopy, as 
well as confocal and time lapse video microscopy, it has been discovered that UPEC 
invade bladder facet cells via a FimH-dependent mechanism (2, 31, 40).  After invasion, 
cytoplasmic intracellular bacterial communities (IBCs) are formed.  Rapid replication of 
the initial invading bacteria results in the formation of an early IBC of loosely-packed rod-
shaped bacteria (31).  The bacteria continue to replicate and progress to form a large 
densely packed mid-stage IBC of morphologically coccoid bacteria (31), with biofilm-like 
characteristics including positive periodic acid-Schiff (PAS) staining (3) and differential 
gene expression throughout the community (3, 73).  After the IBC matures, bacteria 
detach from the biomass, often become filamentous, and spread to neighboring cells 
forming new generation IBCs.  Filamentous bacteria are more resistant to neutrophil 
killing resulting in evasion of neutrophil phagocytosis and promoting bacterial survival.  
Thus, the IBC pathway facilitates massive expansion of the invading bacteria in a niche 
protected from host defenses.  Population dynamic studies using ex vivo gentamicin 
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protection assays demonstrated that ~104 UPEC of an initial 107 inoculum invaded the 
bladder tissue within 15 minutes after infection and that one percent of the invaded 
bacteria went on to form IBCs, resulting in an average of 100 IBCs per infected mouse 
bladder.  If this is extrapolated to the human situation, innate defenses in the bladder 
most likely prevent the majority of bacterial inoculation events into the bladder from 
leading to disease.  However, the ramifications of the IBC cascade are striking.  Invasion 
of a single infecting bacterium can lead to rapid expansion of the infection via IBC 
formation, replicating within hours to 104 bacteria and even higher numbers followed by 
dispersal of the bacteria from the biomass and spreading to neighboring cells to reinitiate 
the IBC cascade.  This process allows the bacteria to gain a critical foothold.  Bacterial 
descendents of the acute IBC cascade have been shown using our murine model, to be 
able to form a quiescent intracellular reservoir (QIR) that can persist, protected from 
antibiotics and seemingly undetected by the host immune system even after the acute 
infection is resolved and bacteria are no longer detectable in the urine (41, 60).  Bacteria 
in the QIR can later seed a recurrent infection (60), manifested by IBC formation, 
bacteriuria and inflammation.  Growing understanding of the bacterial mechanisms of 
virulence and the subsequent host responses have led to new avenues of research and 
identification of powerful new therapeutic targets, diagnostic regimens, and the design of 
anti-virulence compounds.  
 
UPEC Clinical Isolates and the UPEC Pathogenic Cycle 
Due to the unique nature of the UPEC pathogenic cycle in UTI89, translational studies 
were performed in an effort to show that the majority of UPEC isolates form IBCs when 
introduced into the murine bladder and that IBCs and filamentous bacteria occur in the 
urine of human UTI patients (21, 52).  The study began with the enrollment of hundreds 
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of women into three different studies to obtain the four different clinical syndromes of 
UTI.  The four common syndromes of UTI are asymptomatic bacteriuria (ASB), acute 
cystitis, recurrent cystitis (rUTI) and pyelonephritis.  ASB is clinically defined as greater 
than 105 bacteria present in the urine without symptoms of UTI such as dysuria, 
frequency and/or urgency.  Acute cystitis is a one-time UTI event without a subsequent 
UTI event during the course of the study, whereas, rUTI requires recurrent events within 
3 months of the initial UTI.  Lastly, pyelonephritis was defined as fever, back pain and/or 
costovertebral angle tenderness (CVAT) as well as a positive urine culture as with acute 
UTI.  In an effort to determine if a specific genotype would associate with a specific 
clinical syndrome, putative UPEC virulence factors were examined by PCR.  Not 
surprising, there was no correlation between clinical syndrome and virulence genotype.  
Since the study enrolled human subjects, genetic backgrounds and pain thresholds are 
different between subjects likely contributing to the difference in clinical manifestation of 
different isolates.  To confirm the UPEC pathogenic cycle is common among UPEC 
isolates, strains from the study were inoculated in the mouse model of UTI and IBC 
formation was evaluated at 3, 6 and 24 hours post-infection.  Results revealed that IBC 
formation is an almost universal characteristic of UPEC isolates.  Fifteen of 18 isolates 
formed IBCs and the 3 isolates that were unsuccessful at IBC formation had evidence of 
the UPEC pathogenic cycle upon co-inoculation with UTI89.  Additionally, another study 
was performed to identify hallmarks of the UPEC pathogenic cycle within human urine.  
This study revealed the presence of exfoliated umbrella cells containing IBCs and 
filamentous bacteria present in the urine of human subjects.  Also, evidence of IBCs 
were seen significantly more often in Gram-negative isolates than Gram-positive 
isolates.  These two studies demonstrated that IBC formation is common among UPEC 
and evident within humans.  Now that a panel of UPEC isolates that proceed through the 
IBC cascade is available, perhaps this will facilitate the development of a virulence 
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profile identifying E. coli isolates as UPEC.  This will enable rational drug design to target 
virulence factors essential for UPEC infection. 
 
Urovirulence Determinants 
E. coli is an incredibly diverse bacterial species that can colonize numerous niches in the 
environment and the animal host.  Generally, E. coli within the intestinal flora exist as 
commensals that form a beneficial symbiotic relationship with their host (75).  However, 
some strains of E. coli can diverge from their commensal cohorts and cause disease 
within the intestinal tract and elsewhere within the host.  These pathogenic strains are 
broadly characterized as either diarrheagenic E. coli or extraintestinal pathogenic E. coli 
(ExPEC) (32, 53).  ExPEC have maintained the ability to exist in the gut without 
consequence, but have the capacity to disseminate and colonize other host niches 
resulting in disease.  Among ExPEC, strains of UPEC are most commonly associated 
with human disease.  Despite the well-studied nature of UPEC, especially in regards to 
virulence factors and colonization strategies, no single feature accurately defines an 
isolate as UPEC.  All UPEC isolates contain the fim operon encoding type 1 pili, which is 
necessary for binding and invasion within the urinary tract.  However, since the majority 
of E. coli strains possess this operon, it cannot define an E. coli as UPEC.  A better 
understanding of UPEC-associated virulence factors and the coordination of their 
activities during the course of a UTI might significantly enhance our ability to both predict 
and rationally redirect disease outcome.  The most likely place to discover UPEC-




Compared to K12 lab strains and commensal E. coli isolates, UPEC harbor more genes 
encoding virulent capsule antigens, iron acquisition systems, adhesins, and secreted 
toxins.  These genes are often encoded within regions referred to as pathogenicity 
islands (PAIs).  PAIs were first described in pathogenic E. coli, but have now been 
discovered in pathogenic bacteria of species other than E. coli, both Gram-positive and 
Gram-negative.  PAIs posses most, if not all, of the following characteristics: they (i) 
carry genes encoding one or more virulence factors, (ii) are present in the genomes of 
pathogenic organisms but absent from the genomes of nonpathogenic organisms of the 
same or closely related species, (iii) occupy relatively large genomic regions, (iv) often 
consist of DNA regions that differ from the core genome in G+C content and in different 
codon usage, (v) are often flanked by small directly repeated (DR) sequences, (vi) are 
often associated with transfer RNA (tRNA) genes, (vii) often carry cryptic or functional 
genes encoding mobility factors such as integrases, transposases, and insertion 
sequence (IS) elements or parts of these elements, and (viii) often represent unstable 
DNA regions (23).  Due to mobility factors, PAIs often do not represent homogeneous 
pieces of DNA but rather are made up of mosaic-like structures which have been 
generated by a multistep process of genomic acquisition, loss, and rearrangement.  PAIs 
frequently contain genes encoding regulators of virulence factor genes located on the 
same island.  However, various arrangements of regulators and regulatory factors are 
possible, including PAI-encoded regulators that are specific for PAI genes, PAI-encoded 
regulators that also regulate genes located outside the PAI, and regulators encoded 
outside the PAI that regulate genes encoded on the PAI.   
The analysis of the structure of PAIs revealed that these genetic elements have 
been generated after lateral gene transfer processes.  The acquisition of new genes 
following horizontal gene transfer either directly by transformation with naked DNA, 
transduction with phages, or uptake of plasmids or chromosomal fragments by 
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conjugation, results in the generation of new variants of pathogens.  Thus, PAIs 
contributed to the development of pathogenic variants, preferentially in macroevolution.  
The ongoing processes of rearrangements, deletions, and transfer of PAIs, however, 
also have a strong impact on microevolution and adaptation of pathogenic microbes 
during acute infectious processes.  In organisms such as UPEC, whole PAI elements 
can be deleted.  It is suggested that the deletion processes may play a role in the 
adaptation of pathogenic microbes during certain stages of infection.  Therefore, genetic 
flexibility of pathogenic microbes may create selection advantages over other, less 
flexible organisms and may finally result in proper replication in host organisms or other 
ecological niches.   
 
pUTI89 
The majority of PAIs are located on the chromosome; however, they can also be part of 
bacterial plasmids, considered ‘PAI precursors’ or ‘Pre-PAIs’ (37).  UPEC PAIs encode 
adherence factors, toxins and iron uptake systems.  Interestingly, these same virulence 
factors can be plasmid or phage encoded on intestinal E. coli isolates whereas in UPEC 
they are located chromosomally, i.e. alpha-hemolysin.  Thus UPEC PAIs could represent 
former plasmid-derived sequences.  UTI89 carries a large extrachromosomal element 
with many characteristics of UPEC PAIs, however it is not incorporated into the 
chromosome suggesting that it may be a ‘PAI precursor’.  This plasmid, pUTI89, is 
approximately 114 kb and like plasmid F, contains the tra operon, as well as genes from 
known virulence plasmids.  Due to the potential of pUTI89 to be a ‘pre-PAI’ and the need 
to identify genes encoding UPEC-specific virulence factors most likely present on PAIs, 
this plasmid could provide a snapshot for the acquisition of this PAI among future 
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bacteria and enable identification of novel virulence factors. Thus a study was done to 
determine if pUTI89 is important for virulence of UPEC. 
Evidence of pUTI89 is present in the majority of clinical isolates tested 
suggesting maintenance within the community and importance in some aspect of 
virulence.  To assess its role in pathogenesis, pUTI89 was cured from UTI89 to obtain a 
plasmid-less strain.  The in vitro characteristics of UTI89 and ΔpUTI89 were then 
evaluated.  Based on growth, type 1 pili expression and function, and biofilm formation, 
the two isolates were virtually indistinguishable suggesting that pUTI89 is not involved in 
these in vitro characteristics which are used to mimic in vivo virulence capabilities.  
However, it has been shown that in the absence of a Chlamydia trachomatis plasmid 
there was no observable phenotype in vitro, yet in vivo experiments revealed 
significantly lower ID50 and lack of glycogen accumulation (10).  Thus, the plasmid-less 
strain was tested in vivo to see if a similar phenomenon existed.  Using the mouse 
model of UTI, bacterial load, IBC formation and intracellular and extracellular survival 
were examined.  All of these parameters of infectivity, revealed a significant defect in the 
ΔpUTI89 strain to colonize the bladder at early timepoints post-infection.  Interestingly, 
within 24 hours post-infection, normal infection was restored as measured by bacterial 
titers in the bladder.  Through selected deletions of operons on pUTI89, the cjr operon 
was implicated in the observed defect.  The cjr operon, studied in enteroinvasive E. coli 
(EIEC), encodes for CjrA, CjrB and CjrC, is regulated by iron and is involved in uptake of 
colicin Js, although this is likely not its primary function.  Similar to EIEC, a putative iron 
regulation fur box was located upstream of pUTI89 cjrA.  UTI89 CjrB is homologous to 
the TonB protein present in many Gram-negative bacteria which has been implicated in 
energy translocation between the inner and outer membrane.  Furthermore, UTI89 CjrC 
shows homology to putative outer membrane siderophore receptors.  Many studies have 
shown iron’s importance in survival within the urinary tract (24, 38, 48).  Due to the 
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necessity of iron acquisition, many systems are redundant in bacteria explaining the lack 
of complete infection inhibition in the absence of CjrB and CjrC.  This study revealed that 
pUTI89 is very likely a ‘PAI precursor’ and may be incorporated into the genomes of 
future UPEC.  Horizontal gene transfer by pUTI89 may therefore play a role in the 
creation of new pathogenic variants. 
While it is not essential for virulence in UTI89, perhaps in less virulent UPEC 
isolates, pUTI89 will facilitate greater invasion efficiency.  Thus, strains that otherwise 
may not cause disease, with the help of genes on pUTI89, will survive within the urinary 
tract.  Through this work a virulence enhancer has been identified, however, since it is 
not present in all UPEC isolates it cannot, by definition, be added to the urovirulence 
profile.  One virulence factor that is present in all UPEC isolates is type 1 pili.  Thus an 
understanding of this adhesive fiber could ultimately lead to a treatment for UTIs. 
 
Type 1 pili 
Type 1 pili are essential cystitis virulence determinants (6, 39, 40, 74).  Using EM and 
the mouse cystitis model, it has been shown that adhesive type 1 piliated bacteria are 
able to bind and invade host superficial umbrella cells, while UPEC lacking type 1 pili are 
not.  Colonization and invasion of the bladder epithelium is dependent on the FimH 
adhesin located at the distal end of the pilus which interacts directly with receptors on 
the luminal surface of the bladder (Figure 2).  Once inside the cell, type 1 pili are 
expressed within IBCs as shown by pilus-like fibers radiating from bacteria and 
interacting with matrix material (3).  Further work confirmed that not only are type 1 pili 
essential for binding and invasion, they are required for the survival and proliferation of 
UPEC within superficial facet cells, making type 1 pili arguably the most important 




The proteins involved in biogenesis and composition of type 1 pili are encoded by fimA-
H of the fim operon (Figure 3), the expression of which is regulated by an invertible 
promoter switch element (often termed fimS).  Type 1 pili consist of a thicker pilus rod, 
composed of FimA, and a thinner tip fibrillum, composed of FimF, FimG and the 
adhesin, FimH.  The FimH adhesin is a two domain protein, with a receptor binding 
domain linked to a typical pilin domain that joins the adhesin to the pilus fiber.  Binding of 
FimH to its receptor, mannose, initiates a critical initial event in UTI pathogenesis (27).  
The mannose binding site of FimH is a deep and negatively charged pocket at the tip of 
its receptor-binding domain (Figure 4).  The FimH pocket engages in extensive hydrogen 
bonding to mannose, which are abundant in the oligosaccharide moieties of uroplakins 
that coat the luminal surface of the bladder epithelium.  A hydrophobic ridge surrounds 
the mannose binding pocket in a manner that may facilitate polar interactions within the 
FimH pocket.  Mutational studies revealed that each residue is critical in mannose 
binding and pathogenesis, emphasizing why the pocket is invariant among UPEC 
isolates (12, 27).  While the mannose-binding pocket is invariant, residues outside the 
binding pocket are not.  The panel of 18 clinical isolates described above was used to 
assess the role of these variant amino acids.  Three of the 18 clinical isolates did not 
form IBCs and five more did so poorly.  Through FimH sequence alignment it was 
identified that the majority of the poor IBC-formers contained a valine at position 27 
which was a residue shown to be under positive selection (12).  In an effort to 
understand the role of FimH in the pathogenic cycle, the clinical isolates with poor ability 
to form IBCs were manipulated to contain the FimH of UTI89 in the place of their FimH 
on the chromosome, thus under the same regulation and expression.  The hypothesis 
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being that despite the genetic background, with UTI89 FimH, the clinical isolates will be 
able to form IBCs.  One isolate, acute4, was tested and while it still did not form IBCs, it 
did colonize the bladder significantly better with UTI89 FimH.  This result suggests that 
there is more to FimH than IBC formation.  Additional functions of FimH make it an 
extremely enticing drug target. 
 
Small molecule inhibitors 
The FimH-mannose interaction was further investigated in an effort to develop potential 
ligand-based antagonists of UTIs.  The chitobiose unit on oligomannose was found to 
bridge various mannose derivatives to the asparagine in the Asn-X-Ser/Thr motif of 
FimH resulting in higher affinity binding (71).  Crystallization of FimH in complex with 
oligomannose-3 revealed the mechanism of this higher affinity binding.  The non-
reducing Man4 anchors into the mannose-binding pocket while the GlcNAc folds over 
Thr51 allowing specific interactions with a hydrophobic tyrosine gate.  Heptyl mannoside 
mimics the GlcNAc tail of oligomannose-3 and extends it further to increase interactions 
outside the binding pocket resulting in high affinity binding (Kd = 5 nM).  Based on the 
high affinity of heptyl mannose for FimH, its ability to reduce bacterial infection in the 
mouse model of UTI was tested.  Biofilm formation was evaluated as a surrogate for 
IBCs formed in the bladder.  Heptyl mannose at 1 mM inhibited UPEC biofillm formation 
in vitro suggesting that the mannose binding properties of the FimH adhesin is required 
for biofilm formation.  Thus, UPEC strain UTI89 was incubated with heptyl mannose prior 
to inoculation into the bladders of mice.  This resulted in a significant attenuation of 
virulence at 6 hours post-infection at 5 mM heptyl mannose.  The ability of these 
compounds to significantly attenuate virulence establishes mannosides as a potential 
treatment for UTI.  More potent mannosides can now be developed that mimic the 
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natural receptor for FimH but with increased affinity and avidity in order to ultimately 
block bacterial colonization, invasion, IBC formation and disease.  The ramifications of 
this work are immense, since, if effective, these carbohydrate inhibitors of disease can 
be translated to multiple organisms.  Sugars, such as mannose, are the molecules most 
commonly involved in cell recognition playing an important role in microbial adherence.  
Thus, carbohydrate derivatives of host ligands can block the adhesive properties of pili 
on a multitude of bacterial organisms.  In the face of antibiotic resistance, this novel drug 
development could treat otherwise resistant infections.  While this strategy for bacterial 
binding inhibition focuses on occupying the receptor binding pocket with carbohydrates 
mimicking host ligands, a second strategy could eliminate pilus formation all together by 
blocking the chaperone-usher pathway. 
 
Chaperone-Usher Pathway 
Adhesive type 1 pili are prototypic structures of a family of adhesive fibers produced by 
diverse Gram-negative bacteria via the chaperone/usher assembly pathway (Figure 5) 
(57, 69).  The chaperone/usher molecular machine functions to regulate the ordered 
secretion, folding and assembly of hundreds of thousands of subunits into defined 
architectures on the surface of a bacterium.  Hundreds of these operons have been 
reported with as many as twelve encoded in one organism.  UTI89 encodes 10 
chaperone/usher pilus biogenesis systems (13) each encoded by a distinct gene cluster, 
which contains a dedicated chaperone and usher.  Type 1 and P pilus systems are 
prototypes for understanding secretion and assembly via the chaperone/usher pathway. 
Chaperones   
Periplasmic chaperones function to fold their corresponding subunits, shield interactive 
subunit surfaces and deliver the subunits to their outer membrane usher in a process 
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termed donor strain complementation (DSC) (55).  The highly homologous chaperones 
(~25 to 30 kDa) consist of two immunoglobulin-like (Ig-like) domains stabilized by a 
conserved salt-bridge in an overall boomerang shape as seen in the crystal structures of 
PapD, FimC and SfaE (14, 25, 33, 46).  Periplasmic peptidyl-prolyl isomerases and 
DsbA were found to facilitate chaperone folding (7, 8, 30, 76).  Each chaperone contains 
a conserved subunit binding site (29) consisting of two positively charged cleft residues 
that hydrogen bond to their target subunits (34, 63) and solvent exposed hydrophobic 
residues that participate in DSC (28).  In addition to the conserved subunit-binding 
surface, each chaperone contains a conserved patch of solvent exposed residues on the 
back side of domain 2 (28, 29) shown to be important for usher binding as well as for 
subsequent events leading to subunit polymerization (43, 47). 
 
Subunits  
Single domain subunits share a homologous structure consisting of an incomplete Ig-like 
fold and an N-terminal extension (Nte).  The body of each subunit consists of six of the 
seven strands of a standard Ig fold.  In order to form a stable structure, the 
corresponding chaperone for each subunit donates structural information to compensate 
for the missing seventh strand of the subunit thereby completing the hydrophobic core in 
a process known as donor strand complementation (DSC) (14, 55).  During pilus 
assembly, the free Nte of one subunit displaces the chaperone bound to another subunit 
and serves as the seventh strand of the Ig-like fold, in a process called donor strand 
exchange (DSE) (55, 56).  While all subunits share an overall structure and mechanism 
of polymerization, each subunit is adapted for a particular role, which have been 
identified in both the pap and fim systems.  Pilin subunits require the function of the 
chaperone for folding due to the absence of the seventh C-terminal strand which is 
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transiently donated by the chaperone.  In the absence of chaperone, subunits misfold 
into conformations that drive them ‘OFF-pathway’, resulting in non-productive 
interactions and their eventual proteolytic degradation. 
 
Tip adhesins 
Unlike the single domain subunits described above, tip adhesins contain two domains.  
The C terminal domain is homologous to the single domain subunits (14).  The N 
terminal domain folds into a ligand binding structure.  Crystal structures of PapG and 
FimH reveal each adhesin has a unique positioning of the ligand-binding site (17, 27).  
These binding domains serve as the functional end of the pilus, recognizing specific host 
ligands and influencing bacterial tropism for host tissues. 
 
Ushers 
The ushers (~90 kDa) share homology and serve as assembly sites in the outer 
membrane for polymerization of the resulting fibers.  In the absence of the usher the 
corresponding chaperone/subunit complexes accumulate in the periplasm, but are not 
assembled into the final fiber (44).  Ushers also serve as pores (~2 nm) allowing export 
of the growing fiber to the surface of the cell (68).  Ushers PapC and FimD have been 
shown to discriminately bind the different chaperone/subunit complexes of their 
respective systems (16, 58).  Once bound by initiating chaperone/subunit complexes, 
ushers undergo a conformational change (displacement of the β sandwich plug domain), 
which is then maintained throughout fiber assembly such that the polymerized subunits 





The chaperone/usher system has been cited as the most mechanistically understood 
assembly/translocation process at a structural level (15).  The vast understanding of the 
molecular structure and function of chaperones important in bacterial pathogenesis 
facilitates the development of therapeutics capable of targeting and inhibiting the 
formation of these adhesive structures associated with virulence.  Increasing antibiotic 
resistance among chronic bacterial infections necessitates the identification of new 
therapeutic options.  Combinatorial chemistry has identified small molecule inhibitors of 
pilus biogenesis.  The inhibitors were rationally designed based on the knowledge that 
thiazolo ring-fused 2-pyridones are highly useful as scaffolds for the development of 
compounds that inhibit protein-protein interactions in bacteria (1, 47, 67).  The synthetic 
pilicides disrupt an essential protein-protein interaction between the chaperone and 
usher at a site that has been identified by x-ray crystallography resulting in ‘bald’ 
bacteria.  Lack of type 1 pili production results in inhibition of biofilm formation and 
hemagglutination (HA) titer.  Considering type 1 pili are essential for colonization of the 
murine urinary tract, bacteria grown in the presence of pilicide, FN075, failed to establish 
a robust infection in vivo as identified by IBC formation and were significantly reduced in 
bacterial colonization (Cegelski et al, submitted).  Thus, FN075 was successful at 
inhibiting urinary tract infection within the mouse.  The efficacy of FN075 within the 
mouse model suggests it could be used as a therapeutic against UTIs in humans.  
Furthermore, pyridinones are already advantageous because they avoid severe 
drawbacks observed upon use of peptides as drugs such as poor absorption after oral 
administration, rapid enzymatic degradation and quick excretion (67).  This work 
identifies a compound that selectively disrupts protein-protein interactions with a strong 
potential for therapeutic effects on infection, which due to the ubiquitous nature of 
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The high prevalence of UTIs necessitates understanding of the molecular mechanisms 
associated with virulence and infection.  As described above, a multitude of work has 
been done to elucidate the pathway of infection within the bladder.  Discovery of the 
UPEC pathogenic pathway in a multitude of clinical isolates confirmed the relevancy of 
this pathway and its importance in persistence.  Furthermore, identification of hallmarks 
of the UPEC pathway in human urine confirmed that this is not an enigma of the murine 
urinary tract.  Now that it is clear that UPEC proceed through a surprisingly complex 
pathway consisting of extracellular and intracellular niches, one can evaluate each 
aspect of infection to determine if certain virulence factors are important to one or a 
multitude of components within the UPEC pathway.  For example, by examining binding 
and invasion, IBC formation, extracellular filaments and reservoir formation and knowing 
what enables their development, one can start to target these components to disrupt the 
UPEC pathway.  Based on this idea, an extrachromosomal element termed pUTI89 was 
examined to determine its role in the UPEC pathway.  pUTI89 has many characteristics 
of a PAI and was, in fact, shown to play a role in virulence.  The cjr operon on pUTI89 
was implicated in this role in UTI89 infection.  Based on the lack of extracellular 
filaments and gentamicin protection assays, it appears that Cjr proteins may enhance or 
facilitate extracellular survival.  Work is underway to understand the role of Cjr proteins 
and their expression profile.  While a new potential virulence factor, pUTI89, was 
discovered, it has long been know that type 1 pili are an essential virulence factor.  
Without these adhesive fibers, infection is severely depressed.  Thus, due to the 
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necessary function of type 1 pili in infection, they were targeted for development of 
therapeutics.  At the tip of the type 1 pilus is the FimH adhesin.  This molecule 
selectively binds mannosylated residues exposed by uroplakins that coat the surface of 
the bladder.  Due to the necessity of this interaction for binding and invasion and its 
essential role in IBC formation, exogenous carbohydrates were used to prevent binding.  
The rational development of the highest affinity mannose derivatives proved to be 
successful at reducing infection load in the bladder.  Additionally, understanding of the 
chaperone/usher system led to the rational design of 2-pyridone compounds termed 
pilicides.  Testing in vitro and in vivo revealed that these compounds can eliminate pilus 
expression and thus reduce bacterial infection.  Thus, the work described above has 
enhanced our understanding of UPEC infection which led to the development of 
therapeutics to inhibit type 1 pili and reduce infection in vivo.  Further work will continue 
to evaluate even more potent type 1 pili inhibitors.  New mannosides have been 
synthesized with much greater affinity for FimH relative to heptyl mannose and 
preliminary experiments have shown promising results at infection reduction.  
Additionally, once can imagine using a mannoside and a pilicide in synergy: the 
manoside preventing binding to uroplakins by occupying the FimH binding pocket while 
the pilicide enters the bacterial cell and prevents future pilus production thus eliminating 
adherence to urothelial cells and promoting clearance of the bacteria.  We are now 
beginning to deliver compounds to the mouse prior to or during infection to test efficacy 
in a more clinically relevant situation.  Ultimately, we hope that our knowledge of UTIs 
will lead to the severe reduction in prevalence of this disease.
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Figure 1. UPEC pathogenesis pathway.  UPEC utilize a multi-step pathogenic pathway in a 
murine cystitis model.  Upon introduction into the bladder, UPEC bind to the host urothelium via 
type 1 pili and an invasion event ensues.  UPEC escape into the facet cell cytoplasm and 
replicate to form loosely-packed early IBCs and ultimately tightly packed mid and late IBCs.  
Bacteria disperse from the IBC, many in filamentous morphology, bind to another host cell and 
can ultimately reenter this developmental pathway.  In addition, UPEC are able to form 
intracellular reservoirs within different layers of the urothelium that may lead to recurrent 















Figure 2. Type 1 pili interact with uroplakins on the bladder surface.  EM reveals piliated 
bacteria interacting with hexameric uroplakins on the surface of bladder tissue.  This interaction 
results in the subsequent invasion of the bacterium into the host cell.  The FimH adhesin on the 







Figure 3. UPEC type 1 pili encoded by the fim operon.  This schematic representation shows 
the UPEC fim operon.  FimB and FimE are regulatory recombinases controlling the expression of 
fimA-H.  FimA is the major subunit of type 1 pili and forms the helical rod.  FimC acts as a 
chaperone, stabilizing subunits prior to secretion through FimD, the outer membrane usher.  
FimF, FimG, and FimH form the distal tip fibrillum.  The adhesin FimH is composed of a pilin 
domain and an adhesin or receptor binding domain.  Figure adapted from (72). 
cally 1 to 2 !m long (13) but can vary from
a few fractions of a micrometer to greater
than 5 !m in length. It has been proposed that
some types of pili expressed by E. coli and
other species are able to retract (14). Thus, it
is possible that the shorter type 1 pili ob-
served in the electron micrographs are the
result of pilus retraction, which could poten-
tially pull the bacterium closer to the AUM
after attachment to host receptors. In addi-
tion, contact of type 1 pilus tips with the
AUM would potentially impede the growth
of any nascent pili (15), and this could also
account for some of the shortened pili ob-
served. Either hindrance of pilus growth or a
pilus retraction mechanism could result in a
buildup of unassembled pilin subunits in the
periplasm, a condition that is known to acti-
vate signal transduction cascades regulating
gene expression (16 ). This could provide a
means for the infecting bacteria to sense at-
tachment and facilitate their survival.
At higher magnifications, the hexagonal ar-
ray of uroplakin complexes embedded within
the AUM was distinguishable (Fig. 1, E and G).
FimH-containing tips were identified (Fig. 1E,
arrow) and often appeared to be buried among
the uroplakin complexes (Fig. 1G). Each hex-
agonal complex of uroplakins has a 3.7-nm-
wide central cavity that is proposed, on the
basis of cross-linking studies, to be lined by one
or the other of the putative FimH receptors
UP1a or UP1b (17). These cavities could con-
ceivably accommodate the 3-nm-wide adhesive
tips of type 1 pili during bacterial attachment. In
some cases, the AUM appeared to be “zipper-
ing” around and enveloping the attached bacte-
ria (Fig. 1F). Superficial bladder cells can in-
ternalize uropathogenic strains of E. coli (18),
and the image shown in Fig. 1F may represent
an initial step in this process.
One consequence of bacterial colonization
of the bladder is the exfoliation and excretion
of infected and damaged superficial cells (18,
19). This process of cell elimination is pro-
posed to be an innate host defense mecha-
nism of the urinary tract. Terminally differ-
entiated superficial cells have distinctive pen-
tagonal or hexagonal outlines and a charac-
teristic pattern of ridges on their apical
surface and are among the largest cells found
in mammals (Fig. 2A) (20). Two hours after
inoculation with NU14, the bladder epitheli-
um appeared mostly intact, with only a few
areas showing signs of exfoliation (Fig. 2B).
Six hours after NU14 inoculation, massive
exfoliation of the superficial cells had oc-
curred, exposing the underlying, less differ-
entiated urothelial cells (Fig. 2C). Occasion-
ally, regenerating host cells were seen ad-
vancing across ulcerated areas where the
basement membrane had been exposed as a
consequence of infection (Fig. 2D). Such ul-
cerated areas could also be detected at 12, 24,
and 48 hours after infection. However, at
these later time points, urothelial cells that
were more rounded and substantially smaller
than the terminally differentiated superficial
cells covered most of the lumenal surface of
the bladder (Fig. 2E). In many instances, the
small exposed cells appeared to be differen-
tiating, obtaining the outline, flattened pro-
file, and ridged surface pattern associated
with mature superficial cells (Fig. 2, E and F).
The recombinant strain AAEC185/pSH2
(type 1"), which is derived from a laboratory
K-12 strain MM294 (21), also caused mas-
sive exfoliation of urothelial cells within 6
hours after inoculation (11). In contrast to
NU14 and AAEC185/pSH2, the fimH# mu-
tants NU14-1 and AAEC185/pUT2002
caused no obvious alteration of the bladder
urothelium. In addition, AAEC185 express-
ing P pili (21), which are adhesive organelles
more closely associated with upper UTIs,
caused no exfoliation of the bladder epitheli-
um. These results indicate that bacterial at-
tachment mediated by the type 1 pilus FimH





Fig. 1. Type 1 pilus-mediated bacterial adherence to the bladder epithelium. Mouse bladders were
processed for (A and B) SEM (10) or for (C to H) high-resolution EM (12) at 2 hours after infection
with NU14. The boxed areas in (C) and (D) are shown magnified in (D) and (E), respectively. The
arrow in (E) indicates a FimH-containing tip. In (H), type 1 pili span from the host cell membrane
on the right to the bacterium on the left. Scale bars indicate 5 !m (A and B), 0.5 !m (C and F),
and 0.1 !m (D, E, G, and H).
Fig. 2. Progressive ex-
foliation and regenera-
tion of the urothelium
after FimH-mediated
bacterial attachment.
SEM images were taken
of the apical surface of
bladders at 48 hours af-
ter inoculation with
PBS (mock infected)
(A) and at 2 (B), 6 (C
and D), 12, 24, and 48
hours (E and F) after
inoculation with NU14
(8, 10). Scale bars, 50
!m.
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Figure 4. The FimH adhesin accommodates mannose in its binding pocket.  The receptor 
binding domain of FimH has a deep negatively charged pocket that binds mannose.  Outside the 
binding pocket are hydrophobic residues making up the hydrophobic ridge.  Positively charged 
residues shown in blue, negatively charged residues in red, and neutral and hydrophobic 
residues in white.  Adapted from (27). 
 
 
Figure 5. Chaperone/usher mediated pilus biogenesis as shown for the P pilus system. 
FimH (Martinez et al., 2000). Mice and primates vacci-
nated with the FimH adhesin are protected from infection
(Langermann et al., 1997). FimH binds to D-mannose and
mannotriose receptors, with the former being more highly
associated with cystitis isolates (Sokurenko et al., 1995;
1997; 1998; 2001). Attachment of uropathogenic E. coli
(UPEC) to the bladder epithelium is proposed to be medi-
ated by FimH binding to the uroplakins 1a and 1b (Wu
et al., 1996). These cellular receptors contain a single N-
linked carbohydrate of the high-mannose type, common
to most glycoproteins recognized by FimH. Several other
reported FimH receptors include Tamm–Horsfall protein
(Pak et al., 2001), CD48 (Baorto et al., 1997), laminin
(Kukkonen et al., 1993), collagen (Pouttu et al., 1999),
fibronectin (Schembri et al., 2000) and abiotic surfaces
(Pratt and Kolter, 1999). Based on inhibition studies, the
carbohydrate binding site of FimH has been suggested to
be an extended pocket with optimal fit for a trisaccharide
© 2002 Blackwell Science Ltd, Molecular Microbiology, 44, 903–915
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Fig. 1. Crystal structure of FimCH chaperone–adhesin complex bound to a-D-mannose.
A. Overall structure of FimCH with the two domains of the chaperone FimC (purple and pink), the pilin domain of FimH (yellow-green) that is
donor strand complemented by the chaperone (Choudhury et al., 1999) (arrow), and the receptor binding domain (green with blue helices,
secondary structure labelled as described earlier (Choudhury et al., 1999). The receptor-binding domain of FimH is an elongated 11-stranded
b-barrel comprising residues Phe1 to Thr158. The D-mannose (pink), the mannose-interacting residues (green) and the residues of the
hydrophobic ridge around the pocket (white) are shown in ball-and-stick model.
B. A 90° rotation towards the reader of the receptor binding domain shown in A.
C. Stereo presentation of omit electron density at 4s (F -Fc) for the a-d-mannoside bound in pocket of FimH. The interacting amino acids are
shown in ball-and-stick, hydrogen bonds are highlighted in purple.
D. The receptor binding domain of FimH displaying the electrostatic potential surface (Nicholls et al., 1991), with positively charged residues
shown in blue, negatively charged residues in red, and neutral and hydrophobic residues in white. The residues of the hydrophobic ridge
around the mannose-binding pocket are labelled.
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Abstract 
Nearly 50% of women experience at least one UTI in their lifetime.  Studies in mice have 
revealed that uropathogenic E. coli (UPEC) invade superficial umbrella cells that line the 
bladder, allowing them to find a safe haven and subvert clearance by innate host 
responses.  Rapid intracellular replication results in the formation of distinctive 
intracellular bacterial communities (IBCs).  In this study, we evaluated whether UPEC 
strains, cultured from the urine of women and classified as causing acute cystitis, 
recurrent cystitis, asymptomatic bacteriuria (ASB), or pyelonephritis, could progress 
through the IBC cascade in a well-characterized mouse model of cystitis.  Of 18 UPEC 
isolates collected from women, 15 formed IBCs.  Variations in the size, number, and 
kinetics of IBC formation were observed with strains isolated from women with different 
clinical syndromes.  Two of the three isolates that did not form IBCs when inoculated 
alone, were able to do so when co-inoculated with an isolate that was capable of 
generating IBCs.  The mixed infections dramatically altered the behavior of the co-
infecting bacteria relative to their behavior in a single infection.  The study also showed 
that mice with five different genetic backgrounds can support IBC formation.  Although 
UPEC differ genetically in their virulence factors, the majority of UPEC from different 
syndromes of UTI proceed through the IBC pathway confirming the universality of IBCs 




Urinary tract infections (UTIs) account for nearly 7 million office visits per year in 
the United States and cost $2 billion annually (4).  The majority of community acquired 
UTIs occur in women and are caused by uropathogenic Escherichia coli (UPEC) (7).  
Greater than 40% of women who experience acute cystitis develop recurrent UTIs 
(rUTIs) (12).  Uropathogens causing UTIs as well as asymptomatic bacteriuria (ASB) are 
generally thought to emanate from the distal gut, colonize the vagina, and ascend to the 
bladder via the urethra (4).  Likewise, acute pyelonephritis is assumed to be the result of 
an ascending infection from the bladder to the kidney.  However, this widely accepted 
paradigm does not adequately address questions raised by epidemiologic data.  Why 
does an initial UTI predispose a woman to an increased likelihood of a recurrent 
infection?  Why are up to 68% of rUTIs caused by E. coli identical to the original infecting 
strain (23)?  Why are recurrent uropathogens not more representative of the diversity of 
E. coli present within an individual’s gastrointestinal tract (2, 21)?  
Although it is believed that bladder infection in humans does not involve the 
bladder wall, previous studies of human bladders indicated a potential intracellular 
component of UTI (3).  Cultures of bladder biopsies taken from women with sterile urine 
cultures with various urinary tract symptoms revealed the presence of bacteria.  Studies 
in mice have revealed that bacterial invasion of the epithelium lining the bladder lumen 
(urothelium) is an essential component of lower UTI.   
In mice, adhesive bacterial fibers known as type 1 pili are necessary for invasion 
into the superficial umbrella cells of the urothelium (17, 18).  Entry into these host cells 
initiates a program that has been extensively characterized in mice using the human 
cystitis isolate UTI89 and that results in formation of intracellular bacterial communities 
(IBCs).  Early IBCs are seen within 6 hours of infection and consist of loosely packed 
rod-shaped bacteria (19).  Over the next 6 hours, they expand into tightly packed 
consortia of coccoid-shaped bacteria (mid IBC) (15).  Sixteen hours after infection, 
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bacteria detach from the late IBC, elongate into a filamentous form, escape from the 
host epithelial cell, and spread in the bladder to re-initiate the IBC cascade in other host 
superficial umbrella cells (15, 19).  Subsequent rounds of IBC formation allow E. coli to 
build up large populations within the bladder.  Interestingly, within 12 hours of infection, 
virtually all bacteria in the bladder are intracellular, implying that luminal bacteria are 
rapidly eliminated (18).  One consequence of bacterial invasion is establishment of a 
quiescent intracellular reservoir (QIR) in the bladder that can persist for months even in 
the face of antibiotic therapy (25).  In addition, bacteria in this QIR can revert to an active 
metabolic state that is initiated by unknown signals: rapid intracellular bacterial 
replication ensues, re-initiating additional rounds of IBC formation, inflammation, and 
spread of bacterial infection throughout the urinary tract (20).  This model argues that a 
portion of rUTIs in humans could be seeded from bacteria present in a QIR in the 
bladder.  
In this study, we investigated the ability of multiple clinical isolates to form IBCs in 
the mouse model.  We found that (i) the majority of UPEC isolates proceed through the 
IBC pathway; (ii) although isolates from women with ASB, acute UTI, rUTI, and 
pyelonephritis all form IBCs, IBCs from acute UTI isolates are significantly smaller; and 
(iii) isolates unable to from IBCs alone are able to do so in mixed infections where the 
second isolate was an IBC-competent strain.  Together, these results confirm that the 
ability to form IBCs is a common attribute of UPEC isolates.  
 
Materials and Methods 
Patients and strains.   
Clinical studies were approved by the University of Washington Institutional Review 
Board and written informed consent was obtained from all participants.   
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Five isolates causing ASB and four causing first-episode acute cystitis (acute 
UTI) were collected from women enrolled in a previously described study at the 
University of Washington (5).  Briefly, healthy women between 18 and 40 years old who 
were about to start or had started a new method of contraception and had no more than 
one UTI in the previous year were eligible for enrollment.  The study excluded a woman 
if she was pregnant, planned to become pregnant, had a chronic illness, had used 
systemic antimicrobial agents within 14 days, or had a known anatomical or functional 
abnormality of the urinary tract.  Enrollees were monitored for 6 months, during which 
time urine was collected at monthly clinic visits and whenever patients had symptoms 
suggestive of a UTI.  Asymptomatic bacteriuria was defined as >105 CFU of a 
uropathogen per milliliter of midstream urine documented in at least two separate 
cultures obtained at least 24 h apart.  A symptomatic, culture-confirmed episode of 
cystitis was defined as ≥102 CFU of a uropathogen per milliliter of midstream urine from 
a patient with dysuria, frequency, and/or urgency.   
 E. coli isolates from five women with recurrent cystitis were collected from 
another study of healthy women between 18 and 45 years of age who had acute cystitis 
and a history of at least one previous UTI in the past year, who were not pregnant and 
did not plan to become pregnant, and who had no chronic health problems (T. M. 
Hooton, unpublished data).  Approximately 110 women have been enrolled in this 
ongoing prospective study investigating the temporal associations between bacteriuria 
and clinical manifestations of recurrent UTI.  The women are being treated and then 
followed with daily urine cultures for 3 months, during which time they are seen in the 
clinic on a regular basis and whenever they have symptoms suggestive of a UTI.  rUTI 
isolates used in this study were the initial isolate from a women with same-strain 
recurrence.  ‘Same strain’ isolates were identified by chromosomal restriction fragment 
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length polymorphism (RFLP) analysis using pulsed-field gel electrophoresis (PFGE) 
(23).  
E. coli isolates collected from four women between 18 and 45 years old who had 
a clinical diagnosis of pyelonephritis were also included in our analysis (T. M. Hooton 
and W. E. Stamm, unpublished data).  Women were eligible for this study if they had 
fever, back pain and/or costovertebral angle tenderness (CVAT), and a positive urine 
culture, as defined above.   
 
Virulence factor PCR.   
Bacterial chromosomal DNA was isolated using the Wizard® genomic DNA purification 
kit (Promega) from each UPEC strain after growth overnight in Luria Broth (LB).  PCR 
reactions to detect virulence factors were performed as described in Johnson et al. (14).   
 
Western blotting for detecting PapA and FimH protein.   
For immunoblot analysis to detect PapA protein in the pyelonephritis isolates, bacteria 
were grown on tryptic soy agar (TSA) plates at 37oC for 36 hours, scraped, and 
suspended into 1 mL of PBS.  Resuspended cells were heated at 65oC to remove bound 
pili (9), and the supernatants containing pili were heated in SDS sample buffer (0.25 M 
Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 50 mM DTT, bromophenol blue), 4 M Urea at 
95oC and analyzed by SDS-PAGE followed by immunoblotting with antibodies to the P 
pilus (11). 
 For immunoblot analysis of FimH expression, bacteria were grown statically in LB 
at 37oC for 24 hours.  Equivalent numbers of cells (OD600 ~ 1.0) from each isolate were 
suspended in SDS sample buffer, 1 M HCl was added dropwise until pH indicator 
(bromophenol blue) turned yellow, and solution was heated at 95oC for 5 minutes.  The 
samples were then neutralized and analyzed by SDS-PAGE followed by immunoblotting 
 38 
with antibodies to FimH (raised in rabbits using purified FimH protein).  Specific FimH 
proteins were visualized on nitrocellulose membranes by BCIP/NBT Liquid Substrate 
System (Sigma), and analyzed for intensity using ImageJ software (rsb.info.nih.gov/ij/). 
 
Hemagglutination assays for detecting bacterial adhesins.   
Bacteria were grown statically in LB for 24 hours to induce expression of type 1 pili.  
Hemagglutination (HA) assays with guinea pig erythrocytes were performed using well-
established protocols (10, 26).  
 
Mouse strains and infections.   
All studies using mice were approved by the Animal Studies Committee of Washington 
University.  Eight-week-old female mice, belonging to the inbred C3H/HeN strain, were 
anesthetized and inoculated with a 50 ml suspension of ~107 CFUs of a given clinical 
isolate (in PBS) via transurethral catheterization (19).  Three, 6, 12, 16 and/or 24 h after 
inoculation, animals were euthanized, and their bladders harvested, divided in half, 
opened, and pinned on dissecting wax.  Bladders were washed three times with PBS to 
eliminate loosely associated bacteria not likely involved in infection.  The splayed 
bladders were then incubated for 20 min at room temperature with (i) wheat germ 
agglutinin (WGA) (Molecular Probes; 1:1000 in PBS) to stain their luminal surfaces and 
(ii) SYTO® 61 red (Molecular Probes; 1:1000 in PBS) to stain IBCs as well as host 
urothelial cell nuclei.  (Individual bacteria could be visualized in the densely packed 
IBCs, thus distinguishing them from the nuclei).  Trolox (10 µM: Fluka) was added to the 
splayed bladders to reduce photobleaching (24).  The total number of IBCs was scored 
by confocal microscopy (see below).  If all infections were not successful, 5 successfully 
infected mice were used for further evaluation.  The diameters of a maximum of 25 IBCs 
(5 IBCs/bladder/isolate [n = 5 bladders/isolate]) were measured across the width of each 
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IBC, averaged, and standard deviations calculated to estimate differences in the sizes of 
IBCs.  If less than 25 IBCs were observed for a given isolate, the total number of IBCs 
observed were used to calculate the average diameter and standard deviation.  If IBCs 
were not observed in all 5 bladders inoculated with a clinical isolate, more than 5 IBCs 
were measured per bladder containing IBCs to obtain 25 measurements.  After 
microscopy, bladders were homogenized in 1 mL of 0.025% Triton X-100-PBS and 
bacterial titers determined by plating serial dilutions of the homogenates on LB agar 
plates.  Standard gentamicin assays were done to define the number of intracellular 
bacteria in the bladder (19).   
For the single infections with the two laboratory strains, UTI89 and CFT073 were 
genetically engineered to express Green Fluorescent Protein (GFP).  Eight-week-old 
female mice belonging to inbred C3H/HeN, C3H/HeJ, C57BL/6J, CBA/J, and FVB/NJ 
strains were inoculated with UTI89-GFP and CFT073-GFP as above.  At 6 and 24 h 
after inoculation, bladders were harvested as above, however, the splayed bladders 
were fixed and visualized without additional staining due to GFP-expressing UTI89 and 
CFT073.   
 
Co-inoculation of clinical isolate and UTI89.   
Equal amounts of each clinical isolate and UTI89-gfp (cystitis strain engineered to 
express GFP) were mixed to obtain a 50 ml bacterial suspension of ~107 CFUs.  The 
suspension was then inoculated into C3H/HeN mice and infected bladders were 
harvested and visualized as above.  UTI89-gfp contains the kanamycin resistance 
cassette and thus is KanR, whereas the clinical isolate was KanS.  Serially diluted 
bladder homogenates were plated on LB agar plates and LB agar plates containing 
kanamycin (50 µg/ml) and grown overnight at 37oC.  The number of CFU of the clinical 
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isolate was determined by subtracting the number of the kanamycin-resistant UTI89 
from the total number of CFU on LB medium lacking kanamycin. 
 
Confocal scanning laser microscopy.   
Bladders were examined with a Zeiss LSM410 confocal laser scanning microscope 
under a 63X objective.  WGA and SYTO® 61 were excited at 488- and 633-nm, 
respectively.  In co-inoculation experiments using GFP-expressing UTI89 and a clinical 
isolate that did not form IBCs alone, GFP was excited at 488-nm, the clinical isolate was 
stained red by SYTO® 61, and wheat germ agglutinin was omitted. 
 
Statistical analysis.   
Observed differences in IBC diameter between isolates representing the four different 
types of UTI were analyzed for significance using the nonparametric Mann-Whitney U 
test (InStat; GraphPad Software).  
 
Results 
Virulence genotypes of the clinical isolates 
We studied 18 clinical isolates collected from women enrolled in the three 
different studies described above (Table 1).  To characterize the isolates, they were first 
analyzed in vitro for the presence of 29 putative virulence factors by multiplex PCR, as 
previously described (14).   The level of type 1 pili expression was then assessed with 
hemagglutination assays and an immunoblot using FimH antisera.  The isolates were 
then analyzed in a murine model to assess their ability to form IBCs within the bladder.   
UPEC virulence factors are typically involved in colonization and invasion of the 
host and evasion of the immune responses.  Each isolate had a unique combination of 
virulence factors and their prevalence was similar to a previous study analyzing 63 
 41 
UPEC isolates (13), suggesting our small sample size was representative of a larger, 
diverse UPEC group (Table 2).  The most prevalent virulence factors were fimH (100% 
of isolates), fyuA (yersiniabactin receptor; 80%), traT (serum-resistance; 70%), PAI 
(CFT073 pathogenicity-associated island marker for a series of genes that provide a 
mechanism for horizontal transfer of virulence factor genes; 70%), kpsMT II (group 2 
capsule; 70%), sfa/focDE (S/F1 fimbriae; 60%), and hlyA (hemolysin; 50%).  The 
presence or absence of individual virulence factors could not be correlated with a 
particular clinical syndrome.  
Surprisingly, none of the four pyelonephritis isolates had genes within the pap 
operon which encodes for the production of P pili.  Due to the absence of the pap 
operon, anti-P pilus antibodies failed to react with these isolates after growth on TSA, 
which typically induces P pili production (Figure 1). 
 
Type 1 pilus production in clinical isolates 
 Hemagglutination (HA) of guinea pig red blood cells (GPRBCs) was performed 
as previously described (10) to determine the degree of type 1 pilus production by each 
clinical isolate.  Type 1-mediated HA is specifically inhibited by the addition of 
exogenous mannose and this reaction is referred to as mannose sensitive 
hemagglutination (MSHA).   
For this study, bacteria were grown in static culture at 37oC for 24 hours to 
enhance type 1 production.  After 24 hours of static growth, UTI89, a prototypic cystitis 
reference strain shown to proceed through the IBC pathway, produced a MSHA titer of 
64 (values equal 2x where x equals the last well of agglutination).  Comparable MSHA 
titers were seen with the ASB isolates, which ranged from 32-128, suggesting a similar 
level of type 1 production as UTI89 (Table 2).  The first event UTI strains (acute UTI 
isolates) produced MSHA titers ranging from 16-64.  The rUTI isolates had HA titers 
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ranging from 2-8 that could not be entirely inhibited by addition of exogenous mannose.  
The persisting HA titers in the presence of mannose suggests expression of a mannose 
resistant (MR) adhesin system under these growth conditions.  The pyelonephritis 
isolates had MRHA titers ranging from 4-16.   
To further confirm the results seen with HA titer, anti-FimH antibodies were used 
in immunoblots to assess the relative levels of FimH in all of the strains after 24-h growth 
in static broth.  The intensity of each band was quantitated and expressed as a value 
relative to the amount of FimH expressed by UTI89, which was set at 100% (Table 2).  
MC4100, which does not produce type 1 pili, was used as a negative control.  The 
majority of isolates expressed type 1 pili at levels of 50%-99% of UTI89.  Only one 
isolate, ASB3, expressed type 1 pili at a level substantially higher then UTI89, 150%-
199%.  Strains acute1, rUTI1, and rUTI4 did not express detectable levels of type 1 pili, 
and acute3 and CFT073 expressed comparable levels of type 1 pili relative to UTI89 as 
determined by our immunoblot analysis.  These results suggest UPEC isolates from 
different clinical syndromes produce varying degrees of type 1 pili in vitro.  
 
IBC formation by UPEC isolated from women 
First the commonality of the IBC pathway in the face of differing host responses 
was evaluated.  To date the IBC pathway has been best described in the C3H/HeN and 
C3H/HeJ mouse strains with UPEC strains UTI89 and NU14 (1, 15, 18).  A previous 
study evaluated the level of infection and inflammation in different mouse genetic 
backgrounds, but did not examine the IBC pathway (8).  To determine if the cystitis and 
pyelonephritis isolates, UTI89 and CFT073 respectively, form IBCs in various host 
genetic backgrounds, three other strains of mice were infected, C57BL/6J, CBA/J, and 
FVB/NJ.  Mouse strains for use in this study were chosen based on their previous use as 
models for host responses to UPEC infection and/or identification of bacterial virulence 
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factors (16, 18, 27).  At 6 hours post infection, IBCs were detected in all mouse strains 
tested with both UPEC strains.  IBCs from C3H/HeJ (Figure 2D,I) and C3H/HeN (Figure 
2E, J) mice showed the expected IBC morphology inside superficial epithelial cells.  
Early IBCs were readily detected in C57BL/6J, CBA/J, and FVB/NJ (Figure 2A-C,F-H) 
that were visually indistinguishable from IBCs in C3H genetic background.  Occasionally, 
some IBCs in C57BL/6J mice had more loosely defined edges.  The presence of IBCs at 
six hours post infection in five mice strains after infection with UTI89 and CFT073 
suggests that the mechanisms utilized for invasion and intracellular replication in vivo 
are a conserved feature in these strains. 
Next, the commonality of IBC formation among different clinical isolates was 
evaluated.  Eighteen clinical isolates recovered from women enrolled in three different 
UTI studies (Table 1) were evaluated for their ability to form IBCs.  Each isolate was 
inoculated transurethrally into the bladders of young adult female C3H/HeN mice and the 
bladders harvested at 3, 6, 12, 16, and 24 h post infection (n=5 mice/time point/isolate) 
(Table 3 and Figure 3). 
 All five ASB isolates formed IBCs although the time course varied:  IBCs were 
observed 6 h and 24 h after inoculation of strains ASB1, ASB2, and ASB3 (Figure 3E, F) 
while IBCs were only observed at 6 h for ASB4 and at 24 h for ASB5.  This suggests that 
although IBC formation is common, the rate at which the isolates proceed through the 
pathway is potentially strain specific.  In UTI89, first round IBCs are observed at 6 h 
post-infection and second round IBCs are observed at 24 h post-infection despite 
asynchronous micturation among the mice.  Since IBCs were not observed at 24 h in 
ASB4, it is possible that the second round IBCs were either earlier or later and thus 
missed.  The fact that ASB5 only formed apparent IBCs 24 h post inoculation suggests 
that it either proceeds more slowly through the IBC pathway due to slow replication 
within the umbrella cells, or it invades the urothelium at later time points.  ASB5 
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produces a high MSHA titer (128) and FimH was detectable in the immunoblots (Table 
2).  These piliation characteristics strongly argue that the observed delay in IBC 
formation is not related to type 1 pilus expression of the inoculum.  The average 
diameter of ASB IBCs was 51 ± 20 µm (5 IBCs/bladder) which is the same as the 
prototypic isolate, UTI89, which has an average IBC diameter of 51 ± 9 µm at 6 h post 
infection.   
Three of the four acute UTI isolates formed IBCs at the time points examined.  
Again, there were isolate-specific differences in the time course.  IBCs were only 
observed at 3 h in acute3 (Figure 3B), 6 h in acute2, and 12 h in acute1 (data not 
shown) (n = 5 mice for each group).  IBCs in all acute UTI isolates were small with an 
average diameter of 20 ± 8 µm (p<0.01 compared to UTI89 and ASB isolates) and 
sparse (average 3/bladder compared to ~20-100/bladder with UTI89 and ASB isolates, n 
= 15 mice).  No IBCs were observed at any of the five time points surveyed for acute4.  
However, bacteria were visualized on the luminal surface of the bladder and quantitated 
by tissue titer to be greater than 102 CFUs/bladder throughout the time course.  With 
UTI89, by 12 h virtually all of the bacteria have entered an intracellular niche (19).  The 
ability of acute4 to persist extracellularly up to 24 hours emphasizes that different UTI 
strains may use alternative mechanisms to cause infection.  Although acute4 produces 
type 1 pili in vitro it is unable to form IBCs.  Thus, additional factors must be critical in 
IBC formation independent of type 1 piliation.  Acute4 is further analyzed in studies 
described below and in separate studies to investigate the mechanism by which it 
persists in the urinary tract. 
IBCs were observed for four of the five recurrent cystitis isolates.  IBCs were only 
observed at 3 h in rUTI5 (Figure 3A), 6 h in rUTI2 (Figure 3C) and rUTI3, and 24 h in 
strain rUTI4 (n = 5 mice for each group), again showing differences in the IBC pathway.   
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The diameter of the IBCs observed in all 4 isolates was 41 ± 14 µm, a value that is 
significantly greater compared to acute UTI strain IBCs (p<0.05) but not significantly 
different compared to UTI89 or the ASB strains (p=0.274).  Similar to strain acute4, 
rUTI1 bacteria were present in the bladders throughout the time course, as evidenced by 
tissue titers (103-104) but no IBCs were observed by microscopy.  However, in contrast 
to acute4, rUTI1 expressed little to no type 1 pili in vitro (Table 2) even though it contains 
the fimH gene.  The inability to produce type 1 pili in vitro could possibly explain the 
inability of rUTI1 to invade (see below) and form IBCs at the time points tested.  Whether 
type 1 pilus expression can be induced in vivo at later time points and lead to invasion 
and IBC formation is the subject of future studies. 
Of the four pyelonephritis isolates, three formed IBCs and did so by 6 h post-
inoculation (Figure 3D) suggesting similar kinetics in their IBC pathway (n = 5 mice in 
each group).  IBC diameter (55 ± 10 µm) was significantly larger than in acute UTI 
strains (p<0.01).  IBCs were not observed with pyelo3, and, similar to rUTI1, MSHA was 
not detected after growth in static broth in vitro (Table 2).  As seen with the two other 
strains unable to form IBCs, acute4 and rUTI1, pyelo3 was unable to invade into the 
superficial umbrella cells of the bladder (see below). 
 
Invasion defects in strains unable to form IBCs 
Since invasion is a prerequisite to IBC formation, we performed an in vivo 
gentamicin protection assay to assess whether any of the three isolates that did not form 
IBCs: acute4, rUTI1, and pyelo3, had invasion defects.  PCR demonstrated that the fimH 
gene was present in all three strains and HA assays revealed that acute4 produced type 
1 pili while rUTI1 and pyelo3 produced mannose-resistant fibers.  The ability of UPEC to 
invade is thought to be dependant on type 1 pili (17).  At 1 hour post infection bladders 
were removed, bisected, and incubated in gentamicin to kill extracellular bacteria.  
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Homogenates of the treated bladders were then cultured since intracellular bacteria 
have been shown to survive this treatment (19).  Bacterial titers revealed that the three 
non-IBC forming isolates were deficient in invasion compared to UTI89 (Figure 4).  4.4% 
of adherent UTI89 bacteria (defined as bacteria removed from the lumen after multiple 
washes) were able to invade the urothelium (defined as bacteria surviving the 
gentamicin treatment).   In contrast, the three isolates that did not form IBCs (acute4, 
rUTI1, and pyelo3) had invasion percentages of 0.3%, 0.5%, and 1.1%, respectively, 
thus potentially explaining their inability to form IBCs.   
 
Mixed infection model of UTI89 with non-IBC forming isolate 
Due to the complex nature of the intestinal, peri-anal, vaginal, and periurethral 
microbiota, it is likely that the initial inoculum in the human bladder is a mixture of 
bacterial strains.  We sought to investigate whether one isolate could improve the fitness 
or out-compete another isolate in the bladder.  Thus, we investigated the outcome of 
experiments where UTI89 was genetically engineered to express a readily detectable 
green fluorescent protein marker and then co-inoculated with each the three non-IBC-
forming clinical isolates in equal concentrations.  Although IBCs were not observed 
during single infection with acute4, when it was co-inoculated with UTI89, acute4 was 
able to participate in IBC formation, but only as a mixed IBC with UTI89-gfp IBCs (Figure 
5C, D).  When rUTI1 was co-infected with UTI89, rUTI1 formed IBCs at 24 h (Figure 5B) 
and caused UTI89 to form giant IBCs at 6 h (diameter = 130 ± 25 µm) (Figure 5A).  
Pyelo3 was unable to form IBCs in the presence or absence of UTI89 and even 
prevented IBC formation in UTI89.  In the UTI89/pyelo3 mixed infection, most of the 
extracellular (luminal) pyelo3 were filamentous and this same overwhelming 
filamentation phenotype was induced in UTI89 (Figure 5E, F).  Interestingly, although 
two of the three clinical isolates altered the behavior of UTI89, they were present in the 
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bladder in quantities 100-1000 fold less than UTI89 at each time point tested (n = 5 mice 
in each group).  Additionally, all three of the clinical isolates showed altered behavior in 
the presence of UTI89 relative to their behavior when inoculated individually.  Clinically, 
a UTI is often defined as bacteria in the urine in quantities greater than 105 and mixed 
infections with different UPEC strains would typically not be detected.   Thus, small 
amounts of a competing strain in the bladder could possibly have profound and distinct 
effects on the outcome of infection.  
 
Discussion 
The widely accepted paradigm of acute and recurrent infection is that both are 
due to the ascension of bacteria from the gut microbiota to the vagina and then the 
bladder.  In addition, UTIs have clinically been thought to be due to simple extracellular 
colonization of the urothelium by UPEC.   However, recently it has been shown in mice 
that UPEC invade the urothelium in order to subvert innate defenses (15, 17, 18).  
Likewise, intracellular bacteria have been demonstrated in the human bladder following 
UTI (3).  The discovery and characterization of intracellular bacterial communities (IBCs) 
in the murine model of cystitis has challenged the traditional clinical paradigm of UTIs 
and revealed a mechanism by which UPEC are able to build up in numbers in the 
bladder despite potent innate defenses.  The IBC pathway has been well characterized 
with the cystitis isolate, UTI89, in the C3H mouse model of cystitis.  In this study we 
have demonstrated that the IBC pathway is common to most UPEC strains isolated from 
humans with different UTI syndromes and in mice of different genetic backgrounds.   
We found, through multiplex PCR virulence factor assays, that the isolates 
chosen for this study were representative of a larger pool of UPEC isolates (13).  
Surprisingly, none of our pyelonephritis isolates contained any genes within the pap 
operon and thus did not express P pili.  The pap operon encodes for P pili containing a 
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distally located PapG adhesin that binds the globoside receptor in the human kidney 
which has been shown to be critical for the ability of pyelonephritic strains to colonize the 
kidney (22).  The four pyelonephritis strains in this study were obtained from patients 
that had classic symptoms of pyelonephritis, namely fever and CVAT (Table 1).  The 
absence of the pap operon in these strains is intriguing, but given the small sample size, 
further studies will need to be done to interpret the significance of this finding.  In 
contrast, all of the pyelonephritis isolates, as well as the ASB, acute UTI, and rUTI 
isolates, had the fimH gene.  However, expression of type 1 pili after growth in static LB 
broth differed among the strains.  Strains with varying levels of type 1 pili after in vitro 
growth were able to colonize the mouse bladder and form IBCs.  It is possible that the in 
vivo environment in the bladder altered the type 1 pilus expression profile after 
inoculation, thus partially explaining the ability of strains with various levels of type 1 pili 
to colonize and form IBCs within the bladder.  
In our mouse model of UTI, we demonstrated that 15 of 18 clinical isolates from 
various human clinical syndromes proceeded through the IBC pathway when inoculated 
as a single strain.  However, IBC formation differed among the strains in terms of the 
kinetics by which bacterial communities formed, the size of the communities, and the 
number of communities.  While isolates from each clinical syndrome formed IBCs, the 
acute UTI isolates formed significantly smaller and fewer IBCs relative to any other 
syndrome.  In general, ASB, rUTI, and pyelonephritis strains are associated with longer-
term persistence in the host.  The ASB, rUTI and pyelonephritis strains produced more 
IBCs/bladder and the IBCs were of increased size compared to acute UTI strains.  The 
differences in IBC behavior of the acute strains compared to the other three groups 
could potentially explain why the acute strains are less persistent.  
The behavior of the three outlying strains (rUTI1, acute4, and pyelo3) required 
more research to better understand their apparent deviations in IBC behavior with 
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respect to their group.  rUTI1, acute4, and pyelo3 were unable to efficiently invade into 
the superficial umbrella cells of the bladder and thus were unable to form IBCs.  Lack of 
IBC formation in the three isolates could not be associated with a specific virulence 
factor due to their differing virulence factor profiles.  Likely, there are a multitude of 
virulence factors contributing to IBC formation and perhaps some redundancy in the 
necessary factors.  rUTI1 did not produce any detectable levels of type 1 pili in vitro thus 
most likely explaining its inability to invade and form IBCs at the time points tested.  
Acute4 was able to produce type 1 pili in vitro at levels equivalent to or better than 
isolates able to form IBCs suggesting that type 1 pilus expression is not sufficient for IBC 
formation and implicates the importance of other factors in invasion.  Pyelo3 produced a 
small amount of type 1 as determined by immunoblotting with anti-FimH antisera.  No 
MSHA was detected in vitro possibly because of the presence of MRHA adhesins that 
would potentially mask type 1 mediated hemagglutination.  The deficiency of in vivo 
invasion of pyelo3 could suggest that either the MRHA adhesins somehow interfered 
with the process and/or that pyelo3 lacked other factors involved in invasion. 
Given the diverse microbial communities in the rectum and vagina (2, 21), it is 
likely that multiple strains of bacteria are simultaneously introduced into the urinary tract 
of a woman during the early events that lead to a UTI, such as sexual intercourse.  While 
mixed infections may select for bacteria with a distinct competitive advantage, they may 
also allow less virulent bacteria the opportunity to establish a niche in conjunction with 
more efficient UPEC strains.  Co-inoculation of UTI89, a known IBC forming strain, with 
each of the three isolates that were deficient in IBC formation, resulted in dramatic, 
synergistic effects.  Of the three isolates in which IBC formation was not detected, two 
were able to do so in mixed infections with UTI89 (rUTI1, acute4).  This may explain the 
seemingly outlying behavior of these strains when analyzed in single infections.  The 
diagnosis of UTIs rarely delineates whether multiple strains of E. coli are present.  Thus, 
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strains such as rUTI1 and acute4 could have “piggy-backed” with a more invasive IBC 
forming strain that went undetected.  UTI89 formed significantly larger IBCs in the 
presence of rUTI1.  This may be due to potential host responses induced by rUTI1 that 
facilitate bacterial replication in the superficial umbrella cells, or possibly that rUTI1 
induces signals that prevent or slow the dispersal and fluxing of the bacteria in the IBC.  
IBC formation is a clonal process in that each IBC arises from a single bacterium (P. C. 
Seed and S. J. Hultgren, submitted for publication).  Surprisingly, the mixed infection 
with acute4 and UTI89 resulted in non-clonal IBCs.  Acute4 only existed as a mixed IBC 
with UTI89.  The bacteria did not inter-mingle in the IBC but instead each strain seemed 
to group together in patches that melded into one IBC.  These results argue that UTI89 
was able to provide factors in trans that could support acute4 in the intracellular biofilm 
matrix. 
Pyelo3 was the only strain in our study unable to form IBCs under any of the 
conditions tested.  Co-inoculation of UTI89 and pyelo3 resulted in massive filamentation 
of both isolates.  Based on previous work showing that filamentation occurs in response 
to an inflammatory response (15), further study is required to assess whether pyelo3 is 
triggering a more robust innate response that leads to the massive filamentation 
observed.  The complexities we have observed with co-infections between the bacteria 
and with the host might explain the occurrence of different clinical syndromes manifested 
by the same organism (6) or the differing behavior in single versus mixed infections as 
described above.  Alternatively, it is possible that these isolates could represent a class 
of strains that do not use the IBC pathway but instead use a different extracellular 
strategy for persistence.  
In summary, 15 of 18 isolates causing different clinical syndromes in humans and 
possessing various combinations of virulence factors were successful in invading the 
bladder epithelium of mice to form IBCs.  Two of the remaining three isolates were also 
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able to form IBCs in mixed infections with UTI89.  These findings demonstrate that the 
IBC pathway is common to UPEC pathogenesis.  Studies are in progress to determine 
whether UPEC forms IBCs in humans and whether they contribute to same-strain 
recurrences of UTI.  The murine model of IBC formation will allow investigators the 
ability to study the intricacies of host-pathogen interactions in the bladder.  
Understanding the basis of the intracellular niche occupied by UPEC will lead to the 
better evaluation and treatment of UTIs and will foster the development of new 
therapeutic strategies.  
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Figure 1. Immunoblot of pyelonephritis isolates with antibodies against P pili.  P pilus 
antibodies were raised against J96 P pili, thus J96 and UTI89 were used as positive controls for P 
pili production.  Both isolates are positive for P pili due to a PapA-specific band at 16.5 K.  
However, the P pilus antibody did not recognize protein at 16.5 K for the four pyelonephritis 
isolates, confirming the lack of the pap operon seen with multiplex PCR.   Thus, pyelo1, pyelo2, 
pyelo3, and pyelo4 do not contain the genes nor produce protein associated with P pili which are 





Figure 2. UTI89 and CFT073 formed IBCs in multiple mouse strains.  UTI89 and CFT073, two 
commonly used UTI isolates, were inoculated into 5 different mouse strains.  At 6 h post-infection 
each strain of mice was able to support IBC formation by each UTI isolate.  (A-E) represents 






Figure 3. IBCs were formed by UPEC isolated from women.  Clinical isolates (red) were 
inoculated into C3H/HeN female mice and bladders were harvested at 3 h, 6 h, and 24 h.  Fifteen 
isolates produced IBCs at either (A,B) 3 hours, (C,D) 6 hours, or (E,F) 24 hours.  Each clinical 
syndrome is represented above.  The cell surface (green) was stained with WGA and in this 
cross-sectional view can be seen bordering the umbrella cells.  While the majority of isolates 




Figure 4. The three non-IBC forming isolates, rUTI1, acute4, and pyelo3, were deficient in 
invasion in vivo.  C3H/HeN female mice were inoculated with UTI89, rUTI1, acute4, and pyelo3.  
At 1 h post-infection bladders were removed and processed.  The Luminal fraction represents 
luminal bacteria and the Intracellular fraction represents invaded bacteria.  One hour after 
inoculation, 4.4% of UTI89 bacteria invaded whereas for rUTI1, acute4, and pyelo3 only 0.3%, 
0.5%, and 1.1% of luminal bacteria invaded, respectively.  Thus, the three non-IBC forming 




Figure 5. Co-infection with a clinical isolate and UTI89 altered the behavior of the bacteria.  
(A,B) rUTI1 (red) produced IBCs only when co-infected with UTI89 (green) and caused UTI89 to 
produce abnormally large IBCs (compare A to C).  (C,D) acute4 (red) formed mixed IBCs with 
UTI89 (green) which also formed normal IBCs.  (E,F) pyelo3 (red) formed large collections of 
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Abstract 
Urinary tract infections (UTIs) afflict nearly 60% of women within their lifetimes, the 
majority of which are caused by uropathogenic Escherichia coli (UPEC).  Studies in mice 
and humans have revealed that UPEC undergo an unexpectedly complex pathogenesis 
cycle involving both intracellular and extracellular niches.  Despite the commonality of 
the UPEC pathogenesis cycle, no specific urovirulence profile has been determined 
likely due to the fluid nature of the UPEC genome as the result of horizontal gene 
transfer and numerous genes of unknown function.  Horizontal gene transfer results in 
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the uptake of large pieces of DNA termed genomic islands (GIs).  If these GIs contain 
one or more virulence genes they are termed pathogenicity islands (PAIs).  PAIs can 
integrate into the chromosome or remain extrachromosomal as a plasmid.  UTI89 has a 
large extrachromosomal element termed pUTI89.  The pUTI89 plasmid has 
characteristics of both F plasmids and other known virulence plasmids.  This study 
sought to determine if pUTI89 is important for virulence.  Both in vitro and in vivo assays 
were used to examine the function of pUTI89 using plasmid-cured UTI89.  Based on 
growth, type 1 pilus expression and function and biofilm formation, there was no 
difference between UTI89 and plasmid-cured UTI89.  However, upon inoculation into the 
mouse model of UTI, there was a significant decrease in bacterial colonization of the 
pUTI89-cured strain at early timepoints post-infection.  This defect was confirmed using 
bacterial load quantification, gentamicin protection assays, confocal microscopy and IBC 
quantification.  Through directed deletions of specific operons on pUTI89, the cjr operon 
was partially implicated in this observed defect.  This work implicates pUTI89 in early 
aspects of infection. 
 
Introduction 
Urinary tract infections (UTIs) represent, by number, the most important bacterial 
infectious disease in highly industrialized countries (14).  Sixty-percent of all women will 
have at least one UTI within their lifetime (16, 46, 52).  This infection results in nearly 7 
million physicians office visits and $3.5 billion dollars annually in the United States alone 
(15).  It is thought that acute UTIs develop when bacteria from the fecal flora colonize 
the vaginal and periurethral mucosa and are subsequently introduced into the bladder by 
urethral ascension.  Women who present with an initial episode of acute UTI have a 25-
44% chance of developing a second and a 3% chance of experiencing three episodes 
within six months of the initial UTI (14). Recurrence occurs despite appropriate antibiotic 
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treatment and clearance of the initial infection from the urine. A large percentage of 
recurrent UTI (rUTI) are caused by the same strain of bacteria as the initial infection. 
One study followed 58 women and found that 68% of recurrences were caused by the 
same initial index strain of UPEC as determined by restriction fragment length 
polymorphism (RFLP) analysis (54). The high frequency of same-strain recurrences 
supports the notion that a UPEC reservoir may exist in the affected individual.  
Uropathogenic Escherichia coli (UPEC) is the leading causative agent of UTI, 
responsible for up to 85% of community-acquired UTI and 25% of nosocomial UTI (51).  
Using a well-characterized clinical UPEC isolate, UTI89, in a murine cystitis model, it has 
been demonstrated that the pathogenesis of UTI involves intracellular and extracellular 
components (27, 28, 38).  The bladder surface is covered with a urothelium composed of 
very large superficial umbrella cells which are coated with uroplakins that expose a 
terminal mannose moiety (64).  Type 1 pili and its adhesin, FimH, are required for 
attachment and invasion therefore playing a critical role in the infection process (38, 40, 
63).  The FimH protein has a negatively charged pocket that accommodates a mannose 
unit, namely those exposed by uroplakins on the bladder surface (23).  Once bound a 
signaling cascade is initiated resulting in bacterial internalization (37, 38).  Upon 
internalization, bacteria rapidly replicate within the umbrella cell forming tightly packed 
intracellular bacterial communities (IBCs) (1, 27).  These IBCs can be seen throughout 
the murine bladder and have biofilm-like properties.  Meanwhile, the host is attempting to 
eliminate infection by exfoliating the umbrella cells and sending an influx of neutrophils 
(40).  The bacteria combat these defenses by exiting the IBCs and filamenting (41).  The 
filamentous bacteria are resistant to engulfment by neutrophils and can go on to bind 
other umbrella cells, invade, and form second generation IBCs, perpetuating the 
infection (27).  Additionally, bacteria can invade the transitional epithelium beneath the 
umbrella cells, establish a quiescent intracellular reservoir (QIR) and remain dormant 
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until they reemerge and potentially cause a recurrence (42).  The IBC/QIR pathway 
could partially explain the often observed recurrent UTI with isolates identical to the 
primary infection ones (54).  Recent work has shown that this is a common pathway 
among UPEC isolates (17) and evidence of this pathway also has been observed in 
humans (53).   
Horizontal gene transfer is the movement of genetic material between bacteria 
independent of cell division.  It is essential to generating diversity between bacterial 
species and, through natural selection, contributes to the evolution of bacterial species 
(13, 31, 55).  In addition to genetic variability, newly acquired DNA can enable 
adaptation to life in a specialized niche through specific factors.  The acquisition of DNA 
by horizontal gene transfer results in the exchange of large regions of DNA called 
genomic islands (GIs) between bacteria.  GIs can be acquired in several ways; through 
inheritance of a plasmid that can remain autonomous or recombine into the 
chromosome, integration of a lysogenic phage into the chromosome, and insertion of a 
linear DNA fragment into the chromosome usually by transposition or recombination (12, 
34, 58).  Some GIs are referred to as pathogenicity islands (PAIs) if they contain large 
genomic DNA regions greater than 20 kb that carry at least one virulence gene, are 
inserted within or near tRNA genes, contain direct repeats and mobility sequences and 
can be identified by a differing G+C content relative to the host bacteria (19).  
Additionally, PAIs often do not represent homogeneous pieces of DNA but instead are 
mosaic-like structures generated by a multistep process involving genomic acquisition, 
loss and rearrangement (20).  Since UPEC PAIs are among the best understood, UPEC 
is considered the model system for analysis of the genome structure and composition of 
PAIs of pathogenic bacteria in general (6).  Study of UPEC PAIs has revealed that they 
encode adherence factors, toxins and iron uptake systems.  Interestingly, these same 
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virulence factors can be plasmid or phage encoded on intestinal E. coli isolates whereas 
in UPEC they are located chromosomally, i.e. alpha-hemolysin.  Thus, UPEC PAIs could 
represent former plasmid-derived sequences.  Additionally, UPEC PAIs carry many 
cryptic genes, open reading frames of unrelated and even unknown functions, 
pseudogenes and junk DNA sequences.  UPEC isolate, UTI89, carries a large 
extrachromosomal element with many characteristics of UPEC PAIs.  This plasmid, 
pUTI89, has a high proportion of pseudogenes generated by insertion events, open 
reading frames homologous to proteins of non-plasmid origin and orthologs of 
enteroinvasive E. coli (EIEC) proteins found on a large virulence plasmid (10).  These 
features describe a UPEC PAI that has potentially not yet incorporated into the genome, 
known as a ‘PAI precursor’ (32).  pUTI89 is approximately 114 kb and, like plasmid F, 
contains the tra operon for conjugative transfer as well as genes associated with plasmid 
replication and inheritance.   
While UPEC manifest disease in the urinary tract, they normally exist within the 
intestinal tract of humans.  Thus UPEC are distinct from the commensal E. coli residing 
in the GI tract in that they possess virulence factors enabling successful transition to and 
colonization of the urinary tract.  To date, the factors required for successful infection in 
addition to type 1 pili have yet to be fully elucidated (63).  While studies have 
demonstrated that additional adhesin systems, toxins, autotransporters and iron 
acquisition factors may be important in establishing infection, there is also an abundance 
of unknown genes labeled as hypothetical or assigned putative functions that may play a 
role in virulence (26).  This study questions whether pUTI89 is important in the virulence 
of UPEC.  Evidence of regions of pUTI89 are present in the majority of clinical isolates 
tested suggesting maintenance and transmission within the community and importance 
in some aspect of virulence.  Testing of in vitro and in vivo characteristics reveal that 
pUTI89 is involved in an early feature of in vivo infection, while not altering any of the 
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tested in vitro behavior.  A region on pUTI89 encoding the cjr operon found in EIEC may 
be involved in this early defect.   
 
Materials and Methods 
Bacterial strains.   
E. coli UTI89 is a cystitis-derived isolate of serotype O18:K1:H7 (41).  UTI89 was used 
for all assays within this study.  A panel of clinical isolates was used to identify the 
presence of pUTI89.  This panel has been previously described by Garofalo et al. (17). 
 
Plasmid purification and PCR to assay for pUTI89.   
Bacterial cultures from 18 clinical isolates and UTI89 were incubated overnight at 37oC 
under shaking conditions.  Cells were harvested at 6000 rpm for 10 min and 
resuspended in 25 mM Tris-HCl (pH 8.0), 50 mM EDTA.  After the addition of 0.2 M 
NaOH, cells were incubated on ice for 10 min followed by the addition of 5 M potassium 
acetate.  After a 5 min incubation, the solution was spun at 9000 rpm for 15 min.  
Isoproponal was then added to the supernatant and incubated at room temperature for 
20 min.  The solution was spun for 15 min at 3500 rpm at 4oC.  The pellet was air-dryed 
and resuspended in TE buffer.  After resuspension, 10 M NH4OAc was added and 
incubated on ice for 20 min.  The solution was spun, ethanol was added to the 
supernatant and incubated at -20oC for 20 min.  DNA was then precipitated, washed 
twice with 75% ethanol and resuspended in TE buffer.  RNA was eliminated by 
incubation with RNase A.  5 M NaCl and 30% PEG-6000 were added to the solution and 
incubated for 30 min on ice.  After centrifugation, the precipitate was resuspended in TE 
buffer and the DNA was extracted using phenol/chloroform.  DNA was precipitated with 
ethanol, washed twice with 75% ethanol and resuspended in TE buffer.  The purified 
plasmid DNA was then used for PCR analysis.  Using the sequence of pUTI89, primers 
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were designed to amplify regions around the plasmid.  These 8 primer pairs were named 
A-H (Table 1).  A primer pair amplifying ompA was used as a control for genomic 
contamination.  Standard PCR protocols were used.  PCR products were run on a 1% 
agarose gel and bands were detected by eithidium bromide staining.  A band migrating 
the correct distance represented a “+” for that region of pUTI89. 
 
pUTI89 curing.   
Using the phage lambda Red recombinase system (11), UP062 and UP063 encoding 
the stability operon were deleted from UTI89 to make UTI89/pUTI89/ΔUP062-63, 
creating a kanamycin-resistant UTI89.  This mutant of UTI89 was then cured of pUTI89 
by ethidium bromide treatment.  Curing was done essentially as described by 
Bastarrachea and Willetts (4).  Briefly, UTI89/pUTI89/ΔUP062-63 was grown overnight in 
LB + 50 µg/ml kanamycin.  Approximately 102 to 104 cells/ml of the overnight culture 
were inoculated into flasks containing LB + 10 fold dilutions of ethidium bromide 
beginning with 100 µg/ml down to 10 µg/ml and shaken at 37oC for 16 hours.  Using the 
highest concentration of ethidium bromide that sustained growth, the culture was diluted 
and plated on to LB agar plates and grown overnight at 37oC.  Single colonies were 
picked from the LB agar plate and patched on to LB agar plates containing 50 µg/ml 
kanamycin.  Colonies sensitive to kanamycin were grown overnight in LB and subjected 
to plasmid purification and PCR for pUTI89 as described above.  Cultures with no 
positive reactions in the PCR assay were considered to be cured of pUTI89. 
 
Growth curves.   
Standard growth curve assays were performed.  Bacteria were grown in LB at 37oC 
shaking overnight.  Cultures were diluted 1:1000 into either LB or M9 minimal media + 
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10 µg/ml niacin and 200 µl was inoculated into a 96 well plate in triplicate.  A microplate 
reader running the SoftmaxPro program was used to read at 37oC, every 20 min for 10 
hours with shaking at OD600.  Data from each read was averaged and graphed to obtain 
the growth curve. 
 
Immunoblot assay for FimH and FimA.    
 For immunoblot assays of FimH and FimA expression, bacteria were grown statically in 
LB at 37oC for 24 hours to obtain optimal type 1 pili expression.  Equivalent numbers of 
cells (OD600 = 1.0) from each isolate were suspended  in SDS sample buffer, 1 M HCl 
was added dropwise until a pH indicator (bromophenol blue) turned yellow, and solution 
was heated at 95oC for 5 min.  The samples were then neutralized and analyzed by 
SDS-polyacrylamide gel electrophoresis followed by immunoblotting with antibodies to 
either FimH or FimA (raised in rabbits using purified FimH or FimA protein, 
respecitively).  Specific FimH or FimA proteins were visualized on nitrocellulose 
membranes by using the BCIP/NBT liquid substrate system (Sigma) and analyzed for 
intensity using ImageJ software (http://rsb.info.nih.gov/ij/). 
 
Hemagglutination assay.   
Bacteria were grown 24h (as described in the immunoblot assay) to induce expression 
of type 1 pili.  Hemagglutination (HA) assays with guinea pig erythrocytes were 
performed using well-established protocols (22).  Briefly, equivalent numbers of cells 
(OD600 = 1.0) from each isolate were suspended in PBS or PBS + 2% mannose and 
added in 2-fold dilutions to V-bottom 96-well plates (Costar).  Guinea pig erythrocytes 
were cleaned, resuspended in PBS to an OD640 = 1.9 and added to the 96-well plate.  
The plate was incubated at 4oC overnight.  The HA titer was scored by the last well with 
visible agglutination.  An HA titer of 1 equals agglutination at a 1:2 dilution whereas an 
 71 
HA titer of 9 equals agglutination at a 1:512 dilution indicating a high level of type 1 pili 
function. 
 
Biofilm assay.   
Bacteria grown overnight in LB were diluted 1:1000 into LB, M9 minimal media + 10 
µg/ml niacin, or YESCA broth and added to 96-well PVC microtiter plates.  LB and M9 + 
10 µg/ml niacin biofilms were grown at room temperature for 48 hours and YESCA 
biofilms were grown at 30oC for 48 hours.  Plates were rinsed and stained with crystal 
violet and biofilms were quantified at OD600 after solubilization in 33% acetic acid as 
described (45).   
 
Mouse infections.   
All mouse infection studies were approved by the Animal Studies Committee of 
Washington University.  Eight-week-old C3H/HeN (NCI) female mice were anesthetized 
by inhalation of isoflurane and infected via transurethral catheterization with a 50-µl 
suspension of ~1 x 107 CFU of a given isolate.  Bacteria for inoculation were grown 24 
hours at 37oC statically.  At the indicated times post-infection, mice were sacrificed by 
cervical dislocation under anesthesia, and the bladders were immediately harvested and 
processed as described below. 
 
Tissue bacterial titer determination.   
To enumerate the bacteria present, bladders were aseptically harvested 6, 24, 48 h and 
1 and 2 wk post-infection, homogenized in PBS, serially diluted, and plated onto LB agar 
plates.  CFU was enumerated after 16 h of growth at 37oC. 
 
Gentamicin protection assay.  
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 To enumerate the bacteria present in the intracellular versus extracellular 
compartments, bladders were aseptically harvested at 1 and 6 h post-infection.  
Bladders were then bisected twice and washed 3 times in 500 µl PBS each.  The wash 
fractions were pooled, lightly spun at 500 rpm for 5 min to pellet exfoliated bladder cells, 
serially diluted and plated on LB agar to obtain the luminal fraction.  The bladders were 
treated with 100 µg/ml gentamicin for 90 min at 37oC.  After treatment, the bladders were 
washed twice with PBS to eliminate residual gentamicin, homogenized in 1 ml PBS, 
serially diluted and plated on LB agar to obtain the intracellular fraction.  CFU was 
enumerated after 16 h of growth at 37oC. 
 
Confocal scanning laser microscopy.   
To visualize bacterial behavior within the bladder, bladders were aseptically harvested at 
6 h post-infection.  Bladders were bisected and pinned open revelaing the luminal 
surface.  The splayed bladders were then incubated for 20 min at room temperature with 
(i) Alexa Fluor 488-conjugated wheat germ agglutinin (WGA) (1:1000 in PBS; Molecular 
Probes) to stain the bladder luminal surface and (ii) nucleic acid dye SYTO61 red 
(1:1000 in PBS; Molecular Probes) to stain bacteria and bladder epithelial cell nuclei.  
Trolox (10 µM; Fluka) was added to the splayed bladders to reduce photobleaching (56).  
Bladders were examined with a Zeiss LSM 510 Meta Laser Scanning inverted confocal 
microscope using a 63x oil immersion objective.  WGA and SYTO61 were excited at 488 
and 633 nm, respectively. 
Enumeration of IBCs.   
To accurately count the number of IBCs, bladders were aseptically harvested at 6 h 
post-infection, bisected, splayed on silicone plates and fixed in 2% paraformaldehyde.  
IBCs, readily discernable as punctate violet spots, were quantified by LacZ staining of 
whole bladders (29). 
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Results 
UTI89 contains a plasmid of unique characteristics.   
Many E. coli strains possess extra-chromosomal genetic elements carrying 
genes encoding for DNA transfer apparatus. These elements include the conjugative 
plasmids F and R100. Some other plasmids carried by pathogenic strains, such as 
pO157 in EHEC isolates, contain genes encoding for putative virulence factors such as 
toxins, type III secretion apparatus and adhesive organelles (8, 35). Many studies have 
demonstrated the involvement of these plasmids in EHEC pathogenesis (5, 30, 59, 60). 
UTI89 contains an epichromosomal genetic element of 114,230 nt (10).  This 
plasmid could be divided into two major portions based on their homology with other E. 
coli plasmids.  One half of the plasmid contains genes involved in plasmid replication 
and conjugative DNA transfer similar to those on Plasmid F, an archetypical conjugative 
plasmid.  A large number of ORFs on the other half of pUTI89 show homology (>70% at 
the amino acid level) to genes present on plasmids from pathogenic E. coli plasmids 
(Figure 1).  Three pUTI89 ORFs were identified to be orthologs of EIEC O164 cjrA, cjrB 
and cjrC genes.  In EIEC O164, these genes are found on the large virulence plasmid 
and encode proteins involved in uptake of colicin Js (57).  Expression of these genes 
appears to be regulated by both iron and temperature.  Similar to their orthologs in EIEC 
O164 plasmid, a putative iron regulation fur box was also located upstream of pUTI89 
cjrA (nt 21010-21028).  UTI89 CjrB is homologous to the TonB protein present in many 
gram-negative bacteria which is thought to be involved in energy transduction between 
the inner and outer membrane (49).  Likewise, UTI89 CjrC shows homology to putative 
outer membrane siderophore receptors.  Similar to the EIEC O164 large virulence 
plasmid, pUTI89 possesses the senB gene, encoding an enterotoxin, downstream of 
and partially overlapping the cjrC gene.  The senB gene was demonstrated to account 
for at least 50% enterotoxic activity of another EIEC strain, EI34 (44).   
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Six pUTI89 ORFs also showed high identity to those located on UTI89 
chromosome.  Four of these were either transposases or hypothetical proteins of 
unknown function.  Two other ORFs, UP042 and UP043, are homologous to genes 
predicted to posses transport functions at the membrane.  UP042 exhibited 100% amino 
acid identity to a gene encoding a component of a putative ABC transporter system that 
is also found in UPECs F11 and UMN026.  UP043 was 95% identical at the amino acid 
level to an outer membrane heme receptor encoded by the UTI89 chromosome.  Similar 
to their counterparts on the plasmid, the two homologs to UP042 and UP043 in UTI89 
genome (UTI89_C1129 and UTI89_C1130) were also adjacent to each other on the 
chromosome.  Two transposases adjacent to one another on the plasmid, UP040 and 
UP041, also had adjacent homologs (UTI89_C2257 and UTI89_C2258) on the 
chromosome.  However, while these two sets of ORFs were located near each other on 
the plasmid, their homologous sets were actually over 1 megabase apart on the 
chromosome.  It is unclear if these genes were acquired separately or as a result of a 
gene duplication event.   
Several ORFs within pUTI89 are homologous to sequences encoding proteins of 
non-plasmid origin in the database.  These were scsCD [S. typhimurium LT2]), nqrC 
(sodium-translocating NADH dehydrogenase (ubiquinone) gamma subunit [V. cholerae]) 
and iron transporters (putative membrane protein and putative periplasmic protein [Y. 
pestis]).  Acquisition of these genes likely occurred through evolution of the plasmid 
suggesting that pUTI89 is a hotspot for recombination and genetic exchange.  
Furthermore, many pseudogenes were present on the plasmid as the result of gene 
disruption by insertion and deletion (10).  The presence of homologs from pathogenic 
bacteria and the fluid nature of the plasmid genome argue that pUTI89 might play an 
important role in UTI pathogenesis.   
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pUTI89 in UPEC Clinical Isolates.   
We sought to determine if pUTI89 and/or its genes were common among UPEC 
isolates since strong selection to maintain the plasmid by human strains implies 
importance in pathogenesis.  We have previously reported on a panel of UPEC clinical 
isolates that proceed through the IBC pathway, however differ in time, size, and number 
of IBCs (17).  This panel of isolates encompasses all clinical syndromes of UTI to obtain 
a representative pool of strains from women with UTI.  Extrachromosomal DNA was 
purified from 18 clinical isolates and PCR amplification of 8 regions on pUTI89 was used 
to assess its presence in the clinical isolates (Table 2).  Of the 18 isolates, 4 (22%) had 
all 8 regions of pUTI89 suggesting the presence of the entire plasmid and 6 (33%) had 
no evidence of pUTI89.  Of the 12 isolates that had evidence of pUTI89 (67%), 100% of 
them had the region containing UP100 and UP101, both hypothetical proteins.  This 
would suggest that these proteins are an important characteristic of pUTI89 since it is 
most commonly maintained in human UPEC isolates.  Furthermore, the prevalence of 
pUTI89 regions within this panel of clinical isolates (67%) suggests its involvement in 
pathogenesis within the urinary tract.  Due to small amounts of genomic contamination in 
the plasmid preparation it is possible that the regions identified within the clinical isolates 
exist on the chromosome of the isolate rather than as an extrachromosomal element.  
However, that these regions are still maintained in the population is evidence of their 
importance. 
Deletion of pUTI89.   
Due to the unique characteristics of pUTI89, further study was required to 
elucidate its function.  We sought to eliminate pUTI89 from UTI89 and assess the 
behavior of the bacteria without the plasmid in vitro and in vivo.  Currently there are 
multiple ways to eliminate a plasmid from its host.  Traditional ways of curing involve 
intercalating dyes, DNA gyrase inhibitors, Rifampicin, and SDS.  More advanced ways 
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use transposon-based elimination (25) and SacB curing (24).  Unfortunately pUTI89 did 
not respond to any of the above methods and was not successfully eliminated from 
UTI89.  A new approach was taken based on the genes present on the plasmid.  pUTI89 
contains the stability (stb) locus which is involved in stable inheritance of the plasmid.  It 
is thought to be involved in the partition of plasmid molecules to daughter cells during 
cell division, which is essential for stable plasmid inheritance.  Mutations that inactivate 
stb function result in plasmid instability, so that plasmid-free cells are segregated at a 
rate consistent with random distribution of plasmid copies at cell division (39).  We took 
advantage of the requirement of these genes for stability to cure pUTI89.  First, the 
stability locus was deleted using the λ red recombinase system (11).  
UTI89/pUTI89ΔstbA/stbB was then subjected to curing by an intercalating dye, ethidium 
bromide.  At a concentration of 90 µg/mL ethidium bromide, the plasmid was eliminated 
from UTI89; this was confirmed by selective plating and PCR (Figure 2).  Thus, it 
required both gene manipulation and a traditional curing method to delete pUTI89 from 
UTI89. 
 
In vitro affect of pUTI89.   
Once pUTI89 was successfully eliminated from UTI89, we analyzed its effects on 
UTI89 in vitro.  In addition to the tra operon, there are several putative outer membrane 
proteins that may alter the proteinaceous make up of the bacterial membrane and a 
putative regulator that could have an effect on genes expressed under different 
environmental conditions.  Additionally there are many hypothetical proteins that could 
have an effect on growth rate, protein expression and biofilm formation.  Upon testing 
growth in both rich media (LB) and minimal media (M9 + 10 µg/mL niacin), both UTI89 
and ΔpUTI89 grew equally well, suggesting that, under these conditions, the plasmid is 
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not essential for bacterial growth (Figure 3A).  Type 1 pili are an essential virulence 
factor to UTI89 in vivo (63), thus it was very important to identify if expression of the fim 
operon was altered by removal of pUTI89.  An immunblot using anti-FimH and anti-FimA 
antisera showed no difference in expression levels of either protein in UTI89 versus 
ΔpUTI89 bacteria (Figure 3B).  Since expression does not necessarily confirm function, 
the pili were tested for their ability to agglutinate guinea pig red blood cells.  
Hemagglutination (HA) titers were analyzed in the presence and absence of mannose to 
confirm that agglutination was type 1 specific.  Both strains had equal mannose-resistant 
and mannose-sensitive HA titers suggesting that pUTI89 is not involved in type 1 pili 
expression and function (Figure 3D).  Previous work has shown that UTI89 within the 
bladder forms biofilm-like intracellular bacterial communities (IBCs) (1).  Thus, the ability 
of UTI89 and ΔpUTI89 to form biofilms in vitro was evaluated as an indicator of potential 
behavior in vivo.  Furthermore, F plasmids have been shown to promote biofilm 
formation in a K-12 genetic background (18).  In both rich media (LB) and minimal media 
(M9 + 10 µg/mL niacin), ΔpUTI89 behaved identical to wild-type UTI89 (Figure 3C).  
Additionally, it was recently discovered that different media conditions require different 
adhesive fibers for robust biofilm formation, so a second measure of biofilm formation 
was assayed to look for curli-dependent biofilms (Cegelski et al, submitted).  These 
biofilms are grown in YESCA media at 30oC.  Both strains had equivalent curli-
dependent biofilm formation (Figure 3C).  Taken together, these data suggest that UTI89 
and ΔpUTI89 are virtually indistinguishable in these aspects of comparative analysis in 
vitro. 
 
In vivo mouse infection.   
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Although UTI89 and ΔpUTI89 behaved identical in vitro, the loss of pUTI89 could 
have affected the virulence of UPEC in a way that was not measurable by the in vitro 
tests.  The in vivo pathogenesis was subsequently assessed in the UTI mouse model.  
In this infection model, UTI89 as well as multiple clinical isolates proceed through an IBC 
pathway (1, 17, 27).  C3H/HeN mice were inoculated with 107 of either UTI89 or 
ΔpUTI89 and bacterial burden was evaluated at different points during infection.  At 6 
hours post-infection the bacterial load of ΔpUTI89-infected bladders was significantly 
lower (p<0.0001) than UTI89-infected bladders (Figure 4A).  To confirm this observation 
and minimize the possibility that a secondary mutation contributed to the attenuation, 
additional clones of ΔpUTI89 constructed independently also showed a significant defect 
in titers at 6 hours post-infection (Figure 4B).  Nevertheless by 24 hours, ΔpUTI89 titers 
were comparable to UTI89 and remained that way through the entirety of the time 
course.  These data suggest that genes on pUTI89 may be involved in the early stages 
of infection but does not affect the overall outcome of infection.   
 
In vivo survival.   
Due to the significant defect during early infection of the ΔpUTI89 strain despite 
equivalent in vitro type 1 pili expression, we assessed the bacteria’s ability to bind to and 
invade the urothelium in vivo.  Bladders from 1 and 6 hour infected C3H/HeN mice were 
removed and both the intracellular and luminal populations were enumerated.  At both 1 
and 6 hours post-infection there were significant decreases in both binding and invasion 
of ΔpUTI89 relative to UTI89 (Figure 5).  These results suggest pUTI89 is potentially 
enhancing invasion, enhancing extracellular survival or aiding in immune evasion.  In 
order to confirm the phenotype observed in the gentamicin protection assay, we sought 
to visually demonstrate a diminished invasion or reduced extracellular colonization by 
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confocal microscopy.  At 6 hours post-infection, UTI89- or ΔpUTI89-infected bladders 
were removed, splayed and stained.  Although both strains form IBCs successfully 
(Figure 6), the ΔpUTI89-infected bladder had little to no observable extracellular bacteria 
and IBCs were less numerous than its wild-type-infected counterpart.  In addition, 
UTI89-infected bladders had numerous extracellular bacteria, many in filamentous 
morphology.  In an effort to more accurately enumerate IBCs, we performed LacZ 
staining on UTI89- and ΔpUTI89-infected bladders.  This quantification revealed a 
significant defect in the number of IBCs observed between the two isolates (Figure 6).  
These data are consistent with the results from the gentamicin protection assay and 
identifies pUTI89 as a potential mediator in invasion, extracellular survival or host 
evasion at the early stage of infection. 
 
Identification of virulence factors on pUTI89.   
Deletion of pUTI89 alters UTI89’s behavior in vivo.  In an attempt to decipher which 
region of pUTI89 is responsible for this observed phenotype, we eliminated small 
regions of the plasmid and examined their effects in the mouse UTI model.  Table 3 
specifies the gene, size and predicted function of the regions chosen for deletion.  Each 
of the constructed deletions was individually inoculated into the mouse and bacterial 
load was evaluated at 6 hours post-infection.  Of the 7 deletions made, 2 had a 
significant decrease on bacterial load relative to UTI89 at 6 hours post-infection (Figure 
7).  These mutants were ΔUP028-30 and ΔUP062-63.  ΔUP062-63 has a 1.4 kb region 
deleted encoding for the stbA and stbB genes of the stability operon.  These genes are 
involved in maintenance of the plasmid.  The reduction in bacterial titers upon deletion of 
stbA/B confirms the results observed with the ΔpUTI89 mutant (Figure 3); when pUTI89 
is not successfully maintained in vivo the bacterial infection is reduced.  ΔUP028-30 has 
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a 4.7 kb region deleted encoding for cjrB, cjrC and senB.  The cjr operon (for colicin Js 
receptor) encodes for proteins involved in colicin Js uptake as described above (57).  
The operon contains 3 proteins, however it was shown that only CjrB and CjrC are 
essential for colicin Js sensitivity.  This deletion, however, did not cause as much of a 
decrease in bacterial titers as does the loss of pUTI89 which suggests that other genes 
on pUTI89 may also be important during UTI pathogenesis.  With these deletion 
mutants, we have identified at least two regions on pUTI89 that are important for 
virulence.  This work shows that pUTI89 is used to acquire important virulence factors 
for the early stage of infection.  Further work will be required to understand the role of 
these operons in early infection.  Studies are currently underway to examine the 
expression patterns of the cjr and sen loci, and their impact on UTI pathogenesis. 
 
Discussion 
Virulence in Enterobacteriaceae is associated with the acquisition of large 
plasmids that confer distinguishing phenotypic pathogenic traits.  These virulence 
plasmids are generally low copy number, approximately 60 to 200-kb in size and similar 
to F plasmid or R100 plasmid (62).  Virulence plasmids of other pathogenic E. coli, 
enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC) and enteroaggregative 
E. coli (EAEC) are large F-like plasmids that encode different fimbrial adhesins that give 
characteristic modes of colonization of intestinal epithelia (43).  UPEC isolate, UTI89, 
carries a large F-like plasmid, pUTI89.  We attempted to find a role for pUTI89 as a 
virulence plasmid in the setting of urinary tract infections.  The model used to identify 
virulence focused heavily on the IBC pathway within the mouse, looking at interaction 
with bladder epithelia and intracellular and extracellular survival.   
Our studies of the in vitro effects of pUTI89 on UTI89 showed equivalent 
behavior in every aspect tested.  However, many of the genes on pUTI89 encode 
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hypothetical proteins that could be critical in establishing in vivo infection.  A similar 
phenomenon was seen with a Chlamydia trachomatis plasmid where there was no 
observable phenotype in vitro, however upon in vivo infection in the absence of the 
plasmid there was a significantly lower ID50 and lack of glycogen accumulation (9).  The 
defect was partially attributed to plasmid-dependent regulation of multiple chromosomal 
genes.  Plasmid control of chromosomally encoded genes is not a unique attribute 
among bacteria.  Yersinia pestis, EPEC and Bacillus anthracis all have plasmid-encoded 
loci controlling chromosomally encoded genes (3, 7, 48).  We observed similar altered 
regulation of chromosomal genes in the absence of pUTI89, however, the majority of 
these genes are hypothetical and will require further examination (data not shown), 
nonetheless suggesting that pUTI89 functions in trans to regulate the transcription of 
multiple chromosomal genes.  Genes on the chromosome were both positively and 
negatively regulated.  Thus, it is likely that there are multiple transcriptional regulators on 
pUTI89.  However, it is also possible that one regulator may function as both a repressor 
and an activator, as has been reported for some transcriptional regulators (47).  
Approximately 76 plasmid genes were differentially expressed in the absence of pUTI89 
implying their expression in wild type UTI89.  It is clear that all of these genes are not 
transcriptional regulators and may participate in in vivo infection. 
We have demonstrated that pUTI89 is involved in the early aspect of UPEC 
pathogenesis, such as binding, invasion or survival.  The reduction of luminal population 
at 6 hours post-infection as revealed by gentamicin protection assay and confocal 
microscopy (Figures 5-6) suggest the involvement of pUTI89 in extracellular survival 
during UPEC infection.  There may be more to pUTI89 than just extracellular survival 
since upon quantification of IBCs there was a significant reduction in the number 
observed at 6 hours post-infection.  Interestingly, while there is a reduction in IBC 
number there is still chronic-active infection at 2 weeks.  This would suggest that while 
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there are less IBCs the threshold of IBC formation has still been reached to enable 
UTI89 to establish a foothold within the bladder and carry out long term infections.   
Selective deletions of operons on pUTI89 revealed that the cjr operon may be 
playing a role in infection.  CjrC is homologous to a putative outer member siderophore 
receptor and a fur box is located upstream of this operon suggesting it is regulated by 
iron.  Iron is an essential cofactor of many enzymes and bacteria require iron 
concentrations at around 10-7 to 10-5 M to achieve optimal growth.  The level of free iron 
is estimated to be very low in the environment and biological fluids (10-18 M) (2).  Only 
bacteria that have strategies to acquire iron sequestered by the host can survive in 
specific niches and consequently cause infections.  Thus, iron acquisition for the survival 
of UPEC within the urinary tract is extremely important (50, 61, 65).  A recent study 
evaluating the genomic composition specific to UPEC identified that UPEC contain 3-5 
iron acquisition systems whereas fecal/commensal isolates contain 2-3 iron-related 
operons suggesting that the redundancy in these systems may provide a competitive 
advantage to UPEC within the urinary tract (33).  A more recent study comparing 
siderophore production between urinary and rectal isolates within individual patients 
revealed that while all strains produced enterobactin, strong preferential expression of 
yersiniabactin and salmochelin were observed among urinary strains (21).  Reigstad et 
al. showed that in the absence of chuA there is a significant decrease in IBC size but not 
an elimination of IBCs (50).  This result suggests that the redundancy of the iron 
acquisition systems allows alternate systems to compensate for the lack of chuA 
highlighting the importance of iron sequestration and transport within the urinary tract.  
This is why deletion of one system will not completely eliminate infection capabilities as 
seen with the deletion of the cjr operon.  Work is currently underway to complement and 
characterize this operon to understand its role in the early stage of infection.  Perhaps it 
is expressed early in infection whereas other iron acquisition systems are expressed 
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later, potentially explaining the delayed growth in vivo in the absence of the Cjr proteins 
until more systems are turned on. 
Strong selection for UTI89 to maintain pUTI89 provides a compelling argument 
for its importance in pathogenesis.  Large plasmids impose a significant metabolic 
burden on the bacteria and, in the absence of selection, may be lost from the host in 
spite of plasmid maintenance systems that are assumed to prevent loss (62).  pUTI89 
has two prominent features, the presence of the tra operon involved in DNA transfer and 
the presence of virulence genes found on other pathogenic plasmids, in other 
organisms.  Plasmid transfer via conjugation is an important mechanism for DNA 
exchange or dissemination and accelerates the evolution of bacterial pathotypes (19).  
The presence of the tra operon allows pUTI89 to be maintained and disseminated to 
other UPEC and Enterobacteriaceae.  In addition, the large virulence plasmid serves as 
a genetic hot spot where extrachromosomal DNA can be freely acquired without 
disrupting essential genes.  It is likely that free exchange of DNA between the symbiotic 
gut bacteria resulted in the diverse genomes seen in UPEC isolates.  The presence of 
the cjr operon on pUTI89 as well as on a virulence plasmid in EIEC supports the stated 
hypothesis.  The plasmid, pUTI89, serves as a genetic hotspot where virulence genes 
are acquired and lost without selection in the gut.  Only upon invasion and colonization 
of the bladder are genes, which increase fitness, selected for.  In the example of the cjr 
operon the fitness of the UTI89 was increased and thus selected for.  This is supported 
by nearly 50% of isolates tested showing presence of this operon.  This percentage is 
surprisingly high due to the redundancy in iron acquisition operons.  
The presence of pUTI89-like plasmids in UPEC strains could serve multiple 
roles, allowing for efficient incorporation of foreign DNA without disruption of essential 
genes.  Plasmid stability genes ensure newly acquired genes are replicated without the 
strong selective pressure of a bladder environment, while a functional tra operon allows 
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for conjugation and dissemination of these genes to other UPEC and 
Enterobacteriaceae.  All of these activities provide UPEC with a broad arsenal of 
proteins, some of which are necessary for colonization of the bladder.  Due to the lack of 
constant selective pressure, UPEC strains, early in evolution, devised multiple strategies 
for colonization of the bladder, resulting in the diverse genomes of UPEC strains seen 
today.  This process more than likely occurred slowly with virulence plasmids necessary 
for bladder survival being lost in the gut, and virulence genes incorporated in the 
genome resulting in genomic instability.  The acquisition of a large virulence plasmid with 
maintenance and stability machinery solved both of these problems.  Incorporation of 
extrachromosomal DNA did not disrupt essential cellular pathways and a stable plasmid 
allowed genes, which increased fitness in the bladder to be passed on in the bladder or 
gut.  This constant evolution has allowed UPEC to acquire multiple and redundant 
mechanisms to adapt and thrive in the urinary tract environment explaining why despite 
the well-studied nature of UPEC, especially in regards to virulence factors and 
colonization strategies, no single feature accurately defines an isolate as UPEC.  The 
difficulty of this was evident in a study that determined that half of all UPEC isolates 
contain none or only one of the urovirulence determinants to date (36).  Instead, UPEC 
contains a mosaic genome that is the result of genomic acquisition, loss and 
rearrangement.   
It remains unclear as to when, evolutionarily, pUTI89 was acquired, and to what 
extent it helped shape the landscape of the UTI89 genome by acting as a midway point 
for virulence genes incorporation into the genome.   We discovered that the presence of 
pUTI89 increases the ability of UTI89 to invade and colonize the bladder. Further 
investigations will examine how less virulent strains without pUTI89 are influenced by its 
addition. Examining a gain of function in less virulent strains could help elucidate at what 
stage(s) pUTI89 virulence genes function.  Additionally, characterizing plasmids and 
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genes from different UPEC will facilitate our understanding of the mechanism of 
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scsD CATACGCTGGACGGGGAAAC A-forward 143 +4384
GACGCTCTCCCCTTCCGACT A-reverse -4527
senB GCAGATTCGCGTTTTGAGCA B-forward 302 +25705
CGGATCTTTCAACGGGATGG B-reverse -26006
guaA CCCGTAGTGGGGGTGTTGAG C-forward 375 +49081
GCCCCTGCCACCTACCTTCT C-reverse -49456
transposase GCTTCGGGAACGCTGTAACG D-forward 414 +60645
AGAAGGCTGCGGTGCTGAAG D-reverse -61059
ycfA CGCCTGGTGGTGAAGGAAAG E-forward 236 +64115
GACCACCTCCCGCAGAACAC E-reverse -64351
UP100/UP101 TGGGGGCTGAAAACCAGAGA F-forward 531 +75326
ACCGAAGGCACGAACTGCAT F-reverse -75857
traU TTCCTTCTCGCCGGTCATGT G-forward 111 +89649
CCAGCGAGAGCGGGAAAATA G-reverse -89760
traI GCGATGCGGTCAGTGTTCTG H-forward 190 +106531
GGACAGCCGTTCATCCTGCT H-reverse -106721
1
GenBank accession no. - NC_007941
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Strain A B C D E F G H (hrs PI)
ASB1 - - - - - - - - 6,24
ASB2 + + + + + + + + 6,24
ASB3 + + + + + + + + 6,24
ASB4 + + + + + + + + 6
ASB5 - - - - - - - - 24(rare)
acute1 - - - - + + + - 12(rare)
acute2 - - - - - - - - 6 (rare)
acute3 - - - - - - - - 3(rare)
acute4 - - - - - - - - -
rUTI1 - - - - - - - - -
rUTI2 - - - - + + - - 6
rUTI3 - + - - + + - - 6(few)
rUTI4 + + + + + + + + 24
rUTI5 - + - - + + + + 3
pyelo1 - - + - + + - - 6
pyelo2 + + - + - + - - 6
pyelo3 - + - + + + + + -
pyelo4 - - - - + + + - 6
UTI89 + + + + + + + + 3,6,24
% 
prevalence
31.6 47.4 31.6 36.8 63.2 68.4 47.4 36.8
scsD secreted copper-sensitivity suppressor D
senB enterotoxin TieB protein
guaA hypothetical protein
transposase transposase for insertion sequence element IS21
ycfA hypothetical protein
UP100/101 hypothetical proteins
traU F pilus assembly protein
traI DNA helicase I
Gene 
Annotation
Size Gene Name Function




ABC transporter, ATP-binding 
protein, putative thioredoxin-
family protein
UP028-UP030 4.7 kb cjrB/C, senB
colicin Js sensitivity protein 




UP062-UP063 1.4 kb stbA/B
stable plasmid inheritance 
proteins
UP095 0.4 kb psiB regulator of SOS induction
UP145 0.2 kb hmo putative regulator
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Figure 1: pUTI89 diagram.  pUTI89 can be divided into two major portions.  One half 
contains genes involved in conjugative DNA transfer (in blue) and the other half contains 
genes present on plasmids from pathogenic E. coli and other pathogenic bacteria, as 
well as genes encoded chromosomally in other bacteria (in red).  Indicated next to each 







Figure 2: Confirmation of pUTI89 curing by PCR.  pUTI89 was cured from UTI89 by 
ethidium bromide treatment.  Plasmid purification followed by PCR with primer pairs A-H 
was used to identify plasmid-less strains.  UTI89 with intact pUTI89 (top panel) reveals a 
banding pattern as observed with very little genomic contamination as evidenced by the 
ompA band.  PCR of the plasmid-cured strain (bottom panel) revealed no positive PCR 





Figure 3: In vitro characteristics of pUTI89.  Plasmid-cured UTI89 behaved identically 
to UTI89.  (A) Growth of UTI89 and DpUTI89 were equivalent in LB broth (solid line) and 
M9 + 10 µg/ml niacin broth (dashed line).  (B) Type 1 expression based on FimH and 
FimA immunoblots was equivalent in both strains.  Densitometry analysis quantified the 
bands observed.  (C) Biofilm formation under type 1-dependent and curli-dependent 
conditions were indistinguishable in UTI89 versus ΔpUTI89.  (D) Both UTI89 and 
ΔpUTI89 exhibited equal mannose-sensitive HA titers, indicating equal expression levels 
and functionality of type 1 pili. 
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Figure 4: In vivo timecourse of UTI89 and ΔpUTI89.  (A) ΔpUTI89 tested in our mouse 
model of UTI revealed a significant decrease in bladder colonization at 6 h post-infection 
compared to wild type UIT89 (p<0.0001 by Mann Whitney).  However by 24 h post-
infection and beyond, colonization was equivalent in both strains.  (B) Additional clones 
of ΔpUTI89 confirmed that the defect was due to the loss of pUTI89 and not additional 
mutations within the genome. 
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Figure 5: Colonization and invasion of UTI89 versus ΔpUTI89.  One and 6 h 
gentamicin protection assays revealed a significant decrease in both the extracellular 
(luminal) and intracellular population for ΔpUTI89.  A more significant decrease in 





Figure 6: Confocal microscopy and LacZ staining for IBCs.  Mice were infected with 
UTI89 or ΔpUTI89 and bladder were harvest at 6 h post-infection, splayed and stained 
with WGA (green) and SYTO61 (red).  Confocal microscopy revealed IBC formation in 
bladder infected with either isolate.  However, extensive filamentation was only observed 
in wild-type UTI89.  IBCs were quantitated by LacZ staining revealing a significant defect 
in the number of IBCs observed in ΔpUTI89-infected bladders. 
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Figure 7: Identification of virulence factors on pUTI89.  Regions on pUTI89 were 
deleted using the lamda red recombinase system.  Deletions encompassing UP028-30 
and UP062-63 (open circles) resulted in a significant reduction in bacterial load at 6 h 
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Background. Escherichia coli strains adhere to the normally sterile human uroepithelium 
using type 1 pili, that are long, hairy surface organelles exposing a mannose-binding 
FimH adhesin at the tip. A small percentage of adhered bacteria can successfully invade 
bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia 
and α3β1 integrins found throughout the uroepithelium. Invaded bacteria replicate and 
mature into dense, biofilm-like inclusions in preparation of fluxing and of infection of 
neighboring cells, being the major cause of the troublesome recurrent urinary tract 
infections.  
Methodology/Principal Findings. We demonstrate that α-D-mannose based inhibitors of 
FimH not only block bacterial adhesion on uroepithelial cells but also antagonize 
invasion and biofilm formation. Heptyl α-D-mannose prevents binding of type 1-piliated 
E. coli to the human bladder cell line 5637 and reduces both adhesion and invasion of 
the UTI89 cystitis isolate instilled in mouse bladder via catheterization. Heptyl α-D-
mannose also specifically inhibited biofilm formation at micromolar concentrations. The 
structural basis of the great inhibitory potential of alkyl and aryl α-D-mannosides was 
elucidated in the crystal structure of the FimH receptor-binding domain in complex with 
oligomannose-3. FimH interacts with Manα1,3Manβ1,4GlcNAcβ1,4GlcNAc in an 
extended binding site. The interactions along the α1,3 glycosidic bond and the first β1,4 
linkage to the chitobiose unit are conserved with those of FimH with butyl α-D-mannose. 
The strong stacking of the central mannose with the aromatic ring of Tyr48 is congruent 
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with the high affinity found for synthetic inhibitors in which this mannose is substituted for 
by an aromatic group.  
Conclusions/Significance. The potential of ligand-based design of antagonists of urinary 
tract infections is ruled by the structural mimicry of natural epitopes and extends into 
blocking of bacterial invasion, intracellular growth and capacity to fluxing and of 
recurrence of the infection. 
 
Introduction 
 Pili and fimbriae on the bacterial cell are virulence factors that mediate 
adhesion of pathogenic bacteria to host cell receptors [1]. Urinary tract infections (UTIs) 
in humans are  frequently caused by uropathogenic Escherichia coli (UPEC) expressing 
type 1 pili. The FimH adhesin at the tip of type 1 pili recognizes terminal mannose units 
of uroplakin Ia (UPIa), a membrane glycoprotein that is abundantly expressed on 
superficial epithelial umbrella cells of the urinary tract [2]. Bacterial attachment 
stimulates the innate host immune system in a Toll-like receptor 4 - dependent manner 
[3]. This induces the secretion of cytokines by the urothelial cells and recruitment of 
neutrophils to the mucosal surfaces for the elimination of the bacteria [4]. A 
subpopulation of UPEC escapes this eradication mechanism of the host by invading into 
the large superficial epithelial cells in a type 1 pili-dependent mechanism [5,6]. However, 
hosts with a robust and timely innate immune response manage to get rid of this 
bacterial intracellular nesting by exfoliation of the large, superficial umbrella cells and 
discharge of these infected cells with the urine [7,8].  
 Bacteria within the cytosol of umbrella cells replicate and within hours develop 
into tightly packed, biofilm-like intracellular bacterial communities (IBCs) [9]. Upon 
maturation of the IBCs, the bacteria disperse from the IBCs and re-emerge in the 
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bladder lumen in long, filamentous shapes that helps them to evade neutrophil 
phagocytosis [10,11]. They can then reinvade neighbouring epithelial cells to re-
establish infection. As such, even after the acute infection is resolved, bacteria can 
remain within the bladder for many days to weeks, regardless of standard antibiotic 
treatments, and can be implicated in recurrent urinary tract infection (rUTI) [12–14]. Most 
UPEC isolates from women with acute or rUTIs, asymptomatic bacteriuria and 
pyelonepritis replicate in IBCs in C3H/HeN mice, although IBCs from isolates associated 
with acute UTIs remained significantly smaller [15]. UPEC that are unable to express 
type 1 pili are dramatically attenuated in their virulence, refrain from intracellular 
aggregation and maturation into an IBC and therefore fail to flux back out of the cells 
[16].  
 A different, intracellular path of the bacteria is commenced through the 
endocytosis in the fusiform or discoidal vesicles of superficial umbrella cells [17]. The 
bacteria make use of the vesicle trafficking in the umbrella cells to escape elimination 
during voiding. Endocytosis in the umbrella cells is coupled to exocytosis of secretory 
lysosomes [18]. Exocytosis helps to enlarge the apical membrane during bladder filling 
under hydrostatic pressure. High intracellular cAMP and calcium levels enhance 
exocytosis of the UPECs back into the lumen of the bladder [17]. It is unclear whether 
the bacteria are fit enough following their stay in the umbrella cell lysosomes to start 
another invasive cycle [19]. The uroepithelial cell layer underlying the umbrella cells can 
also be subject to invading bacteria, possibly upon the incomplete elimination of type 1 
piliated E. coli during exfoliation of the superficial, highly differentiated umbrella cells [8]. 
In those immature cells, the bacteria do not reside in the cytosol but rather are 
sequestered in late endosomes or lysosomes where they remain in a non-replicating 
state [20]. Those quiescent intracellular reservoirs (QIRs) persist for months even in the 
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face of antibiotics and the host defense, that mainly attack growing bacteria [8,12,13]. 
Only upon differentiation of the immature host cells and rearrangement of the 
cytoskeleton that tends to inhibit the intracellular replication, the QIRs resolve to develop 
intracellular inclusions similar to experimental IBCs [20]. Host cytokeratin intermediate 
filaments are closely associated with and probably help with biofilm formation within 
these pod-shaped inclusions [20].  
The attachment of adhesins on the bacterial cell surface to definite 
carbohydrates on the host tissue surface is considered to be an initial and critical step in 
pathogenesis. Antibodies that specifically block the binding of FimH to its natural 
receptor also prevent infection [21]. Revealing the interaction between FimH and its 
structural receptor would allow the design of carbohydrate-based anti-adhesives [22]. 
The preference of the fimbrial adhesin for structures found in mannosylated N-linked 
glycan chains on eukaryotic cell glycoproteins suggested that these structures would 
serve as the receptors for type 1-piliated E. coli strains [23,24]. The group of Sharon 
described in the early eighties the strong inhibitory potency of Manα1,3Manβ1,4GlcNAc 
on the agglutination of red blood cells and yeast cells and suggested that this 
trisaccharide would best fit the FimH binding pocket [25]. More recently, equilibrium 
dissociation constants (Kd) derived from surface plasmon resonance (SPR) solution 
affinity measurements or from the displacement of tritiated mannose from the receptor-
binding domain (RBD) of FimH, consistently approved the strong preference of FimH for 
oligomannosides exposing Manα1,3Man at the non-reducing end of the D1 arm of high-
mannose glycans [26]. Mannotriose and mannopentaose do not exhibit a significantly 
higher affinity than their linear moiety Manα1,3Man (Kd ~ 200 nM). Conversely, 
oligomannose-3 and oligomannose-5, carrying the β1,4-linked chitobiose as an anchor 
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to an asparagine in the Asn-X-Ser/Thr motif of N-linked glycoproteins, have another 10-
fold increase in affinity for the FimH RBD (Kd ~ 20 nM) over Manα1,3Man [26].  
Regardless of the well-characterized fine-specificity of FimH, FimH variant strains 
have also been categorized into those with a high affinity for D-mannose, predominantly 
represented by UPECs, versus fecal, commensal E. coli strains that only displayed an 
intermediate affinity for mannotriose (Manα1,6(Manα1,3)Man) [27]. These different 
bacterial binding characteristics under static binding conditions had been attributed to 
variation in the FimH RBD. Nonetheless, the isolated RBDs of all FimH variants, except 
for the enterohaemoraghic isolates carrying the Asn135Lys mutation in their pocket, do 
not differ in their affinities for high-mannose glycans [26,28]. Isolated RBDs or fimbrial tip 
adhesin that are out of the context of their own fimbriae have recently been suggested to 
always occur in a high-affinity conformation [29]. On the other hand, when present within 
their endogenous pilus, the adhesin can undergo a transition to the high-affinity 
conformation under shear force enhanced adhesion, and it is this phenomenom where 
amino acid variation in FimH can give rise to ten-fold differences in bacterial adhesion. 
Shear enhanced bacterial adhesion was most pronounced to layers coated with the 
weakly binding mannose than to a surface coated with the more specific mannotriose 
and involved a minimum of shear for the fecal FimH variant E. coli F18 strain [30]. 
However, no such shear threshold was observed for type 1-piliated E. coli binding to 
mannotriose or for a P-piliated pyelonephritis strain binding to Galα1,4Gal [31]. Thus 
changes in the receptor structure, that affect the fine-specificity of FimH, can more 
dramatically than FimH variation impact on the colonization behaviour of type 1-piliated 
bacteria under flow conditions. In this context, the relevance of a shear threshold 
observed for single-exposed mannose is feeble given that mannose, recognized by 
FimH at the termini of naturally occurring glycans, is almost invariably involved in a 
glycosidic linkage.  
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FimH has been reported to bind to several glycosylation-dependent receptors in 
the urinary tract, among which are uroplakin Ia (UPIa) [2], Tamm-Horsfall glycoprotein 
(THP) [32] and very recently β1 and α3 integrins [33]. Many pathogens gain entry into 
target host cells by binding integrins either directly or indirectly via the recognition of 
extracellular matrix proteins. UPIa is an integral membrane protein of the large 
superficial epithelial cells of the bladder located as a FimH receptor on the six inner 
domains of the uroepithelial plaque particle [34]. It belongs to the superfamily of 
tetraspanins [35] that are often found to complex with β1 integrin receptors [36]. Mouse 
UPIa4 presents high-mannose glycans on Asn169 with a heterogeneity ranging from 
Man6GlcNAc2 to Man9GlcNAc2 [37]. The same high-mannose type glycans decorate β1 
and α3 integrins [38]. None of these structures expose Manα1,3Manβ1,4GlcNAc, 
terminally at the non-reducing end of the glycan branch. Perhaps this is not so striking, 
as glycoproteins bearing Man5GlcNAc2 glycans are degraded preferentially [39]. The 
only isomer of oligomannose-6 encountered so far on uroplakins covers 
Manα1,3Manβ1,4GlcNAc with an extra α1,2-linked D-mannose [37], thus masking the 
epitope with high affinity for FimH [40]. THP is secreted in the urine as a natural inhibitor 
of type 1-mediated bacterial adhesion through its high-mannosylated Asn251 residue 
[41]. 
UTIs are one of the most prevalent infections for humans. Almost half of all 
women will experience at least one UTI in their lifetime. More problematic is the 
evolution of acute UTIs into chronic infections, with recurrence of the symptoms two or 
more times within months of a primary infection [42]. Modifications in the glycosylation of 
FimH receptor proteins on eukaryotic cells may alter the host sensitivity to UTI causing 
strains. For example, diabetic patients and elderly women show increased bladder cell 
binding by FimH [43] and this is further correlated with an increased frequency of 
 111 
asymptomatic bacteriuria [44]. Free Manα1,3Manβ1,4GlcNAc oligosaccharide can be 
isolated in abnormally high amounts from urine of patients with mannosidosis [45]. For 
mannosidosis patients the abundance of this high-affinity FimH epitope in the urine may 
act as a natural inhibitor for urinary tract infections, although a decreased risk of UTIs in 
patients with α-mannosidase deficiency has not been described. The high frequency of 
recurrent infections and the increasing antibiotic resistances of UPECs [46] highlight the 
need for alternative treatments using carbohydrate-derived molecules as potential anti-
adhesives. Their non-bactericidal effect makes the selection of strains resistant to such 
agents much more unlikely than those resistant to antibiotics [22].  
Biochemical and docking studies predicted that the enhanced binding of 
Manα1,3Manβ1,4GlcNAc is accomplished by interactions of the central mannose and 
GlcNAc in the tyrosine gate extending from the FimH mannose-binding pocket [26,47]. 
To gain insight into the selectivity of FimH for this trisaccharide epitope, we co-
crystallized FimH with the trisaccharide-presenting oligomannose-3 and investigated the 
importance of the glycosidic linkage of Manα1,3Man with N-acetyl glucosamine 
(GlcNAc) of the chitobiose unit of N-linked glycans. The FimH RBD shows high affinities 
for alkyl α-D-mannosides, with affinities up to a Kd of 5 nM for heptyl α-D-mannose (HM) 
[47]. We set out to explore the inhibitory capacity of HM for lower UTIs caused by type 1-
piliated UPECs in mice. We find that alkyl α-D-mannosides and other synthetic inhibitors 
of FimH confirm binding properties of the high-mannose epitope. The alkyl chain of butyl 
α-D-mannose, bound to FimH in two previously determined co-crystal structures, follows 
the trail of the α1,3 linkage to the central mannose and the first β1,4 glycosidic linkage to 
the chitobiose. The potential of ligand-based design of antagonists of UTIs appears to be 
ruled by structural mimicry of specific spots on mannosylated receptors. This anti-
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adhesive ability extends into blocking of bacterial invasion, intracellular growth and 
capacity to fluxing and recurrence of the infection.  
 
Materials and methods 
Sugar compounds 
Oligomannose-3 was custom-synthesized at the Zelinsky Institute of Organic 
Chemistry (Russia). Methyl α-D-mannose and D-mannose were purchased from Sigma-
Aldrich. Manα1,3ManβOMe (S. Oscarson, to be communicated) and HM [47] have been 
synthesized. Affinity measurements using surface plasmon resonance (SPR) were 
performed as described [26]. Briefly, the equilibrium dissociation constants of mannose 
derivatives for FimH were determined using competition in solution for FimH binding of 
the sugars with an immobilized Fab fragment from the monoclonal antibody 1C10. 
 
Purification of FimH 
The receptor-binding domain (RBD) of the FimH protein (residues 1 till 158 of 
UPEC J96) was expressed from plasmid pMMB91 transformed into E. coli C43 (DE3) 
cells. C43 (DE3) (pMMB91) E. coli cells were grown in minimal medium containing 40 
µg/ml of all the amino acids, 0.4% glucose, 2 µg/ml biotin, 2 µg/ml thiamine, 2 mM MgCl2 
and 25µg/ml kanamycin at 37°C. At OD600nm = 0,6 the bacteria cells were induced with 
1mM IPTG. After overnight incubation at 37°C, cells were collected and the periplasmic 
content was extracted. The receptor-binding domain of FimH was purified by dialysing it 
4h at 4°C against 20 mM Na formate pH 4 and loading it on a Mono S HR column 
(Pharmacia Biotech). The protein was eluted with 20 mM Na formate, 1M NaCl pH 4. 
Fractions containing the FimH receptor-binding domain were pooled and dialyzed 
overnight at 4°C against 20 mM Hepes pH 8 and 150 mM NaCl, before crystallization.  
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Co-crystallization of the FimH RBD with oligomannose-3 
Crystallization conditions were screened at the high-throughput crystallization 
facility of the EMBL in Hamburg. Crystals grew at 292K, using the vapor diffusion 
method with sitting drops composed of 300 nL FimH-oligomannose-3 solution FimH at 
13.6 mg/ml mixed with 2 mM oligomannose-3 in a 2:1 molar ratio and 300 nL precipitant 
(Figure S1), equilibrated against a 100 µl reservoir of 1.0 M lithium sulfate, 0.1 M Tris-
HCl at pH 8.5, 0.01 M nickel (II) chloride. To optimize these conditions, hanging drops 
were set up consisting of 1 µl FimH at 13.6 mg/ml mixed with 2 mM oligomannose-3 in a 
2:1 molar ratio and 1 µl of the precipitant solution, equilibrated against 500 µl of the 
same precipitant complemented with 3% glycerol. Glycerol has a beneficial effect on 
crystallization by preventing showering of the protein prior to nucleation, allowing a more 
controlled crystal nucleation and growth process.
 
Structure determination and refinement 
X-ray data have been collected to 2 Ǻ resolution at the European Molecular 
Biology Laboratory (EMBL) beam line X12 at the Deutsches Elektronen Synchrotron 
(DESY, Hamburg, Germany). The crystal was flash cooled to 100K in the precipitant 
solution complemented with 30% isopropanol. All data were processed with DENZO and 
SCALEPACK from the HKL suite [62]. TRUNCATE from the CCP4 suite was used to 
calculate structure-factor amplitudes from the intensities. The structure has been solved 
by molecular replacement with MolRep [63] using the structure of the receptor-binding 
domain of FimH as the search model (PDB entry code 1UWF) [47]. The model was 
refined using rigid body refinement and the maximum likelihood function of CNS version 
1.1 [64] and Refmac 5.2.0019 [65], with 5% of the data retained for cross-validation 
purposes. The initial molecular replacement solution was submitted to simulated 
annealing refinement. Successive positional and individual temperature factor 
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refinements were alternated with manual model adjustment using TURBO-FRODO [66] 
and COOT [67] graphics.  
 
Structure analysis 
 A Ramachandran plot was drawn using Molprobity [68]. Baverage from the CCP4 
suite [69] defined the average B-factors of the main chain atoms of the protein and of the 
water molecules. The packing contacts were analyzed using the CCP4 program 
CONTACT [69], using an intermolecular cut-off distance of 4 Å. Potential hydrogen 
bonds in the FimH-oligomannose-3 complex were identified using HBPLUS [70]. 
Subsequently, the predicted interactions were carefully checked with Coot [67]. Pictures 
have been generated using Pymol version 0.99.  
 
Bacterial binding in vitro to a human urothelial cell line 
The E. coli strains AAEC185(pUT2002)(pMMB66) and AAEC185(pUT2002) have 
been used in bladder cell binding experiments. AAEC185 E. coli cells are fim-null 
mutants [72]. The pUT2002 plasmid carries the complete fim gene cluster with the 
deletion of fimH, resulting in FimH-deficient type 1 pili [72]. The fimH gene of J96 E. coli is 
located on the pMMB66 plasmid [53]. Strains AAEC185(pUT2002) and 
AAEC185(pUT2002)(pMMB66) were grown statically in 100 ml LB for 48 hours at 37°C 
to induce pili production. The bacterial cells were harvested under sterile condition by 
centrifugation at 3500 rpm for 20 min (Megafuse 1.0R, Heraeus instruments) and 
washed two times in phosphate buffered saline (PBS). The expression of type 1 pili was 
always checked using haemagglutination [26] prior to the infection of the bladder cells. 
Human bladder epithelial cell line 5637 (American Type Culture Collection HTB-9) was 
seeded in 12-well plates and cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium, supplemented with 10% fetal calf serum (FCS). The cells were maintained 2-4 
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days at 37°C in a humidified atmosphere containing 5% CO2  for confluent growth. The 
plate was washed 5 times with PBS complemented with 0.5 mM MgCl2 and 1 mM CaCl2 
directly before use. Each well was incubated with 0.5 ml of 106 to 107 colony forming 
units (cfu) per ml in PBS. The plates were slowly shaken for 15 minutes to allow binding 
of the bacteria to the tissue cells. Five washes were performed with PBS to remove 
unbound bacteria. Bladder cells were lysed by adding 0.4 ml trypsin/EDTA for 10-15 
minutes. Finally, the lysis was stopped by the addition of 10% FCS, when all cells were 
released from the plate. The input colony forming units (cfu) and the output cfu in each 
well were determined by 10-fold serial dilutions (1, 10-2, 10-3, 10-4, 10-5) in PBS and 
spotting 20 µl drops on LB-agar with the appropriate antibiotics. Inhibition of bladder cell 
binding was performed simultaneously as binding on the same 12-well plate, but with the 
bacterial inoculum pre-incubated with different concentrations of mannose or HM. 
 
In vivo bladder binding 
All studies using mice were approved by the Animal Studies Committee of 
Washington University. Eight-week-old female C3H/HeN mice (NCI) were anesthetized 
and inoculated with a 50 µl suspension of ~107 UTI89 (in PBS or sugar solution) via 
transurethral catheterization [12]. Prior to inoculation, the inoculum was incubated for 20 
min at 37oC with one of the following: 1 M methyl α-D-mannose, 0.5 mM heptyl α-D-
mannose, 5 mM heptyl α-D-mannose. Six hours after inoculation, animals were 
euthanized, and their bladders harvested and homogenized in 1 mL of 0.025% Triton X-
100/PBS. Bacterial titers were determined by plating serial dilutions of the homogenates 
on LB agar plates. Duplicate experiments of 5 mice each were performed. 
 
Gentamicin protection assay 
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UTI89 was grown overnight in LB and resuspended in PBS to an inoculum of 
~107 cfu in 50µl.  The inoculum was then incubated for 20 min at 37oC with 5 mM methyl 
α-D-mannose, 0.5 mM heptyl α-D-mannose, 5 mM heptyl α-D-mannose, or PBS. After 
incubation, 6-7 week old C3H/HeN mice were inoculated via transurethral catheterization 
[12]. An ex vivo gentamicin protection assay was performed as previously described 
[11]. Briefly, at 1 hour post-infection, the mice were sacrificed and bladders were 
dissected aseptically. Each bladder was washed 3 times with sterile PBS. The washes 
were collected and plated to obtain the luminal fraction of bacteria. The bladders were 
then treated with 100 µg/ml gentamicin for 90 min at 37oC. After treatment, the 
supernatant was removed and titered to ensure efficient killing of extracellular bacteria. 
The bladders were washed twice more to remove residual gentamicin and homogenized 
in 1 mL 0.025% triton X-100/PBS and bacterial counts were determined by plating serial 
dilutions on LB agar plates. 
 
Biofilm assay 
UTI89 was grown overnight in LB broth at 37oC with shaking and diluted 1:1000 
in LB or LB with varying amounts of methyl α-D-mannose or heptyl α-D-mannose.  96-
well round bottom polyvinyl chloride plates (Falcon) were sterilized in tissue culture hood 
under UV irradiation for at least 30 minutes. 100 µl of the solutions were then added to 
the sterile PVC plate, 6 wells per variable. LB without bacteria was added to 6 wells as a 
blank. The plate was incubated for 48 hours at room temperature, washed 3 times in 
PBS and allowed to dry. 125 µl of 1% crystal violet solution was added to each well for 
10 minutes. After staining, the plates were washed again in PBS 3 times and allowed to 
dry. The crystal violet was solubilized with 150 µl of 33% acetic acid, 100 µl was 
transferred to a flat bottom plate and absorbance was read at 600 nm.   
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Protein Data Bank accession number 
The coordinates and the structure factors have been submitted to the Protein 
Data Bank with accession codes 2vco and r2vcosf respectively.  
 
Results 
The chitobiose anchor to Asn-glycosylated FimH receptors is important for specificity 
Previous epitope mapping on high-mannose glycan receptors revealed the 
highest affinity of the FimH RBD for oligomannose-3 and oligomannose-5 [26]. Both 
these oligomannosides expose Manα1,3Manβ1,4GlcNAc at the non-reducing end of the 
D1 branch and have an increased affinity for FimH over mannotriose and 
mannopentaose that lack the chitobiose unit (Figure 1). The increased affinity was 
thought to be due partially to the β-anomeric linkage to the chitobiose 
GlcNAcβ1,4GlcNAc. The binding constants of the FimH RBD from the J96 cystitis strain 
for Manα1,3ManβOMe and for the anomeric mixture of Manα1,3Man have been 
determined using SPR, to investigate the contribution of the glycosidic linkage. This 
resulted in affinities of Kd = 112 nM and 281 nM respectively, showing that FimH selects 
out the β-anomeric configuration on Man3. It also indicated that the presence of the β-
linkage alone is not sufficient to explain the more significant increase in affinity between 
on the one hand mannotriose or mannopentaose, and on the other hand oligomannose-
3 and oligomannose-5 [26]. Thus the chitobiose unit that bridges the mannosides to the 
asparagine in the Asn-X-Ser/Thr motif of the glycoprotein receptor contributes more 
significantly to the interaction with FimH.  
 
Crystal structure of the FimH receptor-binding domain in complex with oligomannose-3  
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Oligomannose-3 has been crystallized in complex with the FimH RBD. This 
oligosaccharide exposes the substructure Manα1,3Manβ1,4GlcNAc terminally on its D1 
branch (Figure 1). Therefore it is ideally suited to reveal the structural basis of its high-
affinity interaction with FimH. Initial crystals have been grown by equilibration through 
vapor diffusion and the crystallization condition was optimized through the addition of 3% 
glycerol (Figure S1).  
 The solution of the molecular replacement contains two FimH RBDs per 
asymmetric unit in the P3121 space group (Figure 2, Table S1). Upon the first atomic 
refinement a clearly interpretable electron density for Manα1,3Manβ1,4GlcNAc was 
visible, equally well in both RBDs. Refinement against the crystallographic data with a 
2.1 Å high-resolution cut-off led to good protein geometry and oligosaccharide 
conformation determination. The root mean square deviation between the two RBDs is 
0.56 Å for all main chain atoms. The torsion angles of the Manβ1,4GlcNAc and 
Manα1,3Man glycosidic bonds in oligomannose-3 resemble within a few degrees to 
those observed in the crystal structure of the Manα1,3Manβ1,4GlcNAc trisaccharide 
[48]. Although the ψ torsion angle of Manα1,3Man deviates from the average minimum 
energy modelled for these glycans for all distinct conformers of glycosidic linkages found 
in either N- or O-linked glycans [49], it falls well within the range of allowed minimum 
energy conformations for φ and ψ glycosidic torsion angles [50]. 
 Oligomannose-3 conforms into a relatively planar structure that inserts almost like 
a sheet into the tyrosine gate (Figures 2 and 3A), with an angle at both ends. The same 
extensive hydrogen bonding, hydrophobic contacts and van der Waals interactions are 
achieved by binding of oligomannose-3 in both FimH RBDs of the crystal structure 
(Figure 2). The solvent accessible surface area buried through the binding of 
oligomannose-3 leads to a reduction of solvent accessible surface area of 312.1 ± 1.3 Å2 
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for oligomannose-3 and 462.2 ± 6,6 Å2 for FimH both, using the CCP4 program 
NACCESS. Between the two crystallographically-independent FimH RBDs 537.5 ± 6.75 
Å2 is excluded from the solvent. This agrees well with the average areas excluded from 
the solvent by pairwise interactions (388.1 ± 3 Å2 between FimH and oligomannose-3 
and 534 Å2 between the two FimH RBDs) calculated by MSDpisa version v1.14 [51].  
 The non-reducing end Man4 anchors into the mannose-binding pocket, whereas 
the reducing end GlcNAc1 folds over Thr51. Very specific interactions with the tyrosine 
gate occur in the mannose-binding pocket itself and all along Manα1,3Manβ1,4GlcNAc 
via the α1,3 and the first β1,4 glycosidic linkages. FimH is not directly recognizing the 
second non-reducing end mannose, Man4’ (Figure 3). Man4’ and GlcNAc1, the two 
saccharides that exit from the receptor-binding site, display a larger flexibility in an 
extensively hydrated environment, resulting in less-well defined electron density and 
higher temperature factors. Crystal packing contacts with Phe142 and Ile13 of a 
symmetry-related RBD with Man4’ bound to the second RBD (forest-green molecule in 
Figure 2) stabilize some of these waters, whereas Man4’ bound to the first RBD is fully 
solvent exposed. 
For the first time in a FimH structure [47,52,53], a nickel ion was observed, 
interlinked with the mannose binding pocket by Asp47 (Figure 2). The nickel ion is 
ligated in an octahedral setting by the carboxylate group of Asp47, the imidazole group 
of His45 and four water molecules. Also unseen before in any FimH structure are two 
sulphate ions in a highly charged interface in the crystal packing (Figure 2).  
The non-reducing end Man4 of oligomannose-3 (Figure 1) is attracted to the deep, 
monomannose-binding polar pocket (Figure 3A, red) through a hydrophobic tyrosine 
gate (Figure 3A, blue) to make previously well-defined interactions [47,53]. Eleven 
hydrogen bonds are formed between the Man4 and the FimH residues Phe1, Asn46, 
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Asp47, Asp54, Gln133, Asn135 and Asp140 (Figure 4). A water molecule interacting 
with O2 of Man4 is a strongly conserved feature in the mannose binding pocket. The 
apolar B-face of Man4 provides interaction with Ile13 and Phe142, and its C5-C6 bond 
interacts with Ile52. Residues Tyr48, Ile52 and Tyr137 of the tyrosine gate are involved 
in several aromatic/hydrophobic and van der Waals contacts with oligomannose-3, thus 
stabilizing the glycan-lectin complex (Figures 3 and 4). Man3 hooks over the side chain 
of Ile52 while stacking its apolar B-face onto the Tyr48 aromatic side chain (Figures 3A-
C). A close apolar contact is achieved between C5 of GlcNAc2 and Tyr137. The C6-O6 
bond of GlcNAc2 fares well in a hydrophobic environment created by Tyr48 and Ile52 
(Figure 4). This could help to orient the strong (2.7 Å) hydrogen bond of the O6 hydroxyl 
on GlcNAc2 directly towards the hydroxyl of the Thr51 side chain (Figure 3D). This latter 
threonine interacts hydrophobically with the C7-C8 bond of the acetyl group of the 
reducing end GlcNAc1. GlcNAc1 intramolecular hydrogen bonds with GlcNAc2 and its 
N-acetyl group makes a van der Waals contact with the methyl group of the Thr51 side 
chain (Figure 3D). It can be seen that glycosidic linkage of GlcNAc1 via O1 to a 
glycoprotein would pull FimH very close to its receptor upon binding (Figure 3D).  
 
Parallels between the binding of oligomannose-3 and alkyl α-D-mannosides with FimH 
Butyl α-D-mannose is a high-affinity ligand for FimH (Kd = 150 nM) that was 
found serendipitously in two previous FimH crystal structures [47]. We compared the 
interaction interfaces between FimH and oligomannose-3 with those between FimH and 
butyl α-D-mannose. Superposing the mannose of the butyl α-D-mannosides onto Man4 
of oligomannose-3 and application of the transformation matrix to the whole molecules 
showed that the butyl chain follows the hydrophobic trail through the tyrosine gate by the 
Manα1,3Man and Manβ1,4GlcNAc linkages (Figure 5A). In contrast to the stable 
 121 
position of the mannose bound in the monosaccharide-binding pocket, the temperature 
factors of the ligand atoms gradually increase beyond the α1,3 position, both for 
oligomannose-3 and for butyl α-D-mannose.  
The side of oligomannose-3 that is not embraced by the tyrosine gate displays 
hydration of the exocyclic glycosidic oxygens (Figures 4 and 5A) that is maintained 
between oligomannose-3 and butyl α-D-mannose. The hydration on the α-anomeric 
oxygen of the mannose bound into the polar pocket is conserved, as well as its 
hydrogen bonding network with Asn138 and Asp140 (Figure 5B) that are residues in the 
loop connecting β-strands F and G (Figure 3). Also a water molecule hydrogen bonding 
to the exocyclic glycosidic oxygen linking Man3 to GlcNAc2 is maintained (Figures 5 and 
6B). It appears that synthetic inhibitors strive for the best mimic of the interactions of 
FimH with its natural receptor. Previous solution affinity measurements indicated that 
heptyl α-D-mannose is the best-binding alkyl α-D-mannoside (Kd = 5 nM) [47]. A 
simulation in which the butyl chain of butyl α-D-mannose was elongated to a heptyl 
allowed a conformation in which the elongated tail follows GlcNAc2 further along C4-C5-
C6, expecting to form the important interactions with Thr51, Ile52 and Tyr48. The anti-
adhesive proficiency with heptyl α-D-mannose was subsequently tested both on the 
human bladder cell line 5637 and in C3H/HeN mice.    
 
Mannose and heptyl α-D-mannose inhibit  in vitro adhesion of type 1-piliated E. coli  
Type 1 pili-expressing AAEC185(pUT2002)(pMMB66) E. coli cells at 106 cfu/ml 
were supplemented with a ten-fold dilution series of D-mannose (Man) or heptyl α-D-
mannose (HM) and incubated for adhesion on bladder cell line 5637. Increasing 
concentrations of Man or HM caused a significant reduction to complete inhibition of 
bacterial bladder cell binding (Figure 6). Adhesion could be completely inhibited by the 
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addition of 100 mM Man to the bacterial inoculum, or by a 100-fold lower concentration 
of HM. No inhibition was obtained with 100 µM Man, whereas 1 µM of HM still had some 
inhibitory effect. Similar data have been obtained with an inoculum of 107 cfu/ml. These 
results suggest that HM is more efficient at reducing FimH-mediated bacterial 
adherence, in accordance with its higher affinity for FimH.  
 
Heptyl α-D-mannose reduces bacterial levels in a murine cystitis model 
Extensive research has shown that type 1 pili and their adhesin, FimH, are 
essential for binding and invasion in the murine cystitis model [6,33,53]. It was 
hypothesized that blocking of the FimH binding pocket by preferential binding to a 
soluble mannose residue would reduce the binding to uroplakins on the epithelial cell 
surface of the bladder. This loss of binding would result in less invasion and ultimately a 
reduced infection. To test this hypothesis, bacteria were incubated in the presence of a 
derivative of mannose prior to inoculation into mouse bladders. Introductory to this 
experiment, the intrinsic toxicity of HM was assessed in Female BALB/c mice. HM was 
administered at 50 mM concentration through a catheter (50 µl), intranasal (20 µl) and 
intravenously (150 µl) to three mice each, but no acute toxicity has been observed. At 6 
hours post-infection, the bacteria present within the bladder were enumerated. Wild-type 
UTI89 incubated with PBS alone had a mean level of infection of ~3 x 105 cfu/mL (Figure 
7). Incubation of UTI89 with 0.5 mM of HM showed no significant decrease in infection. 
However, at a concentration of 5 mM HM, there was a significant decrease in infection at 
6 hours post-infection (p≤0.0001). Methyl α-D-mannose (MM) gave no decrease in 
bacterial numbers at the same concentration. A significant decrease in bacterial burden 
was only observed when increasing the concentration of MM to 1M (data not shown), a 
200 fold higher concentration then the one sufficient for HM. The tighter binding of HM to 
FimH, as compared to MM, could explain this difference. These results suggest that by 
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inhibiting the ability of FimH to bind to mannosylated uroplakins, the bacterial infection 
can be prevented.   
 
Heptyl α-D-mannose reduces intracellular bacterial levels 
Since there is a reduction in the amount of bacteria present in the bladder at 6 
hours post-infection with HM incubation (Figure 7), we wanted to assess the amount of 
bacteria that went intracellular. Mice were infected with UTI89 in PBS or in a MM or HM 
solution. At 1 hour post-infection, the luminal and intracellular bacterial loads were 
assessed. There was a significant decrease in the number of luminal bacteria bound to 
the uroepithelium when treated with 5 mM and 0.5 mM HM (p≤0.01) (Figure 8). This 
same decrease was not seen when using 5 mM MM. Relative to untreated UTI89, UTI89 
incubated with 5 mM HM had a significant decrease in intracellular population (p≤0.01). 
There was no significant decrease in invaded bacteria treated with 5 mM MM or 0.5 mM 
HM. These data indicate that HM is interfering not only with type 1 pili-mediated bacterial 
binding but also with type 1 pili-dependent invasion of UPEC.   
 
Heptyl α-D-mannose inhibits biofilm formation in vitro 
The development and maturation of IBCs into communities with biofilm-like 
properties has been shown recently to depend on type 1 pili [16]. We speculated that 
blocking the FimH binding pocket on type 1 pili would inhibit biofilm formation by 
inhibiting the adhesive properties of the pili. Bacterial biofilms were grown in the 
presence of varying concentrations of either HM or MM to elucidate their biofilm 
inhibiting properties (Figure 9). Biofilm of UTI89 E. coli was significantly reduced 
(p<0.01) only at the highest concentration of MM, 1 mM. However, in the presence of 
HM, there was a significant decrease in biofilm formation at 10 µM (p<0.001) and both 1 
mM and 100 µM concentrations (p<0.0001). This suggests that blocking of the type 1 pili 
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FimH adhesion with HM inhibits biofilm formation. Interestingly, at the lowest 
concentration of HM (1µM) there was a significant increase in biofilm formation 
(p<0.001). A low concentration of a weak inhibitor appears to allow the bacteria to 
organize into a better matrix through their type 1 pili [54]. 
 
Discussion  
Adhesion, invasion and the formation of intracellular biofilms 
UPEC express type 1 pili which bind to mannosylated residues on the surface of 
epithelial bladder cells. Once bound, some bacteria can invade the cells and rapidly 
replicate into intracellular bacterial communities, named IBCs, which mature into tightly 
packed biofilm-like societies [15,16]. As the infection proceeds, the bacteria filament and 
flux out of the cells [7,11]. They can then reinvade neighbouring cells to re-establish 
infection [14]. Inhibition of UPEC binding to bladder cells will potentially inhibit invasion 
and limit the bacteria’s ability to build up formidable numbers within the bladder. A 
competitive sugar could potentially disrupt the IBC pathway.  
Blocking bacterial invasion could reduce the infection and decrease recurrences. 
It had been demonstrated already from very early on by Sharon’s group that mannose 
can inhibit FimH-mediated bacterial adhesion [55]. We looked into the ability of heptyl α-
D-mannose (HM) to reduce infection, because HM has an optimized alkyl length for 
interaction with FimH [47]. Inhibition by soluble mannose (Man) or methyl α-D-mannose 
(MM) or HM of bacterial adhesion to the bladder cel line in vitro or upon transurethral 
catheterization into the mouse bladder indicates that the bacteria cannot switch between 
HM and the mannosylated uroplakins. Once HM is bound to FimH on the type 1 pili, the 
bacteria are irreversibly inhibited in their binding to the bladder surface and the infection 
is reduced. However, the weak inhibitor MM has a relatively high efficiency in the 
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bladder binding assay that is not in direct correlation with its affinity compared to HM. 
The affinity of MM for FimH is 500-times less than this of HM, but a concentration of MM 
a 100-fold higher than the inhibitory concentration of HM is sufficient. The explanation 
may be in the fact that the in vitro adhesion assay is being performed under shaking 
conditions. Nilsson studied the inhibitory effect of MM on binding of type 1-piliated E. coli 
to mannosylated surfaces under different shear stress conditions. During rolling, FimH 
molecules transiently bind and detach from surface receptors, allowing a weak soluble 
inhibitor such as MM to eventually bind to all FimH molecules, thereby preventing further 
adhesion [54,56]. In contrast, stationary adhesion is mediated by long-lived adhesin-
receptor bonds that prevent inhibitor binding during the time course of the experiments 
(~10 min). HM forms such high-affinity intractions with FimH, also under still conditions. 
The data on the inhibition by MM or HM of adhesion in the C3H/HeN mice indeed pledge 
that, for a free small-molecule ligand to be an efficient FimH anti-adhesive even under 
conditions of fluid flow, such as in the bladder, it must bind significantly tighter to FimH 
than the binding of FimH to the receptor molecules on the bladder cells, in order to 
overcome the shear-enhanced affinity. HM corresponds to these requirements, having 
an affinity for FimH higher than any known natural mannosylated receptor. In this context 
it is interesting to note that whereas human uroplakin UP1a and integrins only carry 
mannose receptors with intermediate affinity for FimH, the abundantly secreted urinary 
glycoprotein human THP displays 8% of the high-affinity oligomannose-5 receptors and 
75% of oligomannose-6 exposing Manα1,3Man on the D2 branch (Figure 1) [57]. 
IBCs are biofilm-like groups of bacteria that form upon adhesion, invasion and 
replication. Biofilm development requires tight interactions between individual cells in the 
community. Biofilm formation and maturation in UPEC IBCs is type 1-pili dependent [16] 
and the homotypic interactions between E. coli by means of type 1 pili are glycan 
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dependent [58]. Therefore, the ability to disrupt biofilm formation using MM or HM was 
evaluated. A significant decrease in biofilm formation was observed with as little as 10 
mM HM, a 100-fold lower concentration than was needed with MM. The only other data 
that exist on the inhibition of biofilm formation by a glycan are the inhibition of Gram-
positive and Gram-negative biofilms by a secreted group II capsule polysaccharide [59]. 
The concentration-dependent inhibition of biofilm formation by mannose glycans 
indicates that the FimH adhesin is involved in biofilm formation [58]. Another very 
interesting observation is the significant increase in biofilm with very low concentrations 
of MM (Figure 9). The presence of low concentrations of a soluble inhibitor such as MM 
during a longer period of time (hours) under conditions of low shear can sometimes help 
the bacteria to spread further and thus colonize larger surfaces [54]. The absence of 
shear and the presence of MM loosen the interactions between the adhering bacteria 
and the surface, allowing them to (re-)organize the biofilm. The extent to which the 
factors that are important for biofilm formation on abiotic surfaces (our assay) are also 
applicable for biofilm formation on biotic surfaces (e.g. in IBCs) needs to be further 
studied. However the observation of bacterial biofilm formation on abiotic surfaces is 
highly relevant in view of the use of medical implants such as urinary catheters. The 
glycan-based inhibition of UPEC biofilms is interesting in view of the thought that 
glycoproteins abundantly secreted in the urine, such as THP, could coat the catheter 
walls and serve as a glue for type 1-piliated E. coli to initiate biofilm growth.  
The IBCs, or the non-replicating bacteria in quiescent intracellular reservoirs 
(QIRs), form a repository that can seed a recurrent infection [12]. It was investigated 
whether the inhibition of binding and biofilm formation in vitro could also reduce this 
intracellular population during UTIs in a mouse model and thus the likelihood of a 
recurrence. In the presence of 5 mM HM a significant reduction in bacterial numbers in 
the bladders occurred. Two-hundred times more MM was needed to obtain the same 
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effect.  The results on inhibition with high concentrations of mannose were less 
consistent, perhaps because FimH can still switch between the mannose on the 
uroplakins and the mannose in the solution. If this switch happens in time, the bacteria 
are not urinated out. The adhesin is more tightly bound to HM, thus the bacteria are 
urinated out before being able to bind to the uroplakins. The tighter binding of the heptyl 
sugar is potentially reducing the number of UPEC able to bind and invade the bladder 
cells, and establish a robust infection. To confirm this, an ex vivo gentamicin protection 
assay was performed. This allows enumeration of both the extracellularly bound and 
intracellular bacteria. There was a significant reduction in both bound and invaded 
bacteria in the presence of 5 mM HM. In summary, HM is interfering not only with 
binding but also with invasion of UPEC. A 5 mM concentration of HM is needed for full 
inhibition of bacterial adhesion in vivo (Figures 7 and 8), versus a 1 mM concentration in 
vitro (Figure 6). In the mouse model, there is likely some loss of the sugar due to voiding 
or possibly degradation in the bladder. It is also not clear how the number and nature of 
mannose receptors in the mouse bladder relate to those on the human bladder cell line 
5637. Moreover in the mouse the innate immune responses has an influence on 
bacterial adhesion and invasion.  
What is clear is that the UTI89 cystitis strain binds HM, which deters binding to 
the bladder cells, limiting invasion, and reducing the level of infection. These data 
confirm that invasion in bladder cells is type 1-dependent [6], as was demonstrated by 
the non-invasive character of FimH mannose-binding pocket mutants [53]. Several 
possible invasion pathways for UPECs have been described. Direct binding of FimH to 
α3 and β1 integrins has been very recently observed and has been shown to depend 
upon the glycosylation of the integrins, because treatment of α3/β1 integrins with 
PNGaseF or EndoHf abolished all binding [33]. Bacterial invasion through glycan-
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mediated interactions of FimH with integrins could also happen indirectly via cellular 
receptors of differentiated bladder cells, such as CD151, CD46 and UPIa [36].  
 
Structure, specificity and drug design 
The type 1 pilus fimbrial adhesin FimH was co-crystallized with oligomannose-3 to study 
in detail the interactions with this most specific and natural glycan receptor for FimH. As 
expected, the tyrosine gate plays a dominant role in the strength and specificity of these 
interactions. A remarkable feature when analysing the PHI/PSI-chology of the FimH 
RBD main chain are the tyrosine residues of the tyrosine gate. Both Tyr48 and Tyr137 
and even Ile13 are on the borderline for allowed main chain conformations of the 
Ramachandran plot [60]. The higher affinity of mannopentaose over mannotriose is not 
reflected in the oligomannose-5 versus oligomannose-3 affinities [26]. The lack of an 
increased affinity of oligomannose-5 over oligomannose-3 indicates that the choice of 
FimH is in both cases directed straightforwardly towards the 
Manα1,3Manβ1,4GlcNAcβ1,4GlcNAc epitope at the non-reducing end of the D1 arm in 
both oligosaccharides (Figure 1). Further substitution on the α1,6 linked mannose 
(Man4’) would at least not hinder binding of oligomannose-5 via the same epitope, as 
Man4’ does not interact with FimH and extends into the solvent. 
The similarity of interactions found in the crystal structures of FimH with 
oligomannose-3 and butyl α-D-mannose is remarkably high. The butyl chain follows the 
hydrophobic trail through the tyrosine gate along the α1,3 and the first β1,4 glycosidic 
linkage to GlcNAc2 (Figure 5A). The same trail is conservedly hydrated near the 
presumable α1,3 and the first β1,4 exocyclic glycosidic linkages (Figure 5B). Finally and 
as expected, the extensive hydrogen network around the non-reducing mannose residue 
in the mannose-binding pocket of FimH is fully conserved [45].  
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Considerable interest exists in the molecular basis for FimH-mediated adhesion, 
being fed by long-standing observations that blocking the FimH-receptor interaction 
prevents bacterial infection [21,55]. Structural insight in the basis for specificity into the 
extended binding site of FimH was lacking until now, seriously hampering and 
invalidating structure-based design of anti-adhesive molecules using organic chemistry. 
Due to the great need for anti-adhesives to treat and prevent UTIs, the search was 
nevertheless continued. Dendrimers of mannose-based inhibitors were most often 
unable to act multivalently on E. coli, however the monovalent moiety of the best 
inhibitors among those dendrimers contain structures whose interactions can closely 
mimic those of oligomannose-3, such as glycocluster 4 in the recent study by Touaibia 
[61]. In these inhibitors, the α-anomeric oxygen of the non-reducing mannose is linked to 
a phenyl ring, containing an ethyn group in the para position and finalizing in a hydroxyl 
or ether function. A cocrystal structure for such a complex is unfortunately unknown, 
however it can be easily imagined that the mannose would anchor in the FimH polar 
pocket, the α-linkage to the phenyl group would resemble the Manα1,3Man linkage, and 
the phenyl group would ideally stack with the aromatic side chain of Tyr48. The phenyl to 
ethyn coupling would strengthen the van der Waals contacts that the Manβ1,4GlcNAc 
glycosidic linkage makes with Tyr137 (Figure 4). The triple-bond character of the ethyn 
could replace the stacking between the C4-C5 bond of GlcNAc2 and the aromatic ring of 
Tyr137 (Figure 4). Finally, the methoxy or methanol carbon atom would mimic the 
interaction of C6 of GlcNAc2 with Tyr48 and Ile52, and the terminal hydroxyl or ether 
oxygen may form a hydrogen bond with Thr51 (Figures 3D and 4).   
In conclusion, subnanomolar inhibitors precisely mimic the kind of interactions 
FimH makes with oligomannose-3, and do so in an enhanced fashion dependent on the 
chemical nature of the synthetic moieties engineered to replace all but the mannoside 
that enters the monosaccharide binding pocket. The knowledge of all specific 
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interactions between FimH and its natural high-mannose receptor and the possibility to 
relate the specificity- and affinity determining spots on the ligand with the efficiency of 
synthetic inhibitors can greatly enhance structure-based drug design against lower UTIs. 
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Figure  1. Oligomannose-3 as part of the high-mannose glycans.  Oligomannose-9 
(Kd ∼ 420 nM) is the full structure here displayed. Oligomannose-3 (blue, Kd ∼ 20 nM) is 
the substructure that was crystallized in complex with the FimH adhesin. It interacts with 
FimH as an extended tetrasaccharide, underlined with a red hatched line. 
Oligomannose-5 (Kd ∼ 12 nM) includes an extra mannotriose core over oligomannose-3 
through addition of ManA and ManB (fuchsia). Mannopentaose (Kd ∼ 120 nM) and 
mannotriose (Kd ∼ 200 nM) are boxed in fuchsia and blue frames respectively.  
UTIs are one of the most prevalent infections for humans.
Almost half of all women will experience at least one UTI in
their lifetime. More problematic is the evolution of acute UTIs
into chronic infections, with recurrence of the symptoms two or
more times within months of a primary infection [42].
Modifications in the glycosylation of FimH receptor proteins
on eukaryotic cells may alter the host sensitivity to UTI causing
strains. For example, diabetic patients and elderly women show
increased bladder cell binding by FimH [43] and this is further
correlated with an increased frequency of asymptomatic
bacteriuria [44]. Free Mana1,3Manb1,4GlcNAc oligosaccha-
ride can be isolated in abnormally high amounts from urine of
patients with mannosidosis [45]. For mannosidosis patients the
abundance of this high-affinity FimH epitope in the urine may
act as a natural inhibitor for urinary tract infections, although a
decreased risk of UTIs in patients with a-mannosidase
deficiency has not been described. The high frequency of
recurrent infections and the increasing antibiotic resistances of
UPECs [46] highlight the need for alternative treatments using
carbohydrate-derived molecules as potential anti-adhesives.
Their non-bactericidal effect makes the selection of strains
resistant to such agents much more unlikely than those resistant
to antibiotics [22].
Biochemical and docking studies predicted that the enhanced
binding ofMana1,3Manb1,4GlcNAc is accomplished by interactions
of the central mannose and GlcNAc in the tyrosine gate extending
from the FimHmannose-binding pocket [26,47]. To gain insight into
the selectivity of FimH for this trisaccharide epitope, we co-
crystallized FimH with the trisaccharide-presenting oligomannose-3
and investigated the importance of the glycosidic linkage of
Mana1,3Man with N-acetyl glucosamine (GlcNAc) of the chitobiose
unit of N-linked glycans. The FimH RBD shows high affinities for
alkyl a-D-mannosides, with affinities up to a Kd of 5 nM for heptyl a-
D-mannose (HM) [47]. We set out to explore the inhibitory capacity
of HM for lower UTIs caused by type 1-piliated UPECs in mice. We
find that alkyl a-D-mannosides and other synthetic inhibitors of FimH
confirm binding properties of the high-mannose epitope. The alkyl
chain of butyl a-D-mannose, bound to FimH in two previously
determined co-crystal structures, follows the trail of the a1,3 linkage
to the central mannose and the first b1,4 glycosidic linkage to the
chitobiose. The potential of ligand-based design of antagonists of
UTIs appears to be ruled by structural mimicry of specific spots on
mannosylated receptors. This anti-adhesive ability extends into
blocking of bacterial invasion, intracellular growth and capacity to
fluxing and recurrence of the infection.
Results
The chitobiose anchor to Asn-glycosylated FimH
receptors is important for specificity
Previous epitope mapping on high-mannose glycan receptors
revealed the highest affinity of the FimH RBD for oligoman-
nose-3 and oligomannose-5 [26]. Both these oligomannosides
expose Mana1,3Manb1,4GlcNAc at the non-reducing end of
the D1 branch and have an increased affinity for FimH over
mannotriose and mannopentaose that lack the chitobiose unit
(Figure 1). The increased affinity was thought to be due partially
to the b-anomeric linkage to the chitobiose GlcNAcb1,4Glc-
NAc. The binding constants of the FimH RBD from the J96
cystitis strain for Mana1,3ManbOMe and for the anomeric
mixture of Mana1,3Man have been determined using SPR, to
investigate the contribution of the glycosidic linkage. This
resulted in affinities of Kd = 112 nM and 281 nM respectively,
showing that FimH selects out the b-anomeric configuration on
Man3. It also indicated that the presence of the b-linkage alone
is not sufficient to explain the more significant increase in
affinity between on the one hand mannotriose or mannopen-
taose, and on the other hand oligomannose-3 and oligoman-
nose-5 [26]. Thus the chitobiose unit that bridges the manno-
sides to the asparagine in the Asn-X-Ser/Thr motif of the
glycoprotein receptor contributes more significantly to the
interaction with FimH.
Crystal structure of the FimH receptor-binding domain in
complex with oligomannose-3
Oligomannose-3 has been crystallized in complex with the
FimH RBD. This oligosaccharide exposes the substructure
Mana1,3Manb1,4GlcNAc terminally on its D1 branch (Figure 1).
Therefore it is ideally suited to reveal the structural basis of its
high-affinity interaction with FimH. Initial crystals have been
grown by equilibration through vapor diffusion and the crystal-
lization condition was optimized through the addition of 3%
glycerol (Figure S1) .
The solution of the molecular replacement contains two
FimH RBDs per asymmetric unit in the P3121 space group
(Figure 2, Table S1). Upon the first atomic refinement a clearly
interpretable electron density for Mana1,3Manb1,4GlcNAc was
visible, equally well in both RBDs. Refinement against the
crystallographic data with a 2.1 A˚ high-resolution cut-off led to
good protein geometry and oligosaccharide conformation
determination. The root mean square deviation between the
two RBDs is 0.56 A˚ for all main chain atoms. The torsion angles
of the Manb1,4GlcNAc and Mana1,3Man glycosidic bonds in
oligomannose-3 resemble within a few degrees to those observed
in the crystal structure of the Mana1,3Manb1,4GlcNAc
trisaccharide [48]. Although the y torsion angle of Mana1,3-
Man deviates from the average minimum energy modelled for
these glycans for all distinct conformers of glycosidic linkages
found in either N- or O-linked glycans [49], it falls well within
the range of allowed minimum energy conformations for w and
y glycosidic torsion angles [50].
Oligomannose-3 conforms into a relatively planar structure that
inserts almost like a sheet into the tyrosine gate (Figures 2 and 3A),
with an angle at both ends. The same extensive hydrogen bonding,
hydrophobic contacts and van der Waals interactions are achieved
by binding of oligomannose-3 in both FimH RBDs of the crystal
structure (Figure 2). The solvent accessible surface area buried
through the binding of oligomannose-3 leads to a reduction of
Figure 1. Oligomannose-3 as part of the high-mannose
glycans. Oligomannose-9 (Kd,420 nM) is the full structure here
displayed. Oligomannose-3 (blue, Kd,20 nM) is the substructure that
was crystallized in complex with the FimH adhesin. It interacts with
FimH as an extended tetrasaccharide, under ned with a red hatched
line. Oligomannose-5 (Kd,12 nM) includes an extra mannotriose core
over oligomannose-3 through addition of ManA and ManB (fuchsia).
Mannopentaose (Kd,120 nM) and mannotriose (Kd,200 nM) are
boxed in fuchsia and blue frames respectively.
doi:10.1371/journal.pone.0002040.g001
Structure-Based FimH Blockers
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e2040
 132 
 
Figure 2. Crystal structure of FimH in complex with oligomannose-3. The two FimH 
RBDs related by non-crystallographic symmetry (green and forest-green, Ig-fold 
labeling) both bind oligomannose-3 (only one is shown in blue cyan), interconnected via 
Asp47 to a nickel ion (green cyan). His45 and Asp47 and four waters ligate the nickel ion 
in an octahedral configuration. Sulphate ions (yellow with red oxygens) stabilize a highly 
charged crystal packing interface by bridging Val112 and Ser113 with Arg132 from the 
two crystallographically independent RBDs with Arg92 and Tyr55 from a symmetry-
related RBD.  
solvent accessible surface area of 312.161.3 A˚2 for oligomannose-
3 and 462.266,6 A˚2 for FimH both, using the CCP4 program
NACCESS. Between the two crystallographically-independent
FimH RBDs 537.566.75 A˚2 is excluded from the solvent. This
agrees well with the average areas excluded from the solvent by
pairwise interactions (388.163 A˚2 between FimH and oligoman-
nose-3 and 534 A˚2 between the two FimH RBDs) calculated by
MSDpisa version v1.14 [51].
The non-reducing end Man4 anchors into the mannose-
binding pocket, whereas the reducing end GlcNAc1 folds over
Thr51. Very specific interactions with the tyrosine gate occur in
the mannose-binding pocket itself and all along Mana1,3-
Manb1,4GlcNAc via the a1,3 and the first b1,4 glycosidic
linkages. FimH is not directly recognizing the second non-
reducing end mannose, Man4’ (Figure 3). Man4’ and GlcNAc1,
the two saccharides that exit from the receptor-binding site,
display a larger flexibility in an extensively hydrated environ-
ment, resulting in less-well defined electron density and higher
temperature factors. Crystal packing contacts with Phe142 and
Ile13 of a symmetry-related RBD with Man4’ bound to the
second RBD (forest-green molecule in Figure 2) stabilize some
of these waters, whereas Man4’ bound to the first RBD is fully
solvent exposed.
For the first time in a FimH structure [47,52,53], a nickel ion
was observed, interlinked with the mannose binding pocket by
Asp47 (Figure 2). The nickel ion is ligated in an octahedral setting
by the carboxylate group of Asp47, the imidazole group of His45
and four water molecules. Also unseen before in any FimH
structure are two sulphate ions in a highly charged interface in the
crystal packing (Figure 2).
The non-reducing end Man4 of oligomannose-3 (Figure 1) is
attracted to the deep, monomannose-binding polar pocket
(Figure 3A, red) through a hydrophobic tyrosine gate (Figure 3A,
blue) to make previously well-defined interactions [47,53]. Eleven
hydrogen bonds are formed between the Man4 and the FimH
residues Phe1, Asn46, Asp47, Asp54, Gln133, Asn135 and Asp140
(Figure 4). A water molecule interacting with O2 of Man4 is a
strongly conserved feature in the mannose binding pocket. The
apolar B-face of Man4 provides interaction with Ile13 and
Phe142, and its C5-C6 bond interacts with Ile52. Residues
Tyr48, Ile52 and Tyr137 of the tyrosine gate are involved in
several aromatic/hydrophobic and van der Waals contacts with
oligomannose-3, thus stabilizing the glycan-lectin complex
(Figures 3 and 4). Man3 hooks over the side chain of Ile52 while
stacking its apolar B-face onto the Tyr48 aromatic side chain
(Figures 3A–C). A close apolar contact is achieved between C5 of
GlcNAc2 and Tyr137. The C6-O6 bond of GlcNAc2 fares well in
a hydrophobic environment created by Tyr48 and Ile52 (Figure 4).
This could help to orient the strong (2.7 A˚) hydrogen bond of the
O6 hydroxyl on GlcNAc2 directly towards the hydroxyl of the
Thr51 side chain (Figure 3D). This latter threonine interacts
hydrophobically with the C7–C8 bond of the acetyl group of the
reducing end GlcNAc1. GlcNAc1 intramolecular hydrogen bonds
with GlcNAc2 and its N-acetyl group makes a van der Waals
contact with the methyl group of the Thr51 side chain (Figure 3D).
It can be seen that glycosidic linkage of GlcNAc1 via O1 to a
glycoprotein would pull FimH very close to its receptor upon
binding (Figure 3D).
Parallels between the binding of oligomannose-3 and
alkyl a-D-mannosides with FimH
Butyl a-D-mannose is a high-affinity ligand for FimH
(Kd= 150 nM) that was found serendipitously in two previous
FimH crystal structures [47]. We compared the interaction
interfaces between FimH and oligomannose-3 with those between
FimH and butyl a-D-mannose. Superposing the mannose of the
butyl a-D-mannosides onto Man4 of oligomannose-3 and
applicati n of the transformation matrix to the whole molecules
showed that the butyl chain follows the hydrophobic trail through
the tyrosine gate by the Mana1,3Man and Manb1,4GlcNAc
linkages (Figure 5A). In contrast to the stable position of the
mannose bound in the monosaccharide-binding pocket, the
temperature factors of the ligand atoms gradually increase beyond
the a1,3 position, both for oligomannose-3 and for butyl a-D-
mannose.
The side of oligomannose-3 that is not embraced by the tyrosine
gate displays hydration of the exocyclic glycosidic oxygens
(Figures 4 and 5A) that is maintained between oligomannose-3
and butyl a-D-mannose. The hydration on the a-anomeric oxygen
of the mannose bound into the polar pocket is conserved, as well as
its hydrogen bonding network with Asn138 and Asp140 (Figure 5B)
that are residues in the loop connecting b-strands F and G
(Figure 3). Also a water molecule hydrogen bonding to the
Figure 2. Crystal structure of FimH in complex with oligoman-
nose-3. The two FimH RBDs related by non-crystallographic symmetry
(green and forest-green, Ig-fold labeling) both bind oligomannose-3
(only one is shown in blue cyan), interconnected via Asp47 to a nickel
ion (green cyan). His45 and Asp47 and four waters ligate the nickel ion
in an octahedral configuration. Sulphate ions (yellow with red oxygens)
stabilize a highly charged crystal packing interface by bridging Val112
and Ser113 with Arg132 from the two crystallographically independent
RBDs with Arg92 and Tyr55 from a symmetry-related RBD.
doi:10.1371/journal.pone.0002040.g002
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Figure  3. Panel of FimH lectin domain interactions along the oligomannose-3 
chain. A, Electron density map, contoured at 1 e/Å³, for oligomannose-3 in the FimH 
receptor-binding site. The surface of the binding site is subdivided into its hydrophobic 
support platform (grey, residues Phe142, Phe1 and Ile13), its polar pocket (red, residues 
Asn46, Asp47, Asp54, Gln133, Asn135, Asn138 and Asp140), the tyrosine gate (blue, 
residues Tyr137, Ile52 and Tyr48) and residue Thr51 (green). B, Aromatic-to-saccharide 
stacking (green dashed lines) of the Tyr48 side chain onto the B-face of Man3. C, van 
der Waals support of the β1,4 linkage (yellow dashed lines) and an hydrophobic contact 
of C5 of GlcNAc2 by Tyr137 (green dashed lines). D, Thr51 tops of the site by 
exocyclic glycosidic oxygen linking Man3 to GlcNAc2 is
maintained (Figures 5 and 6B). It appears that synthetic
inhibitors strive for the best mimic of the interactions of FimH
with its natural receptor. Previous solution affinity measure-
ments indicated that heptyl a-D-mannose is the best-binding
alkyl a-D-mannoside (Kd = 5 nM) [47]. A simulation in which
the butyl chain of butyl a-D-mannose was elongated to a heptyl
allowed a conformation in which the elongated tail follows
GlcNAc2 further along C4-C5-C6, expecting to form the
important interactions with Thr51, Ile52 and Tyr48. The
anti-adhesive proficiency with heptyl a-D-mannose was subse-
quently tested both on the human bladder cell line 5637 and in
C3H/HeN mice.
Mannose and heptyl a-D-mannose inhibit in vitro
adhesion of type 1-piliated E. coli
Type 1 pili-expressing AAEC185(pUT2002)(pMMB66) E. coli
cells at 106 cfu/ml were suppleme ted with a ten-fold dilution
series of D-mannose (Man) or heptyl a-D-mannose (HM) and
incubated for adhesion on bladder cell line 5637. Increasing
concentrations of Man or HM caused a significant reduction to
complete inhibition of bacterial bladder cell binding (Figure 6).
Adhesion could be completely inhibited by the addition of
100 mM Man to the bacterial inoculum, or by a 100-fold lower
concentration of HM. No inhibition was obtained with 100 mM
Man, whereas 1 mM of HM still had some inhibitory effect.
Similar data have been obtained with an inoculum of 107 cfu/ml.
Figure 3. Panel of FimH lectin domain interactions along the oligomannose-3 chain. A, Electron density map, contoured at 1 e/A˚3, for
ol gomannose-3 in the FimH receptor-binding site. The surface of the binding site is subdivided into its hydrophobic support platform (grey, residues
Phe142, Phe1 and Ile13), its polar pocket (red, residues Asn46, Asp47, Asp54, Gln133, Asn135, Asn138 and Asp140), the tyrosine gate (blue, residues
Tyr137, Ile52 and Tyr48) and residue Thr51 (green). B, Aromatic-to-saccharide stacking (green dashed lines) of the Tyr48 side chain onto the B-face of
Man3. C, van der Waals support of the b1,4 linkage (yellow dashed lines) and an hydrophobic contact of C5 of GlcNAc2 by Tyr137 (green dashed
lines). D, Thr51 tops of the site by hydrophilic (red), hydrophobic and van der Waals (yellow) interactions with the chitobiose. The anomeric O1 of
GlcNAc1 would be exchanged for by the nitrogen of the amide of aspargine on a receptor glycoprotein for FimH.
doi:10.1371/journal.pone.0002040.g003
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Figure 4. Scheme of the interactions in the extended FimH receptor-binding 
pocket. A network of hydrogen bonds (green dashed lines) surrounds Man4. Further 
along oligomannose-3, only water molecules make hydrogen bonds along one side of 
oligomannose-3 except for the Thr51 side chain. The residues of the tyrosine gate, 
Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals 
contacts (all marked in red) mainly with Man3 and GlcNAc2.  
Figure 4. Scheme of the interactions in the extended FimH receptor-binding pocket. A network of hydrogen bonds (green dashed lines)
surrounds Man4. Further along oligomannose-3, only water molecules make hydrogen bonds along one side of oligomannose-3 except for the Thr51
side chain. The residues of the tyrosine gate, Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals contacts (all
marked in red) mainly with Man3 and GlcNAc2.
doi:10.1371/journal.pone.0002040.g004
Figure 5. Specificity spots for interaction with FimH. A, Superposing the FimH RBDs with the oligomannose-3 ligand (yellow, PDB entry 2vco,
2.1 A˚ resolution), with butyl a-D-mannose (magenta, 1uwf, 1.7 A˚ resolution) and with butyl a-D-mannose (cyan, 1tr7, 2.1 A˚ resolution). Tyr48 in the
1uwf structure (magenta) adopts a different side chain conformation, for the reason to avoid clashes in the crystal packing. The butyl tail takes on a
conformation that matches the C3-C2-C1 greasy trace of the central Man3 almost precisely. B, Water positions in the crystal structures of the FimH
RBD (green) in complex with the oligomannose-3 ligand (yellow, waters in red and hydrogen bonds in blue dashed lines) match those of the FimH
RBDs of the butyl a-D-mannose-liganded structures (waters in magenta for 1uwf, waters in cyan for 1tr7).
doi:10.1371/journal.pone.0002040.g005
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surrounds Man4. Further along oligomannose-3, only water molecules make hydrogen bonds along one side of oligomannose-3 except for the Thr51
side chain. The residues of the tyrosine gate, Tyr48, Ile52 and Tyr137, interact via aromatic stackings, hydrophobic and van der Waals contacts (all
marked in red) mainly with Man3 and GlcNAc2.
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Figure 5. Specificity spots for interaction with FimH. A, Superposing the FimH RBDs with the oligomannose-3 ligand (yellow, PDB entry 2vco,
2.1 A˚ resolution), with butyl a-D-mannose (magenta, 1uwf, 1.7 A˚ resolution) and with butyl a-D-mannose (cyan, 1tr7, 2.1 A˚ resolution). Tyr48 in the
1uwf structure (magenta) adopts a different side chain conformation, for the reason to avoid clashes in the crystal packing. The butyl tail takes on a
conformation that matches the C3-C2-C1 greasy trace of the central Man3 almost precisely. B, Water positions in the crystal structures of the FimH
RBD (green) in complex with the oligomannose-3 ligand (yellow, waters in red and hydrogen bonds in blue dashed lines) match those of the FimH
RBDs of the butyl a-D-mannose-liganded structures (waters in magenta for 1uwf, waters in cyan for 1tr7).
doi:10.1371/journal.pone.0002040.g005
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Figure  6. Inhibition of bacterial adhesion to 5637 bladder cells by mannose or 
heptyl α-D-mannose. Type 1 pili-expressing E. coli were incubated at 106 cfu/ml 
(FimHpos) with the bladder cells, or had been mixed with a ten-fold dilution series of Man 
or HM prior to incubation, to compare inhibition of bacterial binding by the two sugars. 
An isogenic fimH-negative strain served as a negative control (FimHneg).   
 
 
These results suggest that HM is more efficient at reducing FimH-
mediated bacterial adherence, in accordance with its higher
affinity for FimH.
Heptyl a-D-mannose reduces bac erial levels in a murine
cystitis model
Extensive research has shown that type 1 pili and their adhesin,
FimH, are essential for binding and invasion in the murine cystitis
model [6,33,53]. It was hypothesized that blocking of the FimH
binding pocket by preferential binding to a soluble mannose
residue would reduce the binding to uroplakins on the epithelial
cell surface of the bladder. This loss of binding would result in less
invasion and ultimately a reduced infection. To test this
hypothesis, bacteria were incubated in the presence of a derivative
of mannose prior to inoculation into mouse bladders. Introductory
to this experiment, the intrinsic toxicity of HM was assessed in
Female BALB/c mice. HM was administered at 50 mM
concentration through a catheter (50 ml), intranasal (20 ml) and
intravenously (150 ml) to three mice each, but no acute toxicity has
been observed. At 6 hours post-infection, the bacteria present
within the bladder were enumerated. Wild-type UTI89 incubated
with PBS alone had a mean level of infection of ,36105 cfu/mL
(Figure 7). Incubation of UTI89 with 0.5 mM of HM showed no
significant decrease in infection. However, at a concentration of
5 mM HM, there was a significant decrease in infection at 6 hours
post-infection (p#0.0001). Methyl a-D-mannose (MM) gave no
decrease in bacterial numbers at the same concentration. A
significant decrease in bacterial burden was only observed when
increasing the concentration of MM to 1M (data not shown), a 200
fold higher concentration then the one sufficient for HM. The
tighter binding of HM to FimH, as compared to MM, could
explain this difference. These results suggest that by inhibiting the
ability of FimH to bind to mannosylated uroplakins, the bacterial
infection can be prevented.
Heptyl a-D-mannose reduces intracellular bacterial levels
Since there is a reduction in the amount of bacteria present in
the bladder at 6 hours post-infection with HM incubation
(Figure 7), we wanted to assess the amount of bacteria that went
intracellular. Mice were infected with UTI89 in PBS or in a MM
or HM solution. At 1 hour post-infection, the luminal and
intracellular bacterial loads were assessed. There was a significant
decrease in the number of luminal bacteria bound to the
Figure 6. Inhibition of bacterial adhesion to 5637 bladder cells by mannose or heptyl a-D-mannose. Type 1 pili-expressing E. coli were
incubated at 106 cfu/ml (FimHpos) with the bladder cells, or had been mixed with a ten-fol dilution series of Man or HM prior to incubation, to
compare inhibition of bacterial binding by the two sugars. An isogenic fimH-negative strain served as a negative control (FimHneg).
doi:10.1371/journal.pone.0002040.g006
Figure 7. Bacterial load in the mouse bladder 6 hours post-
infection.Mice were inoculated with UTI89, either untreated or treated
with MM or HM. At 6 hours post-infection there was a significant
decrease in the amount of bacteria treated with 5 mM HM in the
bladder (p#0.0001 by Mann Whitney test). This same decrease was not
observed with bacteria treated with 5 mM MM. Bacteria treated with
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Figure  7. Bacterial load in the mouse bladder 6 hours post-infection. Mice were 
inoculated with UTI89, either untreated or treated with MM or HM.  At 6 hours post-
infection there was a significant decrease in the amount of bacteria treated with 5 mM 
HM in the bladder (p≤0.0001 by Mann Whitney test). This same decrease was not 
observed with bacteria treated with 5 mM MM. Bacteria treated with 0.5 mM HM were 
not significantly reduced relative to the untreated infection. 
 
These results suggest that HM is more efficient at reducing FimH-
mediated bacterial adherence, in accordance with its higher
affinity for FimH.
Heptyl a-D-mannose reduces bacterial levels in a murine
cystitis model
Extensive research has shown that type 1 pili and their adhesin,
FimH, are essential for binding and invasion in the murine cystitis
model [6,33,53]. It was hypothesized that blocking of the FimH
binding pocket by preferential binding to a soluble mannose
residue would reduce the binding to uroplakins on the epithelial
cell surface of the bladder. This loss of binding would result in less
invasion and ultimately a reduced infection. To test this
hypothesis, bacteria were incubated in the presence of a derivative
of mannose prior to inoculation into mouse bladders. Introductory
to this experiment, the intrinsic toxicity of HM was assessed in
Female BALB/c mice. HM was administered at 50 mM
concentration through a catheter (50 ml), intranasal (20 ml) and
intravenously (150 ml) to three mice each, but no acute toxicity has
been observed. At 6 hours post-infection, the bacteria present
within the bladder were enumerated. Wild-type UTI89 incubated
with PBS alone had a mean level of infection of ,36105 cfu/mL
(Figure 7). Incubation of UTI89 with 0.5 mM of HM showed no
significant decrease in infection. However, at a concentration of
5 mM HM, there was a significant decrease in infection at 6 hours
post-infection (p#0.0001). Methyl a-D-mannose (MM) gave no
decrease in bacterial numbers at the same concentration. A
significant decrease in bacterial burden was only observed when
increasing the concentration of MM to 1M (data not shown), a 200
fold higher concentration then the one sufficient for HM. The
tighter binding of HM to FimH, as compared to MM, could
explain this difference. These results suggest that by inhibiting the
ability of FimH to bind to mannosylated uroplakins, the bacterial
infection can be prevented.
Heptyl a-D-mannose reduces intracellular bacterial levels
Since there is a reduction in the amount of bacteria present in
the bladder at 6 hours post-infection with HM incubation
(Figure 7), we wanted to assess the amount of bacteria that went
intracellular. Mice were infected with UTI89 in PBS or in a MM
or HM solution. At 1 hour post-infection, the luminal and
intracellular bacterial loads were assessed. There was a significant
decrease in the number of luminal bacteria bound to the
Figure 6. Inhibition of bacterial adhesion to 5637 bladder cells by mannose or heptyl a-D-mannose. Type 1 pili-expressing E. coli were
incubated at 106 cfu/ml (FimHpos) with the bladder cells, or had been mixed with a ten-fold dilution series of Man or HM prior to incubation, to
compare inhibition of bacterial binding by the two sugars. An isogenic fimH-negative strain served as a negative control (FimHneg).
doi:10.1371/journal.pone.0002040.g006
Figure 7. Bacterial load in the mouse bladder 6 hours post-
infection.Mice were inoculated with UTI89, either untreated or treated
with MM or HM. At 6 hours post-infection there was a significant
decrease in the amount of bacteria treated with 5 mM HM in the
bladder (p#0.0001 by Mann Whitney test). This same decrease was not
observed with bacteria treated with 5 mM MM. Bacteria treated with
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Figure 8. Gentamicin protection assay to determine luminal versus intracellular 
bacterial population. Mice were inoculated with UTI89 either untreated or treated with 
MM HM. At 1 hour post-infection, bladders were harvested and processed. Luminal 
bacteria were obtained from washes of the bladder. The remaining extracellular bacteria 




uroepithelium when treated with 5 mM and 0.5 mM HM
(p#0.01) (Figure 8). This same decrease was not seen when using
5 mM MM. Relative to untreated UTI89, UTI89 incubated with
5 mM HM had a significant decrease in intracellular population
(p#0.01). There was no significant decrease in invaded bacteria
treated with 5 mM MM or 0.5 mM HM. These data indicate that
HM is interfering not only with type 1 pili-mediated bacterial
binding but also with type 1 pili-dependent invasion of UPEC.
Heptyl a-D-mannose inhibits biofilm formation in vitro
The development and maturation of IBCs into communities
with biofilm-like properties has been shown recently to depend on
type 1 pili [16]. We speculated that blocking the FimH binding
pocket on type 1 pili would inhibit biofilm formation by inhibiting
the adhesive properties of the pili. Bacterial biofilms were grown in
the presence of varying concentrations of either HM or MM to
elucidate their biofilm inhibiting properties (Figure 9). Biofilm of
UTI89 E. coli was significantly reduced (p,0.01) only at the
highest concentration of MM, 1 mM. However, in the presence of
HM, there was a significant decrease in biofilm formation at
10 mM (p,0.001) and both 1 mM and 100 mM concentrations
(p,0.0001). This suggests that blocking of the type 1 pili FimH
adhesion with HM inhibits biofilm formation. Interestingly, at the
lowest concentration of HM (1 mM) there was a significant
increase in biofilm formation (p,0.001). A low concentration of a
weak inhibitor appears to allow the bacteria to organize into a
better matrix through their type 1 pili [54].
Discussion
Adhesion, invasion and the formation of intracellular
biofilms
UPEC express type 1 pili which bind to mannosylated residues
on the surface of epithelial bladder cells. Once bound, some
bacteria can invade the cells and rapidly replicate into intracellular
bacterial communities, named IBCs, which mature into tightly
packed biofilm-like societies [15,16]. As the infection proceeds, the
bacteria filament and flux out of the cells [7,11]. They can then
reinvade neighbouring cells to re-establish infection [14]. Inhibi-
tion of UPEC binding to bladder cells will potentially inhibit
invasion and limit the bacteria’s ability to build up formidable
numbers within the bladder. A competitive sugar could potentially
disrupt the IBC pathway.
Blocking bacterial invasion could reduce the infection and
decrease recurrences. It had been demonstrated already from very
early on by Sharon’s group that mannose has an inhibitory can
inhibit FimH-mediated bacterial adhesion [55]. We looked into
the ability of heptyl a-D-mannose (HM) to reduce infection,
because HM has an optimized alkyl length for interaction with
FimH [47]. Inhibition by soluble mannose (Man) or methyl a-D-
mannose (MM) or HM of bacterial adhesion to the bladder cel line
in vitro or upon transurethral catheterization into the mouse
bladder indicates that the bacteria cannot switch between HM and
the mannosylated uroplakins. Once HM is bound to FimH on the
type 1 pili, the bacteria are irreversibly inhibited in their binding to
the bladder surface and the infection is reduced. However, the
weak inhibitor MM has a relatively high efficiency in the bladder
binding assay that is not in direct correlation with its affinity
compared to HM. The affinity of MM for FimH is 500-times less
than this of HM, but a concentration of MM a 100-fold higher
than the inhibitory concentration of HM is sufficient. The
explanation may be in the fact that the in vitro adhesion assay is
being performed under shaking conditions. Nilsson studied the
inhibitory effect of MM on binding of type 1-piliated E. coli to
mannosylated surfaces under different shear stress conditions.
During rolling, FimH molecules transiently bind and detach from
surface receptors, allowing a weak soluble inhibitor such as MM to
eventually bind to all FimH molecules, thereby preventing further
adhesion [54,56]. In contrast, stationary adhesion is mediated by
long-lived adhesin-receptor bonds that prevent inhibitor binding
during the time course of the experiments (,10 min). HM forms
such high-affinity intractions with FimH, also under still
Figure 8. Gentamicin protection assay to determine luminal
versus intracellular bacterial population. Mice were inoculated
with UTI89 either untreated or treated with MM HM. At 1 hour post-
infection, bladders were harvested and processed. Luminal bacteria
were obtained from washes of the bladder. The remaining extracellular
bacteria were killed with gentamicin and invaded, intracellular bacteria
were counted.
doi:10.1371/journal.pone.0002040.g008
Figure 9. Biofilm formation in the presence of methyl or heptyl
a-D-mannose. Standard biofilm assays showed a great reduction of
UTI89 biofilm formation in the presence of 100 mM and 1 mM HM




PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e2040
 139 
 
Figure  9. Biofilm formation in the presence of methyl or heptyl α-D-mannose. 
Standard biofilm assays showed a great reduction of UTI89 biofilm formation in the 
presence of 100 µM and 1 mM HM (p<0.0001) and a significant increase (p<0.01) in the 
presence of 1 mM MM.  
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Figure S1. Crystals of the FimH receptor-binding domain in complex with 
oligomannose-3. The crystals were grown by the vapour diffusion method in 1.0 M 
Li2SO4, 0.1 M Tris pH 8.5, 0.01 M NiCl2, A, in sitting drop, diffracting to 2.6 Å resolution, 
and B, in hanging drop, optimized by the addition of 3% glycerol to the precipitant and 








Table S1. Data collection and processing, refinement statistics and model quality 
Space group     P3121 
Unit cell dimensions (Å)   a = b = 90.562   c = 79.480 
Molecules per asymmetric unit  2 
Solvent content (%)    55.6       
Resolution range (Å)    78.33 – 2.1 
Reflections (total/unique)   142,687 / 22,429 
Completeness (%) a    99.8 (100.0) 
Rmerge 
a,b     0.099 (0.42) 
<I/!(I)> a,b     16.0 (5.8)  
Rfree      0.241 (0.310) 
Rcryst      0.184 (0.228) 
Rall      0.187  
Ramachandran         
% of residues in favored regions    97.12 
   allowed regions  100.00 
Rmsd bond lengths (Å)   0.010 
Rmsd bond angles (º)    1.178 
Average B-factors main chain  24.4    
Average B-factors water   36.1 
 
 
a Values in parentheses indicate statistics for the highest resolution shell (2.14 - 2.1 Å). b 
Rmerge = "h "i |Ih,i - <Ih>|/ "h "i <Ih>, where Ih,i is the ith observation of reflection h and 
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FUTURE DIRECTIONS AND CONCLUDING REMARKS 
 
Conservation of the IBC pathogenic pathway among UPEC 
A study of uropathogenic Escherichia coli (UPEC) clinical isolates from different clinical 
syndromes revealed that the intracellular bacterial community (IBC) pathway is a 
common pathway of UPEC (18).  Additionally, analysis of human urine specimens 
suggests an association between IBCs, filamentous bacteria and acute uncomplicated 
cystitis in young women (42).  The ramifications of this work result in a vastly improved 
understanding of urinary tract infections (UTIs) which will ultimately lead to better 
therapeutic options and less treatment failures.  Clinically UTIs are thought to be due to 
simple extracellular colonization of the urothelium by UPEC, however intracellular 
bacteria have been found in the human bladder following UTI (15).  The notion of an 
intracellular niche in human UTI should change the way physicians treat the disease.  
Episodes of cystitis caused by UPEC in humans likely involve an IBC pathogenic 
pathway similar to that observed in mice.  The ability to utilize an intracellular bladder 
niche in both murine and human infection may represent an imperative virulence 
determinant.  Intracellular bacteria are largely protected from host innate immunity.  
While in the intracellular niche, bacteria are not subject to the shear forces of urine flow 
and are not subject to phagocytosis by host neutrophils or macrophages allowing 
bacteria to build up in numbers despite potent innate defenses.  Additionally, the 
formation of intracellular biofilms may allow bacteria to withstand many antimicrobial 
therapies, as is the case for bacteria in extracellular biofilms (14).  IBC formation may 
also explain how the relatively few bacteria introduced into the bladder with sexual 
intercourse (9, 10, 24) are able to survive and replicate to numbers high enough to elicit 
symptoms in the host.  The introduction of low numbers of bacteria into the bladder is 
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likely a relatively common occurrence but controlled by the host immune system and the 
ability of urothelial cells to expel invaded UPEC (7).  It may be that only in the event of 
invasion, escape to the cytosol and IBC formation can bacteria replicate and persist to 
sufficiently initiate symptomatic cystitis.  In line with this theory, acute UTI isolates 
formed significantly smaller and fewer IBCs within the mouse urinary tract indicative of a 
less robust infection.  In general, ASB, rUTI and pyelonephritis strains are associated 
with longer-term persistence in the human, and, in the murine bladder, IBC size and 
number were significantly greater in these isolates suggesting that IBCs relate to 
persistence.  Since IBC formation is a rare event among acute isolates perhaps they are 
not meeting the threshold of IBCs to establish a persistent infection.  Further 
investigation is required to decipher what acute isolates lack preventing robust and 
numerous IBCs.  Recent studies indicate that complicated signal transduction pathways 
are initiated in response to bacterial binding to eliminate colonization.  Bacteria must 
overcome expulsion in response to increased cyclic AMP (7) and must disrupt F-actin 
and escape the vacuole to achieve access to the cytoplasm for IBC formation (16).  
Perhaps acute isolates lack the necessary factors to overcome these host factors and 
enter their desired niche. 
Evaluation of the immune response elicited by the host in the presence of acute 
isolates versus UTI89 could indicate essential differences in immune evasion strategies 
among acute isolates.  It was shown that UTI89 actually dampens the IL-6 response 
from the host relative to K-12 E. coli strains (27).  Perhaps acute isolates are 
unsuccessful at preventing the robust production of IL-6 by the host and are thus 
eliminated more quickly from the host, reducing the amount that are able to invade and 
form IBCs.  Another way to evaluate the reduction in IBC size and number in the acute 
isolates would be to transform these strains with a fosmid library of UTI89 and screen for 
IBC numbers and size.  Those mutants with enhanced IBC number or size would 
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potentially identify virulence factors involved in IBC formation.  Previously this work was 
laborious due to the absence of a tissue culture model, however, it was recently 
discovered that treating human urothelial cells with filipin facilitates the development of 
IBC-like structures enabling a more feasible screen of mutant bacteria (6).  Knowledge 
as to why acute isolates are less persistent in regards to immune response and IBC 
formation could identify new therapeutic targets to prevent persistent infection observed 
with ASB, rUTI and pyelonephritis isolates. 
The IBC pathogenic pathway is conserved among UPEC and in human UTI.  The 
extent of this conservation and the prevalence of this pathway in patients with cystitis 
remains obscure, however, the commonality of IBCs among UPEC and in humans is a 
remarkable discovery.  This finding changes the historical paradigm that UTI is an 
extracellular infection and validates the already established murine cystitis model.  UTI 
pathogenesis is clearly more complex than once considered and these newly elucidated 
steps in the infectious process raise several novel questions and may provide additional 
therapeutic targets for this common disease. 
 
Evaluation of the Co-infection phenotype 
Of the 18 clinical isolates tested for IBC formation, IBCs were not observed in three 
isolates and they were thus deemed outliers.  An ex vivo gentamicin protection assay 
revealed that the three isolates (rUTI1, acute4 and pyelo3) were deficient in invasion.  
Multiplex virulence factor PCR revealed no association with lack of IBC formation and 
virulence factors.  Likely there is a multitude of virulence factors contributing to IBC 
formation and perhaps some redundancy in the necessary factors.  rUTI1 and pyelo3 did 
not persist in the murine bladder however were isolated from a persistent infection within 
the human.  It is likely that multiple strains of bacteria are simultaneously introduced into 
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the urinary tract of women during the early events that lead to a UTI.  The diagnosis of 
UTIs rarely delineates whether multiple strains of E. coli are present.  Thus, these strains 
could have “piggy-backed” with a more invasive IBC-forming strain that went undetected.  
In an effort to emulate what may have happened with the three outlying strains, each 
clinical isolate was inoculated with equal amounts of UTI89.  Upon co-inoculation, each 
strain demonstrated altered behavior from their single infection phenotype.  These 
results demonstrate the complexities of co-infection and might explain the occurrence of 
different clinical syndromes manifested by the same organism (25) or the differing 
behavior in single versus mixed infections.   
While unable to form IBCs alone, rUTI1 formed IBCs in the presence of UTI89, 
acute4 formed IBCs mixed with UTI89, and pyelo3 was still unable to form IBCs in the 
presence of UTI89.  Instead, co-inoculation of UTI89 and pyelo3 resulted in massive 
filamentation of both isolates.  Since filamentation occurs in response to an inflammatory 
response (28), further study is required to assess whether pyelo3 is triggering a more 
robust innate response that leads to the massive filamentation observed.  Evaluation of 
the immune response elicited by single infection bladders versus co-infection bladders 
could shed some light on the reason for the filamentation phenotype.  First, tissue titers 
revealed that upon individual inoculation of UTI89 and pyelo3, UTI89 had higher titers in 
the bladder at 6 h, 24 h and 2 weeks post-infection, however kidney titers were 
equivalent at all time points post-infection (Figure 1).  Upon co-infection, bacterial load in 
the bladder resembled a UTI89 single infection suggesting that UTI89 is the dominant 
bacteria driving the infection.  Next, the immune response in the single infection tissues 
versus the co-infection tissues was evaluated to determine if the immune response 
mimics the tissue titer observations.  While bacterial load differences were only observed 
in the bladder, evaluation of 12 cytokines revealed no significant difference in immune 
response when single infection of UTI89 and pyelo3 and co-infection were evaluated.  
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However, significant differences were observed in 9 of 12 cytokines in the kidney.  Of the 
observed differences the majority separated UTI89 single infection from pyelo3 single 
infection and co-infection.  Thus, the immune response of the co-infection more closely 
mimicked the immune response of the pyelo3 infection.  This is interesting since the co-
infection mimicked the UTI89 single infection in regards to tissue titers.  In general, the 
immune response in the pyelo3 single infection and the co-infection was much more 
robust (Figure 2).  IL-1β, IL-6, MCP-1 and MIP-1β were significantly elevated in pyelo3 
infection and co-infection relative to UTI89.  All of the above cytokines are secreted by 
macrophages and result in activation of macrophages and lymphocytes, enhancing the 
immune response to the pathogen.  Although certain cytokines were only significantly 
elevated in pyelo3 single infection or co-infection, no cytokines were significantly 
elevated in the UTI89 infection.  Thus, the hypothesis that pyelo3 is triggering a more 
robust innate response that leads to the massive filamentation of both isolates is 
possible.   
We have confirmed that there is a more robust innate response in the presence 
of pyelo3 however, we have not directly identified that it is this response that is driving 
the filamentation phenotype.  The immune response that leads to massive filamentation 
could be teased out using a tissue culture model.  Addition of various cytokines shown to 
be upregulated upon infection with pyelo3 could be added to urothelial cells along with 
bacteria.  Filamentation of bacteria could be observed through microscopy and release 
of IL-6 and IL-8 could be measured through ELISA assay (22).  Since, filamentation is a 
mechanism the bacteria employs to evade neutrophil engulfment and persist in the face 
of massive immune responses, understanding of this process could identify targets for 
therapeutics that inhibit bacterial filamentation and reduce the bacteria’s chances to 
perpetuate the infection.  It has been shown that the loss of the ability to filament results 
in reduced persistence within the bladder (29).   
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Work with the co-infection model has even further changed the paradigm of 
infection.  Not only are UTIs complicated infections involving intracellular and 
extracellular niches, they are compounded by the high likelihood of inoculating multiple 
strains of E. coli into the bladder at one time.  This mechanism of co-inoculation allows 
multiple strains to persist that perhaps would be eliminated if inoculated by themselves.  
Thus, targeting multiple mechanisms of virulence throughout the UPEC pathogenic 
pathway may be necessary to completely eliminate infection and prevent recurrence.  
Further understanding of how bacteria interact with one another and what virulence 
factors are important to each step in the UPEC pathogenic pathway will facilitate the 
development of novel therapeutics that can combat this very common disease. 
 
pUTI89 as a virulence factor 
UTI89 contains a 114 kb extrachromosomal element termed pUTI89.  pUTI89 is a 
unique plasmid containing two regions, the tra operon and genes found on other 
virulence plasmids.  pUTI89 appears to have many of the characteristics common to 
pathogenicity islands (PAIs); it occupies a large genomic region, carries genes encoding 
one or more virulence factors and contains cryptic or functional genes encoding mobility 
factors such as integrases, transposases, and insertion sequences (20).  Yet to be 
discovered, is whether it is present in the genomes of pathogenic organisms but absent 
from the genomes of non-pathogenic organisms.  To assess the presence of pUTI89 in 
pathogenic organisms, 18 clinical UPEC isolates were tested for regions of pUTI89 by 
plasmid purification and PCR.  Evaluation revealed that 67% of UPEC clinical isolates 
had evidence of pUTI89 and 22% appeared to have the entire plasmid based on positive 
PCR reactions.  Due to its maintenance within the population, pUTI89 is likely involved in 
pathogenesis in vivo.  However, non-pathogenic organisms such as K-12 E. coli were 
not tested for the presence of pUTI89.  Furthermore, it would be interesting to test 
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pathogenic organisms from different families of E. coli, such as enterohemorrhagic E. 
coli (EHEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC) and avian 
pathogenic E. coli (APEC).  Identification of pUTI89 genes in the pathogenic classes of 
E. coli but not K-12 E. coli could indentify it as an extraintestinal pathogenic E. coli 
(ExPEC) factor for virulence.  ExPEC diverge from their commensal cohorts, taking on a 
more pathogenic nature and the ability to cause serious disease both within the intestinal 
tract and elsewhere within the host (30, 43).  On the contrary, if evidence of pUTI89 is 
only found in UPEC, then it can be identified as a urovirulence factor.  A urovirulence 
factor implies the presence of genes on pUTI89 in the majority of UPEC isolates 
potentiating the development of a common target for therapeutics.   
The mouse cystitis model was used to determine that pUTI89 contains genes 
encoding one or more virulence factors.  It was shown that pUTI89 enhances survival 
early in infection, however, normal infection levels were restored within 24 hours of 
infection.  Binding and invasion was reduced in the absence of pUTI89.  The cjr operon 
encoding CjrA, CjrB and CjrC was partially implicated in the observed defect.  In EIEC, 
CjrA is an inner membrane protein homologous to PhuW of Pseudomonas aeruginosa 
with unknown function, CjrB is homologous to the TonB protein which is involved in 
energetic transfer between the inner and outer membranes, and CjrC is homologous to 
putative outer membrane siderophore receptors (44).  Located upstream of the cjr 
operon is a fur box implying regulation by iron.  Overlapping the cjrC gene is the senB 
gene which encodes for an enterotoxin that accounts for 50% of the enterotoxic activity 
in EIEC strain, EI34 (38).  Further work needs to be done to complement this operon and 
see a restoration of infection.  Outer membrane proteins can be difficult to complement 
since over expression can lead to cell lysis, thus a low copy or inducible plasmid is 
important for successful complementation.  After successful complementation, the 
expression pattern of the cjr operon should be evaluated to determine if and when these 
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proteins are expressed.  It would be useful to see if their expression profile changes 
during different points of the UPEC pathogenic pathway, for example in intracellular or 
extracellular survival.  Iron acquisition is essential to bacteria residing within the urinary 
tract (23, 41) thus this operon regulated by the fur box is very likely to be expressed in 
iron limiting conditions such as the urinary tract.  Perhaps Cjr proteins are expressed 
early in infection whereas other iron acquisition systems are expressed later, potentially 
explaining the delayed growth in vivo in the absence of the Cjr proteins until more 
systems are turned on. 
 
Immune response in the absence of pUTI89 
It is clear that the immune response elicited by the host, and the behavior of the bacteria 
in response to it, go hand in hand.  UPEC invade to avoid expulsion from the sheer 
forces present during urination as well as avoid attack from neutrophils and 
macrophages (37).  When extracellular, UPEC filament to prevent neutrophil engulfment 
(29).  Additionally, UPEC dampen the IL-6 response mounted by the host relative to K-
12 E. coli (27).  There are a multitude of other mechanisms that UPEC use to evade the 
immune response, thus, due to the necessity of these evasion mechanisms, it is likely 
that pUTI89 may play a role in immune evasion.  However, it is extremely likely that 
immune evasion mechanisms are redundant, thus may not be recognized in a pUTI89 
knock-out strain.  Measurement of 12 cytokine levels in the bladder of UTI89-infected 
and ΔpUTI89-infected bladders at 6 hours post-infection revealed no significant 
difference in cytokine levels (Figure 3).  Thus, either there are no immune evasion 
mechanisms on pUTI89 or the immune evasion mechanisms are redundant on the 




Functional tra operon 
As mentioned above, pUTI89 essentially has two regions; one region contains genes 
involved in conjugative DNA transfer and the other region contains genes found on 
virulence plasmids or in other virulent bacteria.  Since the tra operon makes up such a 
large portion of pUTI89, it is important to understand if it is functional.  Additionally, 
conjugative F plasmids promote biofilm formation perhaps through stimulating synthesis 
of colanic acid and curli (19, 35).  The tra operon promotes transfer of DNA which can 
aid in adaptability of bacteria to a certain niche through uptake of genes needed to 
overcome environmental restrictions for survival and replication (21).  Thus, perhaps 
commensal E. coli can become extraintestinal pathogenic E. coli (ExPEC) through the 
uptake of DNA by conjugation implying that the conjugation machinery are important in 
making virulent bacteria within the gastroinstestinal (GI) tract.  It is easy to see how 
these functions would benefit UPEC.  Not only do they form biofilm-like structures in the 
bladder, but they also must survive in a harsh niche within the urinary tract, both 
extracellularly and intracellularly.   
From plasmid purification and PCR methods, 6 of the 18 UPEC clinical isolates 
had no evidence of pUTI89.  In order to confirm functionality of the tra operon on 
pUTI89, pUTI89 was mated into strains containing no evidence of pUTI89.  To do this, a 
kanamycin cassette was inserted on pUTI89 and a spectinomycin cassette was 
transduced onto the chromosome of the clinical isolates.  Three clinical isolates were 
successfully transduced with the Spec cassette and all three were recipients of pUTI89 
upon plate mating.  Mating efficiencies ranged from 2 x 10=10 to 3 x 10-4.  The reception 
of pUTI89 by clinical isolates not only shows the tra operon is functional it also shows 
that pUTI89 is expressed in vitro.  While this confirms that the tra operon is expressed 
and functional, it does not evaluate its potential role in virulence. 
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As a surrogate for IBC formation, which resembles intracellular biofilms, biofilm 
formation was evaluated.  Since the nutrients within the intracellular environment are not 
entirely known, biofilm was grown in minimal and rich media in an effort to mimic the 
conditions in vivo.  Growth in minimal or rich media was equivalent in the clinical isolate 
relative to its pUTI89-containing counterpart as was biofilm formation (Figure 4).  Since 
lack of pUTI89 does not affect biofilm formation in UTI89, it is not surprising that addition 
of pUTI89 to clinical isolates does not enhance biofilm formation.  However, lack of 
pUTI89 does affect colonization at 6 hours post-infection, which begs the question, does 
addition of pUTI89 to clinical isolates enhance colonization at 6 hours post-infection?  
C3H/HeN female mice were infected with each clinical isolate and its pUTI89-plus 
counterpart and bacterial load was determined at 6 h, 24 h and 2 wk post-infection.  
There was no significant difference in bacterial load in the bladder at 6 hours post-
infection in the clinical isolates versus its pUTI89-plus counterpart, only acute3 + pUTI89 
was close to being significant relative to acute3 (Figure 5).  Additionally, there was no 
difference in bacterial titers of the clinical isolates with and without pUTI89 at 24 hours or 
2 weeks post-infection as was seen with UTI89 in the presence and absence of pUTI89.  
There does not seem to be a gain of function effect on the clinical isolates with pUTI89.  
However, it is extremely possible that some of the genes on pUTI89 are present on the 
chromosome of the clinical isolates since PCR for pUTI89 only tested for 8 small 
regions.  Since these genes are already present within the genome of the clinical isolate, 
adding a second copy from pUTI89 does not, therefore, enhance infection.  Since the cjr 
operon has been implicated in virulence in UTI89, one can now test each clinical isolate 
for the presence of that specific operon.  In fact, nearly 50% of the clinical isolates tested 
positive for the senB gene found in the cjr operon, implying its role in virulence.  Future 
investigation is needed to evaluate IBC formation, filament formation and binding and 
 162 
invasion in clinical isolates conjugated with pUTI89 to determine if pUTI89 is important in 
other UPEC isolates. 
 
pUTI89 has an effect on chromosomal genes 
Yersinia pestis, enteropathogenic E. coli (EPEC), Bacillus anthracis and Chlamydia 
trachomatis all were shown to have chromosomally encoded genes that are regulated by 
plasmid-encoded loci (5, 8, 11, 40).  We sought to determine whether chromosomally 
encoded genes were affected by the loss of pUTI89.  Microarray and 2D gel analysis 
were used to identify if the altered regulation is at the transcriptional and/or translational 
level.  For microarray analysis, we chose to examine bacteria from cultures grown for 
inoculation into the murine cystitis model, as we are unable to isolate enough bacterial 
RNA from infected bladders.  All results presented were obtained from three 
independent culture replicates (biological) consisting of three replicates (experimental) of 
UTI89 and ΔpUTI89.  Principal-component analysis demonstrated a high degree of 
replicate grouping.  Only those genes that were significantly different were graphed.  76 
plasmid genes showed greater than two-fold transcript differential (Figure 6).  
Interestingly, repB, rsvB, stbA and stbB were all extremely down in ΔpUTI89 versus 
UTI89 suggesting that they are on during growth in wild-type bacteria.  Considering 
these genes are involved in plasmid replication and stability it implies the plasmid is 
expressed in vitro.  Furthermore, UP060, UP061, UP097 and UP141 were all extremely 
down suggesting that they are highly expressed in wild-type in vitro.  These genes are 
hypothetical and will require further investigation to determine their function.  Of all the 
genes on the chromosome, only 24 were significantly different in the absence of pUTI89 
(Figure 7) and 14 showed greater than two-fold transcript differential.  Seven genes were 
extremely downregulated in the absence of pUTI89: yccB, UC1727, ydiA, ydjA, c2508, 
ygeA, ygfA and yhfA (Table 1).  Again all of these are hypothetical and will require 
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further examination.  The caveat of this work is that RNA was isolated from cultures 
grown in vitro, while the ΔpUTI89 phenotype was only observed in vivo.  These data 
suggest that pUTI89 functions in trans to regulate the transcription of multiple 
chromosomal genes.  Their role in pathogenesis is the study of future work. 
 This work has demonstrated that pUTI89 increases the ability of UTI89 to invade 
and colonize the bladder.  Additionally, it aids in understanding why UPEC genomes are 
mosaic.  Perhaps these F-like plasmids are shaping UPEC isolates by facilitating 
frequent genomic acquisition, loss and rearrangement.  pUTI89-like plasmids could 
explain why there is not a list of definitive virulence factors that define an isolate as 
UPEC (33).  A greater understanding and characterization of these types of plasmids 
from different UPEC could facilitate the understanding of their mechanism of virulence 
and their evolution, and the design of efficacious strategies to fight UTI. 
 
Type 1 pili as a virulence factor 
Type 1 pili are essential cystitis virulence determinants (4, 34, 37, 48).  FimH, located at 
the tip of type 1 pili, is the essential adhesive domain for binding to mannosylated 
uroplakins on the surface of bladder epithelial (urothelial) cells.  In the absence of type 1 
pili or FimH bacteria are non-invasive, unable to persist in the bladder and are eliminated 
by the host.  Thus, while there are many other virulence factors involved in infection 
such as capsule, siderophores, flagella and certain toxins, type 1 pili are absolutely 
required to initiate infection.  After infection is initiated by type 1 pili, factors downstream 
perpetuate and maintain the infection within the host.   
Sequencing of over 300 fimH genes from UPEC has revealed that the mannose 
binding pocket is invariant (12).  However, amino acids outside the binding pocket vary 
and four residues, 27, 62, 66 and 163, are positively selected in UPEC FimH (Figure 8).  
Their role in infection is yet undiscovered, but suggests that there is more to FimH than 
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just its ability to bind mannose.  Alignment of the FimH sequences from the panel of 18 
clinical isolates previously studied identified the residues differing from UTI89 FimH 
(Table 2).  Since the panel of clinical isolates has been characterized in the mouse, we 
used them to determine the role of these positively selected amino acids and, 
specifically, their role in IBC formation.  We hoped to identify if genetic background plays 
a role or if FimH is the determinant virulence factor for IBC formation.  Based on the 
confocal microscopy results from Garofalo et al. (18), those isolates that did poor in vivo 
were used for IBC quantification by LacZ staining (Figure 9).  Five of the 7 isolates that 
were poor IBC-formers had a valine at position 27 instead of an alanine as in UTI89 
FimH.  Thus, it seems that this residue may be important to IBC formation and/or 
colonization of the bladder.  We hypothesized that UTI89 FimH in place of clinical isolate 
FimH will result in enhanced IBC formation and colonization.  The isolates that were 
poor IBC formers or did not form IBCs were manipulated to contain the FimH of UTI89 in 
place of their FimH on the chromosome, thus under the same regulation.  Thus far, one 
isolate, acute4, was manipulated to contain UTI89 FimH.  IBC quantification revealed 
that IBCs were not observed in either acute4 or acute4 + UTI89 FimH (Figure 10A) 
suggesting genetic background does play a role in IBC formation.  However, bacterial 
titers revealed that while there was no difference at 6 hours post-infection, there was a 
significant difference at 24 hours post-infection, with acute4 + UTI89 FimH colonizing 
nearly 3 logs better than acute4 (Figure 10B).  This suggests that FimH is involved in 
more than IBC formation.  Future studies are needed to identify its role in infection 
outside of mannose binding.  It was shown that FimH is a potent inducer of innate 
antimicrobial responses through direct binding of TLR4 resulting in the production of type 
1 interferon (3).  It is possible that FimH is modulating the immune system to facilitate 
successful colonization of the bladder.  Evaluating the immune response elicited by the 
host to acute4 and acute4 + UTI89 FimH could address this question.  Or perhaps FimH 
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makes contact with a secondary receptor outside of its binding pocket to enhance 
invasion.  Since, in acute4, UTI89 FimH still did not result in IBCs, we can take 
advantage of this to find other factors involved in IBC formation.  If acute4 is lacking an 
essential factor for IBC formation, transformation with UTI89 fosmid library could result in 
IBC formation.  We can then identify the gene(s) involved in IBC formation.  If acute4 
possesses a factor that is preventing IBC formation, a transposon mutagenesis could 
identify a region that is inhibitory for IBCs.  Furthermore, acute4 was unable to form IBCs 
so if we put UTI89 FimH into an IBC-competent strain that made IBCs at low numbers 
such as rUTI3 or acute3 perhaps we can enhance IBC formation.  This would suggest 
that if an isolate has all the capabilities to make an IBC, FimH makes the process much 
more efficient.   
 This work has shown that there is more to FimH than mannose binding.  
Residues outside the pocket are positively selected in UPEC suggesting and important 
role in infection.  Additionally, UTI89 FimH in acute4 increased colonization without IBC 
formation.  Thus, while it is known that type 1 pili are essential for robust UTI, it is not 
known what additional role type 1 pili plays outside of binding and invasion.  While one 
study showed that type 1 pili are expressed inside the IBCs (47), future work is needed 
to identify the additional functions of FimH in UTIs.  Regardless of the additional function 
of FimH, it is clear that it is essential for UTI.  Thus, therapeutics are needed to eliminate 
binding of UPEC to the urothelium.  They have the potential to eliminate this extremely 
common disease. 
 
Treatment of UTIs 
Urinary tract infections (UTIs) are one of the most common bacterial infections in 
industrialized countries and impose a significant financial burden based on physician 
visits and treatment (17).  Posing an even greater threat is the high incidence of 
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recurrence.  Nearly 50% of women who get a UTI will get a recurrence.  Thus, 
treatments that can block a UTI or stop frequent recurrences would be extremely 
beneficial to women and the burden UTIs place on society.  Currently, antibiotics are 
available to treat UTIs, however resistance is rapidly arising.  Thus, new strategies must 
target virulence factors rather than essential growth factors of the bacteria preventing 
selection that requires the bacteria to either evolve or die.  Bacterial colonization begins 
with adherence to host cells.  Disrupting adherence to host cells is an excellent new 
strategy for anti-virulence therapeutics.  The lack of adherence and subsequent 
colonization will give the host time to eliminate the bacteria prior to establishing a 
foothold.  Strategies to eliminate adhesion involve eliminating pilus function and 
biogenesis through carbohydrate mimics and chaperone-usher assembly disruptors.  
This general strategy is described in Appendix 1.  Instead, this section will focus 
specifically on the inhibition of type 1 pili in UTI.   
 
Mannosides 
The first strategy involves inhibiting binding to host cells by blocking the mannose 
binding pocket on FimH.  Based on our extensive elucidation of the UPEC pathogenic 
cascade, we have identified critical nodes in pathogenesis that mannosides would target 
and thereby have powerful and potent therapeutic ramifications. The first step in the 
UPEC pathway involves FimH-mediated colonization of the bladder epithelium via the 
recognition of mannose receptors.  Bacterial invasion into superficial bladder umbrella 
cells can then ensue. By preventing bacterial attachment, mannosides will also inhibit 
the subsequent invasion of bacteria into the bladder epithelial cells.  Crystallization of 
FimH has facilitated a precise understanding of how mannose binds to FimH and the 
interactions that result in high affinity binding (26).  We can therefore take advantage of 
our knowledge of the interactions between mannose and FimH to develop new 
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therapeutics.  Pre-incubation of bacteria with heptyl mannose resulted in significant 
reduction in bacterial load in the murine bladder (46).  These results identify mannose 
derivatives as a potential therapeutic against UTIs.  We can now develop more potent 
inhibitors based on the success of heptyl mannose.   
Mannoside inhibitors were first examined in vitro.  Two FimH function assays 
were used to screen mannosides for inhibitory function; (i) hemagglutination of guinea 
pig red blood cells by type1 piliated UPEC and (ii) a type 1 dependent biofilm assay.  
These assays have shown that 23 of 37 currently synthesized and tested compounds 
are more potent inhibitors of HA titer and biofilm formation than anything commercially 
available and previously tested, some by as much as 2 logs (Table 3).  Future studies 
will use a more rigorous assay to test the ability of the strongest inhibitory mannoside 
derivatives to reverse hemagglutination of guinea pig red blood cells and to disrupt 
preformed type 1 dependent biofilms.  The most potent compounds will be subjected to 
crystallography to better understand their increased activity and to inform further 
chemical synthesis of even better inhibitory compounds. Further, a fluorescent 
polarization assay has been developed and miniaturized to monitor the direct binding of 
a synthesized fluorescently labeled butyl mannose derivative to the FimH receptor as 
well as competitive displacement by other synthetic mannosides. This fluorescent 
polarization assay provides a rapid method for monitoring improvements to receptor 
affinity during the synthetic process, as well as providing Kd binding affinity 
measurements.   
After in vitro examination, the most potent mannosides were tested in vivo.  
Utilizing a well-established gentamicin protection assay to determine the luminally bound 
fraction versus the intracellular fraction, there was a significant reduction in intracellular 
bacteria at 1 hour post-infection in the presence of mannosides ZFH177 and ZFH253 
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(Figure 11), arguing that the mannosides are disrupting specific type 1-mediated binding 
required for subsequent invasion.  It is not clear why a reduction was not observed in the 
luminal UPEC population.  This may be due to contamination from bacteria in the urine 
or bacteria that are non-specifically associated with the epithelium.  In any case, 
blocking invasion blocks the ability of the bacteria to rapidly expand in numbers.  This is 
due to the ability of the mannosides to block the IBC mechanism.  After invasion, UPEC 
are able to rapidly replicate to form IBCs, thus dramatically expanding in numbers.  The 
ability of mannosides to block IBC formation was evaluated based on LacZ staining of 
whole mount bladders to enumerate IBCs.  Whole bladder titers were also determined 
by quantifying colony forming units (CFUs) at 6 hours post-infection and later time 
points.  In the presence of mannosides ZFH177 and ZFH253 there was a significant 
decrease in IBCs observed 6 hours post-infection at concentrations as low as 0.1 mM 
and almost no IBCs observed at 1 mM mannoside (Figure 12A).  A significant decrease 
was also seen in CFUs at 6 hours post-infection with 1 mM ZFH177 and ZFH253 (Figure 
12B).  These results strongly argue that the mannosides are able to inhibit first round 
IBC formation by preventing FimH-mediated binding and invasion into the bladder 
epithelial cells.  The success of these experiments lead us to believe that these 
compounds will have dramatic potential as potent therapeutics for treating UTI.   
 
Pilicides 
The second strategy to inhibit pilus mediated adhesion is to disrupt 
chaperone/usher pilus assembly using compounds termed pilicides.  A pilicide that 
inhibits the production of type 1 pili has a powerful potential as a non-antibiotic 
therapeutic and such compounds will become more necessary in the face of antibiotic 
resistance. Ring-fused 2-pyridones can be found in many biologically active compounds 
and natural products ranging from the multi-fused natural product Nauclefine and 
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Camptothecin (a potent anti-cancer drug) to bicyclic systems like the 2-pyridone acid 
A58365A (an Angiotensin-Converting Enzyme (ACE) inhibitor at nM concentrations) (2, 
13, 31) (Figure 13).  Thiazolo ring-fused 2-pyridones are highly useful as scaffolds for 
the development of compounds that inhibit protein-protein interactions in bacteria (1, 39, 
45) and we have already produced more than 250 of these compounds with a variety of 
R group constituents (Figure 13).  We have done limited screening on a subset of the 
available compounds and have identified compounds we call “pilicides” that bind to the 
chaperone to inhibit its function.  Future work continues to screen these compounds to 
identify ones that hold promise as potential novel antibacterial agents that target 
bacterial virulence.  We have performed limited analysis on a subset of compounds in 
the library and showed that many of these compounds affected type 1 piliation in HA and 
biofilm assays.  Continued research is need to perform extensive studies on the entire 
library of compounds, screening for inhibitory activity in type 1 dependent biofilms and 
HA assays.  
We have assessed the ability of the best pilicides, discovered above, to treat or 
prevent UTI in the murine model.  UTI89 is grown in the presence of the pilicide prior to 
inoculation into the bladders of mice.  In the presence of the pilicide FN075, UPEC 
colonization and invasion in the murine mouse model as measured by bacterial load and 
IBC formation was severely attenuated thus potentiating the therapeutic potential of 
pilicides (Figure 14).  This experiment confirmed that pilicide FN075 treatment inhibited 
IBC formation and thus colonization of the murine bladder thus attenuating virulence. 
Future investigation is required to assess the ability of pilicides to function during 
infections.  
Preliminary studies have revealed that mannosides and pilicides are effective at 
reducing infection in vivo.  However, many studies remain to prove their efficacy within a 
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more clinically relevant setting of UTI.  First, studies are needed to evaluate the 
bioavailability and toxicity of these compounds.  It needs to be determined the best 
method of delivery, oral, IP or IV, to obtain high levels of intact compound in the bladder 
without detrimental effects to the mouse as measured by weight loss and survival.  We 
have shown that 1 to 0.1 mM of mannoside is needed to inhibit infection, thus, it needs 
to be determined if it is possible to achieve this level of mannoside within the bladder.  
However, we have yet to examine synergistic effects of these compounds.  Perhaps in 
the presence of mannoside and pilicide, less compound will be needed to successfully 
inhibit UTI.  One could imagine the mannoside first occupying the FimH mannose 
binding pocket and preventing initial binding, while the pilicide crosses the membrane 
and prevents future pilus synthesis, thus allowing the bacteria to be excreted in the urine 
or phagocytosed by macrophages.  Additionally, reduced amounts of antibiotics could be 
added to further lower the dose required to inhibit bacterial colonization thus reducing 
the selective pressure for resistance.  Once bioavailability and toxicity have been 
determined, a more clinically relevant situation can be evaluated by treating a pre-
existing UTI with compound and see if the infection can be eliminated.  Future studies 
are needed to evaluate the dose, frequency and time of treatments post-infection.  
Additionally, the prophylatic ability of mannoside could be evaluated to determine if this 
could be a daily supplement for women who suffer frequent recurrent UTIs. 
Clearly there is a lot of work left to do to determine the efficacy of mannosides 
and pilicides.  However, these anti-virulence therapeutics have numerous attractive 
qualities.  There is less selective pressure for the bacteria to evolve resulting in 
resistance since unlike traditional antibiotics they do not target essential growth factors 
of the bacteria.  Additionally, these therapeutics will leave the commensal bacteria 
unperturbed.  Loss of commensal gut isolates upon treatment with antibiotics usually 
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results in side effects including diarrhea and secondary opportunistic infections, such as 
yeast infections.  Furthermore, since chaperone/usher systems are numerous to a 
multitude of Gram-negative pathogens, these strategies can be applied to a multitude of 
pathogens.  Adhesion is the first step in nearly every bacterial infection, thus a ligand-
based approach, such as the mannosides, to infection inhibition could translate to an 
even greater expanse of pathogens encompassing Gram-positives as well.  In fact, 
exogenous sugars have proved efficacious at inhibiting adhesion of Pseudomonas 
aeruginosa, Staphylococcus and Streptococcus in vitro (32, 36).  The development of 
anti-virulence therapeutics indicates a paradigm shift in the understanding of bacterial 
pathogens and their interactions with the host and environment.  A multitude of virulence 
factors in addition to adherence are being targeted such as capsule, flagella, 
siderophores, toxins, type III secretion systems (TTSS) and virulence gene regulation.  
Vigilance and basic research in the understanding of basic processes associated with 




 In summary, this thesis work set out to better understand the pathogenesis of 
UPEC in the urinary tract to facilitate the development of new anti-virulence therapeutics.  
Prior studies have revealed that UPEC employs a complex developmental process in 
mice, initiated by the intimate contacts between the pathogen adhesive organelles and 
the host epithelium, to successfully colonize and persist within the harsh environment of 
the urinary tract.  The IBC pathogenic pathway is critical in the ability of UPEC to cause 
UTI and interferences at any step in this pathogenic cycle could alter the infection 
course.  This thesis extends our knowledge of the IBC pathogenic pathway in three 
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important ways.  First, this study has demonstrated the commonality of the IBC pathway 
implying its relevance to UPEC and identifying that targets against this pathway will 
target a multitude of UPEC isolates.  Second, this work identified a virulence plasmid 
that enhances early events in UTI89 infection and its tra operon may contribute to the 
mosaic nature of the UPEC genome by allowing uptake, deletion and rearrangement of 
genes throughout the genome.  Third, based on the ubiquitous and essential qualities of 
FimH, this work identified novel anti-virulence therapeutics targeted at adhesion 
disruption.  These findings indicate the importance of thoroughly understanding the 
mechanisms that underlie this process and how these differ among UPEC.  These 
discoveries alter the current paradigm of bacterial pathogenesis in the urinary tract and 





Table 2. Alignment of FimH sequences 
 
 Highlighted residues differ from UTI89 residues 
 Only residues that differ from UTI89 are shown 




Gene transcripts passing all statistical and quality tests performed as described in
Materials and Methods.
b
Change in !pUTI89 signal compared to UTI89 signal.
Table 1. Chromosomal genes demonstrating a twofold or greater transcript 










hypothetical yfaQ precursor UTI89_C2508 -43.3
hypothetical UTI89_C3244 -23.2
conserved protein YdjA UTI89_C1960 -14.5
hypothetical UTI89_C4976 -4.7
hypothetical UTI89_C1130 -3.0
outer membrane heme/hemoglobin receptor UTI89_C1129 -2.6
lambdoid prophage Qin tail fiber assembly protein-like protein UTI89_C0564 -2.4
hypothetical UTI89_C0954 2.5
bacteriophage ST64T antitermination protein gp23 UTI89_C2663 2.8
hypothetical UTI89_C1727 6.9
a
Gene transcripts passing all statistical and quality tests performed
b
Change in !pUTI89 signal compared to UTI89 signal.
IBCs present
Strain 9 27 62 66 70 78 106 117 163 166 195 106 269 (hrs PI)
ASB1 T A S G S N A G V R Y N Q 6,24
ASB2 T A S G N N A G V R Y N Q 6,24
ASB3 T A S G N S A G V H Y N Q 6,24
ASB4 T A S G N S T G V R Y N Q 6
ASB5 T V S G S N A G V R Y N Q 24 (rare)
acute1 T V S G N S A G V R Y N Q 12 (rare)
acute2 T A S G N S A G V R F N Q 6 (rare)
acute3 T V S G N S A G V R Y N Q 3 (rare)
acute4 T A S S S N A G V R Y N Q -
rUTI1 A A S G N S A R V R F S Q -
rUTI2 T A S G N S A G V R Y N K 6
rUTI3 T V S G N S A G V R Y N Q 6 (few)
rUTI4 T A S G S N A G A R Y N Q 24
rUTI5 T A S G S N A G V R Y N Q 3
pyelo1 T A S C N S A G V R Y N K 6
pyelo2 T A S G N S A G V R Y N Q 6
pyelo3 T V S G N S A G V R Y N Q -
pyelo4 T A S G S N A G V R Y N Q 6
UTI89 T A A G S N A G V R Y N Q 3,6,24
Position
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Figure 1. Bacterial load in the bladder and kidney of UTI89 and pyelo3 in single 
and mixed infections.  (A) At 6h and 24h post-infection, bacterial load was significantly 
lower in the pyelo3-infected bladders than in the UTI89-infected bladders (***p<0.001 
and *p<0.05 by Mann-Whitney).  Total titers in the mixed infection more closely 
resembled UTI89 infected bladders.  (B) There was no significant difference at any 
timepoint between any infection in the kidneys. 
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Figure 2. Cytokine levels in the kidney of UTI89, pyelo3 and co-infections.  
Cytokines IL-1β, IL-6, MCP-1 and MIP-1β were elevated in pyelo3- and co-infected 
kidneys relative to UTI89-infected kidneys.  Thus, co-infection immune response more 













































































































































Figure 3.  Immune response at 6h in UTI89 and ΔpUTI89 infected bladders.  There 




Figure 4. Biofilm formation in the presence or absence of pUTI89.  Blue bars 
represent biofilm formed in LB and red bars represent biofilm formed in M9 + 10 µg/ml 
niacin.  Acute3+, ASB1+ and rUTI+ all represent strains that have received pUTI89.  In 
the presence of pUTI89 there was difference in biofilm formation in LB or M9 media.  
Additionally, there was no difference in biofilm formation in either media in the absence 












Figure 5. Bacterial load in the bladder of clinical isolates with and without pUTI89.  
Acute3+, ASB1+ and rUTI1+ represent strains that received pUTI89.  At 6 h, 24 h, and 2 
wk post-infection there was no significant difference in bacterial load of each isolate with 




Figure 6. Plasmid genes demonstrating greater than two-fold change in ΔpUTI89 
signal compared UTI89 signal.  repB, rsvB, stbA and stbB were all down suggesting 
they are expressed in vitro and encode plasmid replication and maintenance proteins.  
UP060, UP061, UP097 and UP141 were also down suggesting their expression in vitro 
and are all hypothetical proteins requiring further study.   
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Figure 7. Chromosomal genes demonstrating greater than two-fold change in 
ΔpUTI89 signal compared UTI89 signal.  In the absence of pUTI89 24 chromosomal 
genes showed significantly altered regulation.  The most significantly different 
expression levels were down in the absence of pUTI89. 
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Figure 8. FimH residues under positive selection.  FimH is in green and FimC (the 
chaperone) is in gray.  In red are residues under positive selection.  In blue are residues 
not under selection.  Mannose is bound at the tip of FimH.  All of the positively selected 
residues are located outside the mannose-binding pocket. 
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Figure 9. Quantification of IBCs at 6h post-infection from bladders infected with 
clinical isolates.  Below each isolate is listed the amino acids that differ from UTI89.  
Amino acids at position 27, 62 and 66 are under positive selection.  Isolates with * had 
significantly fewer IBCs than UTI89 (p<0.05 by Mann-Whitney).  Five of the 7 isolates 
that were significantly different from UTI89 had a valine at position 27 instead of the 




Figure 10. acute4 + UTI89 FimH alters colonization but not IBC formation.  (A) IBC 
quantification at 6h post-infection showed no difference in acute4 and acute4 + UTI89 
FimH.  (B) Tissue titers at 6h post-infection revealed equal levels of colonization.  
However, at 24h post-infection, acute4 + UTI89 FimH significantly colonized bladders 





Figure 11. Mannosides ZFH177 and ZFH253 reduced intracellular bacteria at 1 
hour post-infection.  A 1 hour gentamicin protection assay was used to evaluate the 
amount of bacteria present in the luminal versus intracellular fraction in the presence of 
mannosides ZFH177 and ZFH253.  A small decrease was seen in the luminal fraction in 
the presence of ZFH177 (p<0.05) whereas a significant decrease was seen in the 











Figure 12. Mannosides ZFH177 and ZFH253 reduce infection capacity in vivo.  (A) 
6 hour LacZ reveals significantly reduced IBCs at 1mM and 0.1mM mannoside for both 
ZFH177 and ZFH253 (p<0.0001).  (B) 6 hour bacterial load quantification reveals 
significantly reduced colonization with 1mM ZFH177 and 1mM ZFH253 treated bacteria, 




Figure 13. Structures of 2-pyridone compounds. (A) Chemical structure of a ring-
fused 2-pyridone with substituent addition sites (R1-R4).  (B) Chemical structures of 
biologically active ring-fused 2-pyridone compounds.  Naucietine (1),Camptothecin (2) 
and A58365A (3).  The 2-pyridone core is shown in red.  
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Figure 14. FN075 has an effect on UTI89 bladder colonization in vivo.  When 
inoculated in the presence of FN075, UTI89 makes significantly less IBCs in the bladder 
(A) and has a significantly reduced bacterial load within the bladder at 6 hours post-
infection (B).  p<0.0001 
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Abstract 
 The prevalence of antibiotic resistance among microorganisms that cause 
infectious diseases has necessitated the use of new strategies for the development of 
novel therapeutics.  In an effort to thwart this resistance, novel therapeutics are being 
developed that target bacterial virulence factors as an alternative to the traditional 
antibiotics which target essential microbial processes promoting bacterial evolution 
resulting in resistance.  While many anti-virulence targets exist, this feature will discuss 
adhesion as an anti-virulence target using pili of uropathogenic E. coli as a model 
system.  The two strategies of drug development discussed in this review involve 
inhibition of bacterial binding to the host tissue by the addition of exogenous sugars and 
the disruption of chaperone-usher (CU) pilus assembly through disruption of protein-
protein interactions.  However, the commonality of adhesion to infectious disease 
processes and CU pili to many pathogens makes these strategies discussed here 
translatable to a multitude of organisms. 
Keywords 




 More than a century ago, the discovery of Penicillin marked a significant, albeit 
not immediately recognized, advance in the field of medicine.  By the middle of the 20th 
century this naturally occurring fungal antibiotic had single-handedly vanquished the 
biggest wartime killer -- infected wounds.  Just four years after the mass production of 
penicillin began in 1943, resistant microbes started to appear beginning with 
Staphylococcus aureus, followed shortly thereafter by Streptococcus pneumoniae and 
Neiserria gonorrheae.  Today this list includes antibiotic resistant Enterococcus, 
Salmonella, Mycobacterium tuberculosis and Escherichia coli, to name just a few.  The 
bacterial infections which contribute most to human disease are also those in which 
emerging and microbial resistance is most evident: diarrheal diseases, respiratory tract 
infections, urinary tract infections, meningitis, sexually transmitted infections, and 
hospital acquired infections.  Thus, there is dire need for new therapeutics to save the 
lives and ease the suffering of millions of people.   
 
Rising antibiotic resistance 
 The antibiotics that are available today are primarily variations on a single 
theme—bacterial eradication based on inhibition of essential molecular processes 
required for bacterial growth (bacteriostatic) or cellular maintenance (bactericidal).  
Some target cell-wall biosynthesis, whereas others inhibit protein synthesis or DNA 
replication.  These life or death treatments put selective pressure on the bacteria to 
adapt or die, selecting for antibiotic resistance.  Second generation drugs were 
developed to combat the resistances that arose, however, they employed the same 
general mechanism of action.  In addition, while some last resort drugs have minimal 
resistance thus far, they are much more expensive, often are more toxic and typically 
unavailable to many countries around the world.  Consequences of treatment failure due 
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to antibiotic resistance are high with greater morbidity, mortality and transmission of the 
resistant organism.  Even if pharmaceutical companies increased efforts to develop next 
generation replacement drugs, bacterial evolution is outpacing drug development for 
these classes of antibiotics.  We are nearing an end to the seemingly endless flow of 
antimicrobial drugs.  We are now faced with a long list of microbes that have found ways 
to circumvent different structural classes of drugs and are no longer susceptible to most, 
if not all, therapeutic regimens.  New tactics and weapons are needed to combat 
bacteria that are, owing to evolution and selection, moving targets.  
 
Alternative antibiotic targets  
Targeting bacterial virulence is an alternative approach to the development of 
new classes of antimicrobials that can be used to specifically target and disarm 
pathogens in the host, while leaving commensal bacteria unperturbed.  Prevention of the 
activity of virulence factors will render the bacteria less able to colonize and give 
beneficial symbionts and the host immune system time to eradicate the disease causing 
pathogen prior to colonization or facilitate clearing of an established infection.  
Furthermore, stripping microorganisms of their virulence properties without threatening 
their existence may offer a reduced selective pressure for drug-resistant mutations and 
provide increased potency.  Upon exposure to the host, bacteria respond by the 
production of an arsenal of virulence factors to combat host immune responses and 
facilitate persistence in their desired niche.  There are many examples of virulence 
factors that represent potential therapeutic targets.  Polysaccharide capsules prevent 
phagocytosis.  Siderophores facilitate iron acquistion.  Flagella promote motility and 
chemotaxis.  Some bacterial species secrete toxins that alter and disrupt the eukaryotic 
host cell resulting in disease.  Yet another strategy employed by bacteria is the 
production of a molecular syringe, known as a type three secretion system, that injects 
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effectors into the host cell causing disease.  Another fundamental virulence property of 
nearly all microbes is their ability to adhere to host cells.  This step is typically crucial in 
pathogenesis and without it bacteria are more likely to be eradicated by the host.  
Bacterial adhesins typically mediate attachment to a specific receptor with 
stereochemical specificity, a process that is thought to determine the host and tissue 
tropisms of a pathogen.  While many virulence factors may represent attractive 
therapeutic targets, this review will focus on two strategies to develop anti-virulence 
therapeutics based on targeting adhesive pili using uropathogenic E. coli (UPEC) as the 
model system.  The first strategy depends on competitively inhibiting bacterial binding to 
host cells through addition of exogenous carbohydrates that mimic host ligands.  The 
second strategy targets the mechanism by which adhesive pili are assembled thus 
inhibiting bacterial adhesion to host cells.  Thus, both strategies could be used in 
synergy: the first compound prevents bacterial attachment and colonization by 
occupying the binding pocket of the bacterial adhesin while the second compound enters 
the cell and prevents future pilus production.  Such a two-pronged approach could 
eliminate adherence to host cells and promote clearance of the bacteria.  
 
Pili in bacteria 
Pathogens are capable of presenting multiple adhesins that can be expressed 
differentially to permit binding in specific sites and at particular times over the course of a 
complex infectious cycle.  To achieve this, many bacterial species possess long 
filamentous structures known as pili or fimbriae extending from their surfaces.  Pili are 
extracellular polymers that also have been shown to play a role in invasion, biofilm 
formation, cell motility, and protein and DNA transport across membranes.  Pilus 
formation is common to many pathogenic bacteria, both Gram-negative and Gram-
positive pathogens.  Despite the diversity in pilus structure and biogenesis, assembly 
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mechanisms among Gram-negative and Gram-positive bacteria are conserved within 
each group.  Gram-positive pili are formed by covalent polymerization of pilin subunits in 
a process that requires a dedicated sortase enzyme.  In contrast, Gram-negative pili are 
typically formed by non-covalent homopolymerization of major pilus subunit proteins.  
This review will focus on a major family of adhesive pili in Gram-negative bacteria that 
are classified by their mechanism of assembly; the so-called chaperone/usher (CU) pili 
(Table 1).  
In Gram-negative bacteria, one of the best-characterized pilus assembly systems 
is the CU pathway.  Hundreds of operons encoding CU systems have been reported in a 
plethora of pathogenic organisms with as many as twelve encoded by a single organism.  
Examples of CU-assembled adhesive virulence fibers include: Type 1 and P pili 
predominately on UPEC that cause urinary tract infection (UTI), S pili of E. coli strains 
that cause sepsis, meningitis and UTI and Hif pili of Haemophilus influenza which 
causes otitis media.  The causative agents of whooping cough (Bordetella pertussis), 
gastroenteritis (Salmonella typhimurium), and pneumonia (Klebsiella pneumoniae) also 
assemble fibers through the CU pathway.  Additionally there are ‘non-pilus adhesins’ 
assembled by the CU pathway that are generally homopolymers composed of a single 
protein subunit, like the Afa/Dr family of adhesins of E. coli and the polymeric F1 
capsular antigen of Yersinia pestis.  The ubiquitous nature of this pathway paves the 
way for a potentially broad-spectrum anti-virulence therapeutic that disrupts the 
assembly of the pilus fibers thus eliminating bacterial colonization. 
 
Pili in UTI 
 Of the CU pathway assembled pili, P and type 1 pili are the most extensively 
characterized.   Type 1 pili are expressed throughout the Enterobacteriaceae family but 
have been shown to be essential for UPEC in colonization of the urinary epithelium.  
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UPEC is the leading causative agent for greater than 80% of UTIs which is one of the 
most common bacterial infections in industrialized countries.  UTIs are a significant 
burden, resulting in more than 8 million outpatient visits per year in the United States 
and expended costs of US $3.5 billion annually for evaluation and treatment.  Women 
are the most frequent sufferers – a female has a 60% chance of suffering from at least 
one UTI in her lifetime.  Additionally, up to 44% of women who present with an initial 
episode of UTI will experience recurrence.  While the increased likelihood of recurrence 
it not entirely understood, data suggests that bacteria can persist within bladder tissue 
despite antibiotic treatments, and may serve as bacterial reservoirs for recurrent 
infections. 
 Type 1 pili are expressed by virtually all UPEC isolates.  The FimH adhesin at the 
tip of type 1 pili achieves specific binding to host cells within the urinary tract.  FimH 
specifically binds mannose groups that abundantly decorate uroplakins on the luminal 
surface of the bladder.  A deep, negatively charged pocket in the N-terminal receptor-
binding domain of FimH accommodates the mannose with stereochemical specificity.  
Once bound, a pathogenic cascade is initiated that involves several distinct phases as 
examined in the murine cystitis model and human UTIs.  Numerous innate defenses are 
activated early in an attempt to stem off the infection.  These defenses include, cytokine 
induction followed by inflammation, iron sequestering, exfoliation of the colonized 
epithelial cells and sheer forces elicited by urine flow.  Even if UPEC successfully invade 
into a bladder epithelial cell, the bladder cell has been shown to be able to expel UPEC, 
potentially serving as an additional innate defense.  However, if UPEC are able to 
escape into the cytoplasm of superficial umbrella cells, they are able to rapidly replicate 
to form tightly packed intracellular bacterial communties (IBCs) with biofilm-like qualities.  
Within the urothelial cells, the bacteria are protected from the flow of urine and host 
defenses.  Eventually UPEC detach from the IBC, disperse and initiate new rounds of 
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IBC formation.  This represents a mechanism by which a single invasion event 
dependent on type 1 pili adhesion can lead to rapid bacterial expansion and colonization 
of the urinary tract.  IBC formation occurs in the acute states of infection.  One long-term 
outcome of infection is that UPEC are also able to form a quiescent intracellular 
reservoir (QIR) within the bladder.  Bacteria in the QIR do not rapidly replicate, but 
remain dormant, hidden from the immune system and antibiotics.  They are then able to 
reestablish an infection at later timepoints post-treatment resulting in a recurrence.  Due 
to this alternative pathway of continuous colonization, UTIs are more frequently being 
identified as chronic infections.  Detailed analysis of the UPEC pathogenic cascade has 
identified several potential targets to inhibit virulence, such as siderophores, capsule and 
flagella.  However, type 1 pili represent a particularly attractive drug target because they 
are ubiquitous among UPEC, and are required to initiate a pathogenic cascade that 
evades the host immune system and can lead to acute, chronic, persistent or 
asymptomatic infection.  Disruption of type 1 pili function could break the cycle of chronic 
infection.   
 
New drug development strategies to inhibit pilus mediated function 
Carbohydrates of various forms are abundantly expressed on the animal cell 
surface.  Microbes have taken advantage of this property and evolved with the ability to 
adhere to sugar receptors in an organ-specific manner for colonization and infection.  
Sugars are commonly involved in cell recognition and communication playing important 
roles in microbial adherence and uptake, colonization and biofilm formation, and in 
virulence.  Since bacterial adhesion to host cells is extremely specific, exogenous sugars 
can block binding to carbohydrate receptors and competitively displace or inhibit bacteria 
from attachment to cells.   The ability to impair bacterial adhesion represents an ideal 
strategy to combat bacterial pathogenesis because it targets an important early step in 
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the infectious process, and would also be suitable for use as a prophylactic to prevent 
infection.  In the case of UPEC, knowledge of the structural basis of how FimH 
recognizes the mannose receptor, has lead to the development of a ligand-based 
antagonist, termed mannoside, that mimics the natural receptor for FimH but with 
increased affinity and avidity.  Mannosides effectively block the adhesive properties of 
type 1 pili by inhibiting bacterial colonization, invasion, IBC formation and disease.  
Furthermore, the sequence of approximately 300 fimH genes of clinical UPEC isolates 
showed that the mannose-binding pocket is invariant.  Thus mannosides are a powerful 
new class of therapeutics that could have a potent therapeutic effect by preventing 
UPEC pathogenesis and disease.  This approach can be readily extended to other 
adherent organisms by tailoring the anti-adhesive compounds to antagonize their 
specific receptor-ligand interactions (Figure 1).  Indeed, sugars designed to target 
adhesive structures of organisms such a Pseudomonas aeruginosa, Stapyhlococcus 
and Streptococcus have already proved efficacious at inhibiting adherence in vitro. 
The goal of the second strategy is to interrupt pilus assembly, which, like the first 
strategy, blocks pilus-mediated adhesion and subsequent disease.  To disrupt pilus 
assembly, one must first understand the mechanisms employed by bacteria to form 
fibers.  Chaperone-usher mediated assembly prevents premature subunit aggregation 
and facilitates the ordered secretion, folding and assembly of hundreds of thousands of 
subunits into fibers on the surface of a bacterium.  Components of the pilus are secreted 
through the general secretory pathway into the periplasm.  Once in the periplasmic 
space, a specific chaperone binds each pilus subunit to facilitate proper folding and 
prevent premature assembly of subunits.  Each subunit consists of six of the seven 
strands of a standard immunoglobulin (Ig)-fold and an N-terminal extension (Nte) (Figure 
2A).  In order to form a stable structure prior to incorporation into the growing fiber, the 
chaperone donates structural information to each subunit, its G1 β strand, to 
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compensate for the missing seventh strand of the subunit in a process called donor 
strand complementation (DSC) (Figure 2B).  DSC prevents aggregation of the subunits 
prior to fiber formation.  The pilin/chaperone complex is then delivered to the usher, 
which is a pore in the outer membrane and serves as a platform for pilus assembly.  
During pilus assembly, the free Nte of one subunit displaces the chaperone bound to 
another subunit and serves as the seventh strand of the Ig-like fold in a process called 
donor strand exchange (DSE) (Figure 2C).  DSE leads to the polymerization of the fiber 
extending from the bacterium.  Since chaperone-usher systems are necessary for the 
assembly of extracellular adhesive organelles in a wide range of pathogens, inhibitors 
may serve as broad-range anti-virulence therapeutics, an attractive feature that would 
enhance the marketability of an effective drug.   
Pilicides are a class of pilus inhibitors that target chaperone function and inhibit 
pilus biogenesis.  A recent study (Pinkner JS et al: PNAS (2006) 103(47):17897-17902) 
identified a new class of pilicides based on a bi-cyclic 2-pyridone chemical scaffold that 
inhibit pilus assembly by binding to the chaperone and disrupting the chaperone-usher 
interaction.  As a result, pilicides inhibit pilus dependent activities such as colonization, 
invasion and biofilm formation.  Biofilms are structured communities of microorganisms 
encapsulated within a self-developed polymeric matrix that defends them against 
antibiotics and the host immune system.  They are of great medical importance, 
accounting for over 80% of microbial infections in the body.  Pilicides target regions on 
the chaperone that are highly conserved among chaperone-usher pathways and are 
thus able to inhibit assembly of multiple pilus systems (type 1 and P pili of E. coli) 
(Figure 1).  Pyridinones also avoid the severe drawbacks observed for peptide-based 
drugs; poor absorption after oral administration, rapid enzymatic degradation, and quick 
excretion.    
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Another distinct mechanism of adhesive fiber assembly among Gram-negative 
bacteria is fibers assembled by the extracellular nucleation/precipitation pathway (curli).  
Curli are proteinaceous fibers found on enteric bacteria such as E. coli and Salmonella 
spp.  Despite curli’s unclear role in pathogenesis, their biochemical and structural 
properties resemble eurkaryotic amyloid fibers found in neurodegenerative diseases, 
such as Alzheimer’s, Parkinson’s, and prion diseases making them an ideal model 
system to study amyloid biogenesis.  Curli are heteropolymers that consist of a major 
subunit, CsgA, and minor subunit, CsgB.  CsgA and CsgB are secreted into the 
extracellular milieu via the outer membrane pore, CsgG.  With the help of two 
chaperone-like proteins, CsgE and CsgF, CsgA is nucleated into a fiber by CsgB.  Curli 
fibers have been implicated in biofilm formation, environmental survival and resistance to 
sanitizing agents.  A recent study (Cegelski L et al: submitted) showed that derivatives of 
the 2-pyridone compounds mentioned above were able to inhibit curli assembly giving 
them the name curlicides.  The lack of curli fibers prevented curli-dependent biofilm 
formation and reduced infection load in vivo as measured by the murine model of UTI.  
Pilicides and curlicides selectively disrupt a protein-protein interaction required for the 
biogenesis of a bacterial virulence factor instead of targeting a process essential for 
survival.   
Employing both anti-virulence strategies, inhibition of receptor binding and 
disruption of pilus assembly, could result in very potent anti-adhesive therapeutics.  For 
example, synergistic effects could be obtained by inhibiting pre-existing type 1 pilus 
function through mannosides while also eliminating the ability to produce new pili 
through pilicides.  Furthermore, if infection is not entirely controlled by the two-pronged 
approach, antibiotics can be added, however, at much lower concentration to reduce the 
opportunity to develop resistance.  Type 1 pili are an essential virulence factor for 
colonization of the urinary tract and are the most extensively studied chaperone-usher 
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fimbrial system.  Thus, they have been described in this review as an excellent target 
resulting in the development of new prototypic therapeutics to treat UTIs.  This new drug 
class could translate into a multitude of other therapies for Gram-negative infections.   
 
Conclusion 
While this review focuses on the development of therapeutics to inhibit adhesion, 
there are many other virulence factors employed by bacteria to colonize and persist 
within the host.  The general strategy of inhibiting virulence factors rather than essential 
growth factors changes the paradigm of drug development and reduces the evolutionary 
pressure for bacteria to develop resistance.  Bacteria can survive in the presence anti-
virulence drugs, but will be eliminated by the host immune system prior to establishing a 
foothold.  Furthermore, since a complex virulence mechanism is targeted, if mutants 
arise, they will most likely be avirulent.  If the host immune system cannot resolve any 
residual infection, it is possible to couple anti-virulence therapeutics with traditional 
antibiotics although at lower doses thus reducing resistance potential.  A commitment to 
developing therapeutics that target virulence requires a serious change in our 
perspective for treating infectious diseases and increased efforts should be focused on 
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P PapA PapD/PapC PapG Uropathogenic E. coli (UPEC) pyelonephritis
Prs PrsA PrsD/PrsC PrsG E. coli cystitis
S SfaA SfaE/SfaF SfaS E. coli UTI, meningitis, sepsis
Hif HifA HifB/HifC HifE Haemophilus influenzae otitis media, meningitis
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Pef PefA PefD/PefC unknown Salmonella typhimurium gastroenteritis
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MR/K MrkA MrkB/MrkC MrkD K. pneumoniae pneumonia
Myf fimbriae MyfA MyfB/MyfC unknown Yersinia enterocolitica enterocolitis
PMF PmfA PmfC/PmFD PmfF Proteus mirabilis UTI
Dr DraA DraB/DraC DraE UPEC pyelonephritis
Diffuse adhereing E. coli 
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cystitis
Afa AfaA AfaB/AfaC AfaE UPEC cystitis, diarrhea
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Figure 1. Two strategies to inhibit bacterial binding to host cells.  The schematic 
diagram shows the model of chaperone-assisted pilus assembly and the mode of 
mannoside (left panel) and pilicide (right panel) action. During normal pilus biogenesis, 
newly synthesized pilus subunits cross into the periplasm via the Sec secretion pathway. 
These pilus subunits bind to their periplasmic chaperone proteins (orange molecules) 
and fold into correct confirmations (1). In the absence of the chaperones, pilus subunits 
are degraded (*). Chaperone-subunit complexes (2) are transported to the outer 
membrane usher proteins (blue cylinders) for assembly (3). Pilus assembly follows an 
ordered process with the chaperone-adhesin complexes as the initiators (4). As subunits 
are assembled into the growing pilus, accompanying chaperones disassociate from the 
membrane complexes (5), which could potentially be recycled to bind newly synthesized 
subunits. Mannosides (teal triangles) interact with the pilus adhesin and prevent binding 
to mannosylated residues (light brown triangles) on the surface of epithelial cells.  
Pilicides (yellow circles) can cross freely through bacterial outer membranes and bind to 
periplasmic chaperones (B). Pilicides block the interaction of chaperone-subunit 




Figure 2.  Chaperone-subunit donor strand exchange (DSE) and donor strand 
complementation (DSC).  (A) Each subunit consists of six of the seven strands of a 
standard immunoglobulin (Ig)-fold and an N-terminal extension (Nte).  (B) In order to 
form a stable structure prior to incorporation into the growing fiber, the chaperone 
donates the missing seventh strand of the subunit in a process called donor strand 
complementation (DSC).  (C) During pilus assembly, the free Nte of one subunit 
displaces the chaperone bound to another subunit and serves as the seventh strand of 
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